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ABSTRACT 
 
Rapid rotation of guanine base derivatives about Pt–N7 bonds results in fluxional 
behavior of models of the key DNA intrastrand G–G cross-link leading to anticancer 
activity of Pt(II) drugs (G = deoxyguanosine). This behavior impedes the characterization 
of LPtG2 models (L = one bidentate or two cis-unidentate carrier ligands; G = guanine 
derivative). The objective of this study is to understand the types of conformers formed 
as L is systematically varied. This work, relevant to Pt(II) anticancer drugs, has evolved 
from published studies with sp3 N-ligands (e.g., 2,2′-bipiperidine), to C2 symmetrical or 
unsymmetrical sp2 N-ligands having pyridine and/or triazine rings.  
NMR spectroscopy provided conclusive evidence that LPtG2 (L = 5,5′-dimethyl-
2,2′-bipyridine (5,5′-Me2bipy), 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine) 
(MepyMe2t), and bis-3,3′-(5,6-dialkyl-1,2,4-triazine)  (R4dt)) complexes exist as 
interconverting mixtures of head-to-tail (HT) and head-to-head (HH) conformers. The 
triazine rings have a N plus lone pair in the same position as the C6H of pyridine rings, 
and NMR spectral studies indicate that the LPtG2 adducts are more dynamic when L has 
a triazine ring. For the first time, the two possible HH conformers (HHa and HHb) were 
identified for (MepyMe2t)Pt(5′-GMP)2, an adduct having an unsymmetrical L. Although 
O6–O6 clashes involving the two cis G bases favor the HT over the HH arrangement, the 
HH conformer of (R4dt)Pt(5′-GMP)2 adducts has a high abundance (~50%), a finding  
attributed to a reduction in O6–O6 steric clashes permitted by the overall low steric 
effects of R4dt ligands.  
 The (R4dt)Pt(d(G*pG*)) adduct (G* = N7 platinated G residue linked with a 
sugar-phosphodiester backbone), is the first adduct having a high abundance of a fourth 
 xx
form. The characteristics of this form suggest it is the elusive ΛHT conformer; in 
addition, this adduct had the normally observed HH1, HH2 and ∆HT conformers. Studies 
with the (R4dt)Pt(d(G*pG*)) adducts provided the first clear evidence that the sugar-
phosphodiester backbone between two adjacent G’s slows the rate of exchange between 
the conformers. For (R4dt)Pt(d(G*pG*)), a 3′-flanking T has no significant influence on 
the structure of the d(G*pG*) cross-link or the distribution of conformers, whereas the 5′-
T residue led to the exclusive presence of the HH1 conformer. 
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CHAPTER 1. INTRODUCTION 
Rosenberg’s serendipitous discovery of the anticancer activity of cisplatin, cis-
Pt(NH3)2Cl21, has stimulated extensive interest in the interaction of platinum complexes with 
nucleic acids. Despite the success of cisplatin in treating several forms of cancer, including 
ovarian, testicular, cervical, head and neck, and non-small-cell lung cancer,2-5 the exact features 
that render this simple molecule an effective anticancer agent are still controversial. Also, the 
treatment is limited by side effects including nephrotoxicity, emetogenesis and neurotoxicity.6-8 
Thousands of platinum analogues have been synthesized and screened for anticancer activity in 
an attempt to overcome these limitations and to broaden the range of treatable tumors.2,9-14  
1.1 Cisplatin 
1.1.1 Cellular Pathway  
 
 
Figure 1.1 Schematic representation of cellular uptake and activation of cisplatin (cis-
Pt(NH3)2Cl2) prior to DNA binding.  
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Cisplatin circulates in the bloodstream, primarily as the chloride form. Upon entering the 
cell, where the chloride ion concentration is significantly lower (~4 mM) than in the blood 
plasma (100 mM), the chloride ligands are displaced by water to form aqua and hydroxo species 
(Figure 1.1).5,15-20  These hydrolyzed cisplatin complexes are thought to be the active form of the 
drug.5,15,16 Within the cell, cisplatin can form covalent adducts with a number of macromolecules 
including peptides, proteins, and nucleic acids.16,21 However, DNA is widely accepted as the 
critical target responsible for the anticancer activity of cisplatin.2,5,15,16,21 
1.1.2 DNA Binding 
Platinum compounds can bind to DNA by either covalent or non-covalent interactions. 
X-ray structures and NMR data have established that at biologically relevant pH values platinum 
complexes bind almost exclusively at the N7 atom in purine bases, with a preference for guanine 
over adenine (Figure 1.2).2,5,10,15,22-29 Several types of DNA adducts occur with platinum 
compounds, including monofunctional, intrastrand cross-links, and interstrand cross-links 
(Figure 1.3).30-32 Cisplatin forms predominantly 1,2-intrastrand d(G*pG*) and d(A*pG*) cross-
links (G* = N7-platinated G), and to a lesser extent, 1,3-intrastrand and interstrand cross-links.33-
36
 Consequently, attention has focused on these adducts as the active lesions responsible for the 
anticancer activity of cisplatin.2,4,29,37-39 Additional support for this conclusion arises from the 
inability of the inactive trans isomer (transplatin) to form this 1,2-intrastrand adduct because of 
geometrical constraints.40,41 These discoveries suggested that the cytotoxicity of cisplatin 
originated from the 1,2-intrastrand cross-links, which the geometry of transplatin does not 
allow.25  The extent of this cross-link formation is correlated with treatment outcomes.42,43 The 
distortions induced in the DNA structure upon formation of the 1,2-intrastrand cisplatin-DNA 
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lesion have been shown to inhibit the processes of replication and transcription, resulting in cell 
death.41,44 
 
 
Figure 1.2 Structure and numbering scheme for DNA nucleobases. Dashed lines represent base-
pair hydrogen bonds. Base and sugar are in the anti conformation. N- and S-pucker 
conformations are given for sugar moieties.  
 
 
 
Figure 1.3 Chart showing common Pt-DNA binding modes resulting in monofunctional adducts 
(A), interstrand (B) and 1,2-intrastrand bifunctional cross-links (C). 
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Alterations of the B-DNA structure caused by cisplatin binding have been detected by 
several methods such as melting temperature and CD spectroscopy.45-50 There is a degree of 
uncertainty in defining the structure of duplexes bearing Pt drug lesions, and controversy exists 
as to the details of the structure.26,29 For this reason and because one might gain better insight 
into the causes of the distortions and interactions in duplexes by examining small models, many 
investigators have been drawn to the study of small non-duplex models by both crystallography 
and spectroscopy. Three classes of models are often employed to study the structural 
consequences of platinum binding and formation of the 1,2-d(G*pG*) intrastrand adduct in 
DNA:  (i) DNA oligonucleotide duplexes with intrastrand and interstrand G-Pt-G cross-
links,29,37,40,51-58 (ii) adducts with single-stranded DNA have been studied as models of the 
intrastrand cross-link,22,29,39,59-65 and (iii) complexes formed with unlinked guanine derivatives 
(G) are the simplest models.29,66-68  These model types also allow the practical application of 
NMR spectroscopy, an invaluable technique for structural characterization in the biologically 
relevant solution state.29,47   
1.2 Conformations of LPtG2 Adducts 
Although the Pt-duplex DNA adducts are the most reliable model types, their size often 
complicates analysis designed to uncover the specific conformational changes inducted by 
cisplatin bonding. For the other two simpler model types, namely cis-Pt(NH3)2G2 and cis-
Pt(NH3)2(d(G*pG*)), bases can adopt a head-to-head (HH) or head-to-tail (HT) conformation 
(Figure 1.4). In the HH conformer, the H8 atoms of both G bases are on the same side of the 
platinum coordination plane, whereas in the HT conformer, the two H8 atoms are on the opposite 
sides of the platinum coordination plane. Two chiralities are possible for the HT form:  ∆ or Λ. 
These conformers can interconvert via rotation of the bases about the Pt–N7 bond (Figure 
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1.4).29,66 The untethered G’s normally preferentially adopt an HT orientation,69,70 whereas the 
bases in d(GpG) cross-links having a sugar phosphate backbone preferably adopt the HH 
orientation, especially when there is a 5′ residue.39,59,61,63-65,69,71-73  
 
 
Figure 1.4 Schematic representation of possible HH and HT conformers in (a) LPtG2 and (b) 
LPt(d(G*pG*)) type model complexes. The large arrows represent the guanine base, with the 
arrowhead representing the H8 (shown below the scheme), and the small arrows in (b) indicate 
the direction of propagation of the phosphodiester backbone. The platinum carrier ligand is to the 
rear; for LPtG2 adducts when L is unsymmetrical (N′ ≠ N), there are two HH conformers, but 
when symmetrical (N′ = N), only one HH conformer is possible. Rotation of one base about the 
Pt–N7 bond leads to another conformer, but in each case the base orientation changes from HT 
to HH and vice-versa.  
 
1.3 Dynamic Motion Problem 
Both cis-Pt(NH3)2G2 and cis-Pt(NH3)2(d(G*pG*)) model adducts exhibit only one set of 
1H NMR resonances for each type of G or G* residue.61,63,66,68 However, two different 
interpretations have been proposed for this same observation. Detection of one set of 1H NMR 
signals for cis-Pt(NH3)2G2 complexes has been attributed to a dynamic interchange between 
multiple conformers.66,68 However, in the absence of an X-ray structure, the observation of only 
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one set of 1H NMR signals for cis-Pt(NH3)2(d(G*pG*))61,63 has been interpreted to imply that the 
presence of the phosphodiester backbone in this cross-link model favors only one conformer 
(anti, anti HH1), which undergoes slow Pt–N7 bond rotation.41,59,61,63-65 Because of these 
conflicting interpretations, the cis-Pt(NH3)2(d(G*pG*)) model of the cisplatin-DNA intrastrand 
adduct is said to suffer from the "dynamic motion problem".69,74-77 
1.4 Retro-modeling 
 To resolve the “dynamic motion problem”, the “retro modeling” approach has been 
employed. In this approach analogues of cisplatin are synthesized with bulky ligands designed to 
reduce dynamic motion by destabilizing the transition state for Pt–N7 rotation.29,69-71,74,78,79 These 
carrier ligands are more complex than the freely rotating ammonia groups of the parent 
compound, cisplatin. An important feature of the design is to minimize steric effects of the 
ground state equilibrium species to allow conformers likely to be present in dynamic cis-
Pt(NH3)2G2 adduct to exist in the new adducts also.  The carrier-ligand bulk plays a role in 
influencing both the biological activity and the properties of adducts. 
NMR spectroscopy provides evidence of coexistence of multiple conformers for LPtG2 
models (L = one bidentate or two cis-mondentate N-donor carrier ligands) suggesting slow 
rotation about the Pt–N7 bond. The number of observable NMR signals for LPtG2 complexes is 
determined by the local symmetry of the ligand and the asymmetry of the G ribose residue. For 
the most simple case, in which the L is C2 symmetrical and G does not have a ribose group (e.g., 
9-ethylguanine), the two HT rotamers (∆ and Λ) are enantiomers and the two HH forms are 
equivalent because they are related by C2 symmetry;  each base arrangement (HH or HT) gives 
rise to only one 1H NMR resonance for each proton type because the two G bases, in either the 
HH or HT arrangement, are equivalent. When the G contains a sugar moiety, the chirality of the 
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ribose group breaks the enantiomeric relationship of the two HT conformers, but the two HH 
forms are still equivalent;  the two G bases are still related by C2 symmetry in the HT 
conformers, but are no longer equivalent in the HH arrangement. Thus, for a LPtG2 complexes 
with a C2-symmetrical L and a G containing a sugar moiety, observation of up to four 1H NMR 
signals for each proton type is possible (one for each HT form (∆ and Λ) and two signals of equal 
intensity for the HH form). When L is an unsymmetrical carrier ligand, the two HH (HHa and 
HHb) and the HT (∆ and Λ) conformers are not equivalent and maximum of eight H8 signals are 
possible. 
1.4.1 sp3 N-donor Ligands 
Unlike the cis-Pt(NH3)2G2 complexes, for which conformer distributions are not known, 
observation of individual forms for retro-model complexes allows assessment of conformers. 
The downfield G H8 signals, in a less crowded, more disperse region of the spectra, are 
particularly useful for assessing the nature and distribution of conformer. Early retro-modeling 
studies employing Pt complexes of N,N′-dimethyl-2,3-diaminobutane (Me2DAB)71,72,78 and 2,2′-
bipiperidine (Bip)69,70 carrier ligands produced some interesting results. The Pt coordinated 
chelate ligands  have two energetically favored C2-symmetrical geometries, with S, R, R, S or R, 
S, S, R configurations at the asymmetric N, C, C, and N chelate ring atoms (Figure 1.5). These 
retro models provided the opportunity to define the solution structure of conformers by NMR 
methods, allowing the identification of the HH form of an LPtG2 adduct for the first time80 and 
to define the absolute conformation in solution.38 
In addition to the commonly found HH1 conformer, a novel HH form (HH2) was 
discovered for (R, S, S, R)-BipPt(d(G*pG*)).74 This new form, comparable in stability to the 
HH1 conformer, differs from HH1 with respect to the direction of propagation of the 
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phosphodiester backbone. HH1 and an HT form (∆HT1) were observed for the (S, R, R, S)-
BipPt(d(G*pG*)) adduct.79 Secondly, the stereochemistry of these ligands was found to dictate 
the favored HT chirality;  subsequently, they were termed chirality-controlling chelate (CCC) 
ligands.78 Thirdly, for all Me2DABPtG2 adducts, the favored HT form was always one having 
the G O6 atoms and the cis Me2DAB NH groups on opposite sides of the platinum coordination 
plane; such results suggested that carrier ligand NH-G O6 H-bonds are not a great stabilizing 
force in such conformers.78 Fourthly, it was found that the G N1H is a key feature stabilizing the 
favored HT conformer by participating in hydrogen bonding to the phosphate group of the cis G; 
such interligand phosphate-cis G N1H interactions were called “second-sphere communication” 
(SSC).26,76,81,82 The fifth and the final key point that emerged from these studies was the 
establishment of a strong correlation between the observed CD signal and the dominant HT 
rotamer (∆ or Λ).78  
 
 
Figure 1.5 Ball-and-stick representation of PtG2 adducts of sp3 N-donor ligands (Me2DAB and 
Bip). Balloon-type structures (middle) depict the ligand bulk relative to the Pt coordination 
plane. Stereochemistry is indicated for the N, C, C, and N ring atoms of the Bip and Me2DAB 
ligands. 
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Figure 1.6 Schematic representation of canting orientations for the BipPt(d(G*pG*)) HH1, HH2 
and ∆HT conformers. Shaded balloon-like shapes depict the bulk of the Bip ligand distributed 
slightly above and/or below the Pt coordination plane. Each arrow represents the guanine base. 
The phosphodiester backbone is omitted for clarity. Double-headed arrows show the possible 
Bip NH–G*O6 hydrogen bonds.  
 
Studies on cross-linked adducts employing the Bip carrier ligand proved to be very 
revealing. As for the BipPtG2 systems, the chirality of the Bip ligand was found to play a role in 
conformer distribution in cross-linked adducts. Carrier-ligand chirality also influenced structural 
properties of observed conformers; namely, G* base canting orientations. Canting can be either 
right (R)- or left (L)-handed (Figure 1.6). (S, R, R, S)-BipPt(d(G*pG*)) forms had L-canting, 
whereas conformers of (R, S, S, R)-BipPt(d(G*pG*)) favored R-canting (Figure 1.6). For all 
conformers, the favored canting orientation was consistent with the presence of at least one Bip 
NH-G O6 H-bond. Consequently, carrier ligand-NH group-G O6 H-bonds were postulated to 
influence conformer stabilities and base canting for the forms of BipPt(d(G*pG*)) adducts.74,75,79  
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This proposed role regarding carrier-ligand NH-G O6 H-bonds thus seems to contrast with 
conclusions drawn from unlinked model (i.e., G2) studies. 
Another sp3 N-donor carrier ligand studied earlier is N,N′- dimethylpiperazine (Me2ppz, 
Figure 1.5). The ligand possess in-plane bulk to slow the dynamic motion, but lack the chirality 
and NH groups typically designed into cisplatin derivatives.66,83-85  The reduced dynamic nature 
of Me2ppzPtG2 complexes allowed assessment and potential identification of factors relevant to 
the relative stabilities of different conformers.76,86  The absence of NH groups in the Me2ppz 
ligand eliminates the possibility of any carrier ligand NH-G O6/phosphate group H-bond.  The 
three typical conformers (∆HT, ΛHT, and HH) were observed for Me2ppzPtG2 adducts.  
Furthermore, in a rare example of cross-link models, three conformers (HH1, HH2, and ∆HT1) 
were observed and characterized for Me2ppzPt(d(G*pG*)).87  This marked the first report of 
three conformers in one Pt cross-link adduct.  Comparison of the results for BipPt(d(G*pG*)) 
and Me2ppzPt(d(G*pG*)) adducts suggested that carrier ligand NH-G O6 H-bond has no 
influence on base canting orientations and is not a significant stabilizing factor for conformers.87 
1.4.2 sp2 N-donor Ligands 
Retro models with sp3 N-donor ligands have been studied more often69,86,88,89 than those 
with sp2 N-donor heterocyclic chelating ligands. Studies of (Me2phen)Pt(Guo)2 complex90 
(Me2phen = 2,9-dimethyl-1,10-phenanthroline; Guo = guanosine) and (5,5′-
Me2bipy)Pt(d(G*pG*)),77 (5,5′-Me2bipy = 5,5′-dimethyl-2,2′-bipyridine) have demonstrated the 
coexistence of different rotamers exchanging slowly relative to the NMR time scale. A Pt(II) 
complex having aromatic ligands can not only bind to nucleobases but can also intercalate into 
DNA.8,91-97 Aromatic ring stacking between nucleobases and the intercalating molecule is 
considered to be one of the driving forces leading to binding; the extent of binding is expected to 
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depend on the planarity of the complex.94,98 Because of the planar nature of bipyridine ligands, 
intercalation of Pt bipyridine complexes has been a focus of considerable interest.92,94,99,100 
 
 
Figure 1.7 Line drawing and numbering scheme for the sp2 N-donor ligands; Me2bipy = 
dimethyl-2,2′-bipyridine, R1pyR2R3t = 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine and 
R4dt = bis-3,3′-(5,6-alkyl-1,2,4-triazine). 
 
The studies presented here utilize sp2 N-donor heterocyclic aromatic bidentate ligands, 
namely dimethyl-2,2′-bipyridine (Me2bipy), 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine 
(R1pyR2R3t) and bis-3,3′-(5,6-disubstituted-1,2,4-triazine (R4dt) ligands  (Figure 1.7). These 
ligands like Me2ppz lack the NH group and the ligand bulk lie in the Pt coordination plane. 
Platinum complexes of these ligands were synthesized and crystallized. Structural analysis of 
these complexes allowed evaluation of the effect of substituents and their positions on distortions 
from planarity of these complexes. In LPtG2 adducts, the effect of the presence of H6/6′ protons 
in Me2bipy that project toward the G bases compared to the equivalently placed lone pairs on the 
N atoms in R4dt ligands on the conformer distribution and canting of the bases is analyzed.  The 
unsymmetrical R1pyR2R3t ligand forms a connecting link between the two symmetrical ligands 
above, in having both the pyridyl and the triazine ring.  
Studies involving the above sp2 N-donor ligands, using linked (d(GpG) and oligos) and 
unlinked (guanosine, 5′- and 3′-GMP's) model types were undertaken in order to have a better 
understanding of the factors that contribute to the conformer stability and their structural 
properties. Specifically, the importance of electrostatic interaction between the carrier ligand and 
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the bases will be addressed. In addition to the characteristic H8 and sugar proton shifts of the G 
bases, the chemical shifts of the H6 or H6′ proton signals will also be used to explain the 
structural features of the adducts. The concept that the ability of the carrier ligand to favor 
specific conformers may be related to the activity (or inactivity) of cisplatin derivatives has been 
discussed.75 The populations of conformers other than the HH1 conformer favored by the 
cisplatin-DNA intrastrand cross-linked adduct may reduce anticancer activity because such 
lesions may be better recognized and more easily corrected by DNA repair mechanisms. For 
example, proteins bearing the HMG domain are assumed to play an essential role in cisplatin’s 
anticancer activity;44,101,102  such proteins recognize the cisplatin-DNA lesion and are believed to 
protect the site from repair mechanisms. This protein may not recognize other conformers. Thus, 
identification of carrier-ligand features which favor the biologically relevant lesion may 
ultimately prove beneficial in designing better and hence more active platinum anticancer drugs. 
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CHAPTER 2. CHEMISTRY OF HIV-1 VIRUCIDAL Pt COMPLEXES HAVING 
NEGLECTED BIDENTATE sp2 N-DONOR CARRIER LIGANDS WITH LINKED 
TRIAZINE AND PYRIDINE RINGS: SYNTHESIS, NMR SPECTRAL FEATURES, 
STRUCTURE, AND REACTION WITH GUANOSINE* 
 
2.1 Introduction 
In comparison to agents of purely organic molecules, considerably less effort has been 
devoted to studying metal-containing drugs. Platinum complexes, which have been found to be 
the most promising,1-7 have the advantages of inertness, low coordination number, and 
preferential binding to the more limited soft centers in proteins and nucleic acids. The non-
leaving carrier ligand on Pt can modify binding sites and thus activity. Cisplatin (cis-
Pt(NH3)2Cl2) and its analogues, cis-PtA2X2 (A2 = two amines or a diamine), interact with DNA 
by forming a 1,2-intrastrand N7−Pt−N7 crosslink between two adjacent guanines.8 Pt(II) 
compounds also have an extensive history of exhibiting antiviral activity against numerous 
viruses, including topical antiviral activity.9-15 In addition, we have clear evidence that the carrier 
ligand influences the antiviral activity.13 Structural modifications of the carrier ligand in cisplatin 
may broaden the range of antitumor and antiviral activity and may provide valuable insight into 
the mechanism of action of the drug.3,16  
Development of multi-purpose drugs with wider application is desirable. Numerous 
platinum coordination compounds have been synthesized and shown to have both antiviral and 
antitumor activities.14 Hybrid drugs of the type, cis-[Pt(NH3)2(B)Cl]+, containing a cisplatin-like 
moiety and an antiviral guanosine-type ligand (B = acyclovir or penciclovir),14,15 are known. 
______________________________________________________________________________  
* Reproduced with permission from American Chemical Society: Maheshwari, V.; 
Bhattacharyya, D.; Fronczek, F. R.; Marzilli, P. A.; Marzilli, L. G., "Chemistry of HIV-1 
Virucidal Pt Complexes Having Neglected Bidentate sp2 N-donor Carrier Ligands with Linked 
Triazine and Pyridine Rings. Synthesis, NMR Spectral Features, Structure, and Reaction with 
Guanosine," Inorganic Chemistry, 2006, 45, 7182-7190. Copyright 2006 American Chemical 
Society. 
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Collaborative studies from this laboratory have shown that platinum compounds 
containing one or two N-donor aromatic 3-(pyridin-2′-yl)-1,2,4-triazine ligands (ptt) possess 
great potential as anti-HIV microbicides.13  
The [(ferene)PtCl2]2- and [(ferene)2Pt]2- (ferene = 3-(pyridin-2′-yl)-5,6-bis(5-sulfo-2-
furyl)-1,2,4-triazine; in Figure 2.1, R2 = R3 = 5-sulfo-2-furyl) complexes are among the most 
virucidal ptt compounds.13 However, these agents with sulfonated ring substituents were not 
isolated as crystals, have very complicated 1H NMR spectra, and thus were not well defined 
chemically. For example, the triazine ring binding mode (N2 or N4, Figure 2.1) or a mixture of 
such binding modes, could not be resolved for the ferene agents. 
 
 
Figure 2.1 Synthesis of 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine (L) 
 
In this study, we utilize six ligands, L, bearing a 3-(pyridin-2′-yl)-1,2,4-triazine moiety 
(Figure 2.1). Three ligands contain the pyridin-2′-yl group: 3-(pyridin-2′-yl)-5,6-dimethyl-1,2,4-
triazine (pyMe2t), 3-(pyridin-2′-yl)-5-phenyl-1,2,4-triazine (pyPht), and 3-(pyridin-2′-yl)-5,6-
diphenyl-1,2,4-triazine (pyPh2t)), and the other three ligands contain the 4′-methylpyridin-2′-yl 
group: 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine (MepyMe2t), 3-(4′-methylpyridin-
2′-yl)-5-phenyl-1,2,4-triazine (MepyPht), and 3-(4′-methylpyridin-2′-yl)-5,6-diphenyl-1,2,4-
triazine (MepyPh2t)). We describe here the synthesis of LPtCl2 and [L2Pt]X2 complexes (Figure 
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2.2), along with their characterization by 1H NMR spectroscopy and, for selected examples, by 
single-crystal X-ray diffraction methods. The pyridyl triazines are relatively neglected ligands; no 
crystal structures involving 3-(pyridin-2′-yl)-1,2,4-triazines with Pt have been reported. However, 
crystal structures of pyPh2t complexes of Cu,17 Sn,18 and Ru19 have been reported. Also known 
is a crystal structure of [Ce(Mebtp)3]3+ (Mebtp = 2,6-bis(5,6-dimethyl-1,2,4-triazin-3-yl)-
pyridine) complex with the Mebtp tridentate ligand containing the pyMe2t moiety.20 
 
 
Figure 2.2 Synthesis of LPtCl2 and [L2Pt]2+ Complexes. Reagents and conditions: (i) A:B = 1:1, 
CH3OH, 60 °C, 12 h; (ii) A:B = 1:2, CH3OH, 60 °C, 24 h. 
 
Pt(II) compounds have high affinity for reacting with S-containing biomolecules such as 
methionine and also with N7 of purine bases in nucleic acids, but the target for virucidal activity 
is not known. Carrier-ligand bulk plays a role in influencing both biological activity and the 
properties of adducts. Because platinum complexes of 3-(pyridin-2′-yl)-1,2,4-triazines may form 
1,2-intrastrand GG crosslinks with RNA in HIV-1 and because the observation of rotamers 
formed by restricted rotation about the N7 bonds in Pt(Guo)2 adducts provides information on 
ligand steric bulk, we assessed whether rotamers can be detected for [(MepyMe2t)Pt(Guo)2]2+. 
The carrier ligands in cisplatin and other Pt(II) anticancer drugs usually are not bulky enough to 
impede rotation of N7-bound guanine about the Pt–N7 bond, but planar sp2 N-donor ligands such 
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as 5,5′-dimethyl-2,2′-bipyridine (5,5′-Me2bipy)21 and 1,10-phenanthroline (phen)22 allow 
detection of rotamers on the NMR time scale. The aromatic portion of the 3-(pyridin-2′-yl)-1,2,4-
triazine carrier ligands in ptt compounds can also possibly intercalate into nucleic acids.23 Thus, 
all these reasons prompted us to conduct this study of the synthesis and characterization of ptt 
compounds related to ptt compounds with ferene that are known to be HIV-1 virucidal.13 
2.2 Experimental Section 
2.2.1 Starting Materials 
The starting material, pyridine-2-carboxamide hydrazone (2-pyridylamidrazone), was 
synthesized by a known method24 (Figure 2.1) in yields above 90%. 4′-Methyl-substituted 
pyridine-2-carboxamide hydrazone (4′-methyl-2-pyridylamidrazone) was synthesized as 
described by Case.25 Guanosine (Guo) (Sigma) and pyPh2t (Fluka) were obtained from 
commercial sources. cis-Pt(Me2SO)2Cl2 was prepared as described in the literature.26 Elemental 
analyses (C,H,N) were performed by Atlantic Microlabs, Atlanta, GA. 
2.2.2 NMR Measurements 
1H NMR spectra were recorded on Bruker spectrometers operating at 400 or 500 MHz. 
We used the values of 0.00 and 4.78 ppm to reference signals to TMS in DMSO-d6 solutions and 
to the residual HOD signal in D2O/DMSO-d6 solutions, respectively. DNO3 and NaOD solutions 
(0.1 M in D2O) were used to adjust the pH of D2O/DMSO-d6 solutions. 2D ROESY 
experiments27 were performed at 25 °C by using a 500 ms mixing time (128 scans per t1 
increment). NMR data were processed with XWINNMR or Mestre-C software.  
2.2.3 Synthesis of L = 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine and 3-(4′-
Methylpyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine 
 
The pyMe2t, pyPht, pyPh2t ligands and their 3-(4-methylpyridin-2′-yl) analogues, 
MepyMe2t, MepyPht, and MepyPh2t, were prepared as described in the literature25,28,29 (Figure 
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2.1), with minor modifications. An ethanol solution (30 mL) containing 2-pyridylamidrazone, or 
its 4′-methyl analogue (2.5 mmol), and an α-diketone (2.5 mmol) was heated at reflux for 3 h. 
The volume of the solution was reduced to one-fourth by rotary evaporation. Addition of an 
excess of hexane afforded the desired pure crystalline 3-(pyridin-2′-yl)-1,2,4-triazine in 90% 
yield. 
2.2.4 Synthesis of LPtCl2 Complexes  
Two methods, A and B, were employed to obtain LPtCl2 complexes (Figure 2.2). Method 
A involved heating a methanol solution (30 mL) of cis-Pt(Me2SO)2Cl2 (0.101 g, 0.24 mmol) and 
L (0.24 mmol) at 60 °C for 12 h. The yellow solid that precipitated was collected, washed with 
diethyl ether followed by chloroform, and dried in vacuo. Method A resulted in high yields of 
powdered LPtCl2 product that required no further purification. Method B, employed to obtain X-
ray quality crystals, involved mixing an acetonitrile solution of cis-Pt(Me2SO)2Cl2 (4.22 mg,10 
mM in 1 mL) with L (10 mM in 1 mL) and allowing this mixture to stand at 23 °C. Thin needles 
of LPtCl2, varying in color from greenish-yellow to orange, were obtained in ~15% yield after 24 
hours. 
2.2.4.1 (pyMe2t)PtCl2 (1). Method A gave a yellow precipitate; yield, 0.077 g (71%). 
Method B afforded orange needle-shaped crystals. 1H NMR (ppm) in DMSO-d6 : 9.57 (d, H6′), 
8.60 (d, H3′), 8.48 (t, H4′), 8.03 (t, H5′), 2.75 (s, CH3), 2.59 (s, CH3). Anal. Calcd for 
C10H10Cl2N4Pt: C, 26.56; H, 2.23; N, 12.39. Found: C, 26.77; H, 2.29; N, 12.37. 
2.2.4.2 (pyPht)PtCl2 (2). Method A gave a yellow powder; yield, 0.084g (75%). Method 
B produced yellow-green needles. 1H NMR (ppm) in DMSO-d6: 10.18 (s, H6), 9.62 (d, H6′), 
8.78 (d, H3′), 8.54 (t, H4′), 8.11 (t, H5′), 8.64 (d, o-PhH), 7.85 (t, p-PhH), 7.71 (t, m-PhH). Anal. 
Calcd for C14H10Cl2N4Pt: C, 33.61; H, 2.01; N, 11.20. Found: C, 33.48; H, 1.95; N, 11.10. 
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2.2.4.3 (pyPh2t)PtCl2 (3). Method A gave a yellow solid; yield, 0.099 g (83%). Orange 
needles were obtained by method B. 1H NMR (ppm) in DMSO-d6: 9.63 (d, H6′), 8.62 (d, H3′), 
8.53 (t, H4′), 8.09 (t, H5′), 7.38-7.51 (PhH). Anal. Calcd for C20H14Cl2N4Pt: C, 41.68; H, 2.45; 
N, 9.72. Found: C, 41.45; H, 2.37; N, 9.80. 
2.2.4.4 (MepyMe2t)PtCl2 (4). Method A resulted in a yellow powder; yield, 0.096 g 
(77%). X-ray quality crystals in the form of yellow needles were obtained by method B. 1H NMR 
(ppm) DMSO-d6: 9.35 (d, H6′), 8.26 (s, H3′), 7.85 (d, H5′), 2.74 (s, CH3), 2.57 (s, CH3), 2.53 (s, 
CH3). Anal. Calcd for C11H12Cl2N4Pt: C, 28.34; H, 2.59; N, 12.02. Found: C, 28.32; H, 2.58; N, 
11.82. 
2.2.4.5 (MepyPht)PtCl2 (5). The complex was obtained as a yellow powder by method 
A; yield, 0.095 g (68%). 1H NMR (ppm) in DMSO-d6: 10.15 (s, H6), 9.41 (d, H6′), 8.61 (s, H3′), 
7.91 (d, H5′), 8.65 (d, o-PhH), 7.84 (t, p-PhH), 7.70 (t, m-PhH), 2.59 (s, CH3). Anal. Calcd for 
C15H12Cl2N4Pt: C, 35.03; H, 2.35; N, 10.89. Found: C, 34.81; H, 2.31; N, 10.65. 
2.2.4.6 (MepyPh2t)PtCl2 (6). Method A resulted in a reddish-yellow precipitate; yield, 
0.112 g (79%). Method B produced yellow needles. 1H NMR (ppm) in DMSO-d6: 9.44 (d, H6′), 
8.49 (s, H3′), 7.93 (d, H5′), 7.75 (d, o-PhH), 7.45-7.63 (m, p-PhH), 2.58 (s, CH3). Anal. Calcd for 
C21H16Cl2N4Pt: C, 42.72; H, 2.73; N, 9.49. Found: C, 42.75, H, 2.58; N, 9.43. 
2.2.5 Synthesis of [L2Pt]X2 Salts 
cis-Pt(Me2SO)2Cl2 (0.042 g, 0.1 mmol) was added to a methanol solution of L (0.4 
mmol, 10 mL) and the resulting suspension became a solution when stirred at 60 °C for 24 h 
(Figure 2.2). The mixture was allowed to cool to room temperature. Any precipitate that formed 
was removed by filtration, and the clear filtrate was treated with a methanol solution of an excess 
of NaBF4 or NaPF6 to precipitate the [L2Pt]X2 salt. The solid was collected, washed twice with 
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methanol followed by anhydrous diethyl ether and allowed to dry in air. Yields of the [L2Pt]X2 
salts were 35-45%. The 1H NMR spectra and shifts for representative [L2Pt]X2 complexes appear 
in Supporting Information. 
2.2.5.1 [(pyPht)2Pt](PF6)2 (7). The method described above afforded a yellow solid upon 
addition of an excess of NaPF6; yield, 0.30 g (36%). The 1H NMR spectra of the BF4 and PF6 
salts were identical. Anal. Calcd for C28H20N8P2F12Pt: C, 35.27; H, 2.11; N, 11.75. Found: C, 
35.54; H, 1.89; N, 11.85. 
2.2.5.2 [(pyPh2t)2Pt](BF4)2 (8). Crystals were obtained by the general method described 
above, but by very careful dropwise addition of a methanol solution of NaBF4 (5 mmol) to the 
filtrate, until the solution first became cloudy. Thin, yellow, needle-shaped crystals were obtained 
by allowing the solution to stand undisturbed for 2 days.  
2.2.5.3 [(MepyPh2t)2Pt](PF6)2 (9). This product was obtained as a yellow solid in the 
same way as for (7); yield, 0.041 g (40%). The 1H NMR spectra of the BF4 and PF6 salts were 
identical.  Anal. Calcd for C42H32N8P2F12Pt: C, 44.49; H, 2.84; N, 9.88. Found: C, 44.58; H, 
2.68; N, 9.94. 
2.2.6 Reaction of ptt’s with Guo 
A 14 mM (1.63 mg) solution of (MepyMe2t)PtCl2 (4) in DMSO-d6 (250 µL) was treated 
with a Guo solution (1.98 mg, 15.5 mM in 450 µL of D2O) to give a 1:2 ratio (5 mM: 10 mM) of 
Pt:Guo, and the solution (pH ~4.6) was kept at 25 °C. The mixture of D2O and DMSO-d6 
solutions was used to improve the solubility of 4. The pH of the solution decreased with time and 
had to be adjusted to ∼4.6. The solution was monitored for six days until the 1H NMR signals of 
free Guo disappeared.  However, the reaction was repeated several times, and to decrease the 
time for the reaction to reach completion, an excess of Guo was often employed. A DMSO-d6 
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solution (250 µL) of [(MepyMe2t)2Pt](BF4)2 (2.69 mg, 14 mM) was treated with Guo (1.98 mg, 
15.5 mM) solution in D2O (450 µL) to give a 1:2 ratio of Pt:Guo, and the solution maintained at 
pH ~4.6 at 25 °C. The solution was monitored by 1H NMR spectroscopy, and no evidence of any 
reaction was found even after 36 h. 
2.2.7 X-ray Data Collection and Structure Determination  
Single crystals were placed in a cooled nitrogen gas stream at ~100 K on a Nonius Kappa 
CCD diffractometer fitted with an Oxford Cryostream cooler with graphite-monochromated Mo 
Kα (0.71073 Å) radiation. Data reduction included absorption corrections by the multi-scan 
method, with HKL SCALEPACK.30 
All X-ray structures were determined by direct methods and difference Fourier techniques 
and refined by full-matrix least squares, using SHELXL97.31  All non-hydrogen atoms were 
refined anisotropically. All H atoms were visible in difference maps, but were placed in idealized 
positions. A torsional parameter was refined for each methyl group. For all structures, maximum 
residual densities were located near the Pt positions. 
2.3 Results and Discussion 
2.3.1 X-ray Crystallography 
Structures of pseudo square-planar complexes reported here include LPtCl2 (L = pyMe2t, 
pyPht, pyPh2t), and [(pyPh2t)2Pt](BF4)2 (Tables 2.1 and 2.2; Figures 2.3 and 2.4). The atom 
numbering systems in these ORTEP figures are used to discuss the solid-state structures. A 
superscript i denotes the atoms of the other ligand in [L2Pt]X2 salts. When referring to the X-ray 
numbering system, the number will appear in parentheses, whereas for other purposes (e.g., 
NMR discussion) we shall use the general numbering system in Figure 2.1, and the number will 
not be enclosed in parentheses. Likewise, in some cases we shall designate the Pt-bound N’s as 
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N(t) and N(py), in the triazine and pyridine rings, respectively. The numbering scheme for 
bipyridines is given below in Figure 2.5. 
Table 2.1 Crystal Data and Structure Refinement for LPtCl2 (L = pyMe2t (1), pyPht (2), pyPh2t 
(3)) and [(pyPh2t)2Pt](BF4)2 (8) 
 (pyMe2t)PtCl2 (pyPht)PtCl2 (pyPh2t)PtCl2 [(pyPh2t)2Pt]
(BF4)2 
Empirical  formula C10H10Cl2N4Pt C14H10Cl2N4Pt C20H14Cl2N4P
t•CH3CN 
C40H28B2F8N8Pt    
•0.59H2O 
Fw 452.21 500.25 617.40 1000.00 
space group Pbca P21/c P21/c C2/c 
Unit cell dimensions 
a (Å) 7.3055 (10) 9.236 (5) 10.202 (2) 35.253 (5) 
b (Å) 17.923 (4) 7.496 (4) 7.4820 (10) 7.8417 (15) 
c (Å) 17.977 (4) 19.789 (13) 27.278 (7) 13.811 (3) 
β (°) 90 94.312 (18)  93.513 (7) 99.270 (7) 
V (Å3) 2353.8 (8) 1366.2 (14) 2078.3 (7) 3768.1 (12) 
T (K) 102 100 100 110 
Z 8 4 4 4 
ρcalc (mg/m3) 2.552 2.432 1.973 1.763 
abs coeff (mm-1) 12.356 10.658 7.029 3.809 
2θmax (°) 65.2 55.0 63.0 56.6 
R indicesa 0.029 0.062 0.034 0.033 
wR2 = [I> 2σ(I)]b 0.060 0.155 0.059 0.065 
data/param 4267/157 3085/190 6483/272 4639/275 
aR = (∑||Fο| - |Fc||)/∑|Fο|; bwR2 = [∑[w(Fο2 - Fc2)2]/∑[w(Fο2)2]]1/2, in which 
w = 1/[σ2(Fο2) + (0.0787P)2] and P = (Fο2 + 2Fc2)/3 
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Table 2.2 Selected Bond Distances (Å) and Angles (deg) for LPtCl2 (L = pyMe2t (1), pyPht (2), 
pyPh2t (3)) and [(pyPh2t)2Pt](BF4)2 (8) 
 (pyMe2t)PtCl2 (pyPht)PtCl2 (pyPh2t)PtCl2 [(pyPh2t)2Pt](BF4)2 
bond distances 
 
Pt–N(1) 2.001(3) 1.996(11) 1.996(3) 2.019(3) 
Pt–N(4) 2.020(3) 2.011(11) 2.027(3) 2.050(3) 
Pt–Cl(1) 2.2969(11) 2.304(4) 2.2920(10) Pt–N(4)i 2.050(3) 
Pt–Cl(2) 2.2899(10) 2.292(4) 2.2972(10) Pt–N(1)i 2.019(3) 
bond angles 
N(4)–Pt–N(1) 80.33(12) 79.8(4) 80.38(11)  78.68(13) 
N(1)–Pt–Cl(1) 174.83(9) 173.3(3) 174.90(8)  N(1)–Pt–N(1)i 180.0 
N(1)–Pt–Cl(2) 96.05(9) 96.2(3) 95.86(8)  N(1)–Pt–N(4)i 101.32(13) 
N(4)–Pt–Cl(1) 94.50(10) 93.8(3) 94.60(8)  N(4)–Pt–N(1)i 101.32(13) 
N(4)–Pt–Cl(2) 176.30(9) 176.0(3) 176.24(8)  N(4)–Pt–N(4)i 180.0 
Cl(2)–Pt–Cl(1) 89.13(3) 90.12(13) 89.16(3) N(4)i–Pt–N(1)i 78.68(13) 
C(5)–C(4)–C(3) 123.0(3) 124.7(13) 122.9(3) 123.1(4) 
N(4)–C(4)–C(3) 114.1(3) 113.6(12) 114.5(3) 114.4(3) 
N(3)–C(3)–C(4) 120.1(3) 119.4(12) 121.0(3) 120.6(3) 
N(1)–C(3)–C(4) 114.8(3) 114.2(11) 115.0(3) 114.6(3) 
 
In order to discuss structural features of the pyridyl triazine ligands, we shall use some of 
the terminology employed for the common symmetrical sp2 N-donor L’s, e.g. 2,2′-bipyridine 
(bipy) or phen ligands. The M−N distance for which there would be no in-plane distortion 
(Figure 2.5) has been estimated to be 2.72 Å.32 Hazell concluded that the stress in coordinated 
2,2′-bipyridines caused by the close proximity of the hydrogen atoms on the carbons ortho to the 
bridging atoms is reduced by the twisting of the pyridine rings about the bond bridging the two 
pyridine rings and by an in-plane bending (Figure 2.5).33 Likewise, in compounds such as 
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[(bipy)2Pt]2+ the M−N distance for which there would be no distortion of the overall 
coordination environment from planarity has been estimated to be 2.8 Å.34 Therefore, we begin 
our discussion of the structures with bond lengths and angles involving Pt.  
                  
 
Figure 2.3 ORTEP plots of (a) (pyMe2t)PtCl2 (1) and (b) (pyPht)PtCl2 (2). Thermal ellipsoids 
are drawn with 50% probability. 
     
 
Figure 2.4 ORTEP plots of (a) (pyPh2t)PtCl2 (3) and (b) [(pyPh2t)2Pt](BF4)2 (8). Thermal 
ellipsoids are drawn with 50% probability. 
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Figure 2.5 Distortions in bipyridyl ligands: (a) in-plane, (b) twist, and (c) bowing. 
 
2.3.1.1 Structures of LPtCl2 
• Coordination Parameters. The size of the group on the C(1) and C(2) positions 
has little effect on the coordinated bond distances and angles (Table 2.2). The Pt−Cl or Pt−N(py) 
bond distances found for 1, 2, and 3 are not significantly different from those in the structure of 
(4,4′-Me2bipy)PtCl2 (work in progress). All three LPtCl2 complexes and (4,4′-Me2bipy)PtCl2 
have comparable N–Pt–N bite angles. For 1 and 3, in which the Pt−N distances are more 
precisely determined, the Pt−N(py) bond (Pt−N(4)) is slightly longer than the Pt−N(t) bond 
(Pt−N(1)) (Table 2.2). We attribute this apparently slightly smaller Pt−N(t) bond to an attractive 
interaction of the positive Pt center with the lone pair on N(2), the triazine N bound to N(1). In 
contrast, the hydrogen on the C(8) atom of the pyridine ring (in the position corresponding to 
N(2)) will have a repulsive interaction with the positive Pt center. 
In 1, 2, and 3, the cis N(t)–Pt–Cl(2) angle is significantly larger than the cis N(py)–Pt–
Cl(1) angle. There is a slight attractive interaction between Cl’s cis to a pyridyl ring and the 
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nearby pyridine ring H atom (labeled A, Figure 2.6). The repulsion (labeled R, Figure 2.6) 
between the lone pair on N(2) and the cis Cl creates a larger than normal N–Pt–Cl angle. The 
apparent net effects of the non-bonding interactions involving the lone pair are a shorter Pt–N(t) 
bond and a wider cis N(t)–Pt–Cl angle. 
 
 
Figure 2.6 Attractive and repulsive interactions in LPtCl2 and (bipy)PtCl2. 
 
• Bidentate Ligand Parameters. Distortions in the ligand (Figure 2.5) will occur if 
the M−N distance is typical (~2.0 to 2.2 Å).33 Because the distances of the C3H and C3′H atoms 
of bipyridines (Figure 2.5) to the C3′ and H3′ atoms and the C3 and H3 atoms on the other ring, 
respectively, are less than the sum of the van der Waals radii,35 it has been suggested that the 
resulting repulsive interactions (labeled R, Figure 2.6) cause distortions.32,33 The difference in 
two exocyclic angles (C(5)–C(4)–C(3) and N(4)–C(4)–C(3), see Figure 2.4) of the pyridine ring 
can be used as a simple means for estimating the in-plane bending (Figure 2.5).33 The differences 
in these two angles for (4,4′-Me2bipy)PtCl2 are comparable to the differences for LPtCl2 
complexes (Table 2.2), although for LPtCl2 complexes the hydrogen on the pyridyl C ortho to the 
bridging carbons and the lone-pair-bearing triazine N(3) (in 3, Figure 2.4, the H(5) to N(3) 
distance = 2.630 Å, and the C(5) to N(3) distance = 2.900 Å) should create a slight favorable 
attractive interaction (labeled A, Figure 2.6). Therefore, any stress due to H3-H3′ repulsion in 
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(4,4′-Me2bipy)PtCl2 does not lead to an apparent substantial effect on the in-plane bending. 
However, this repulsion could account for the slight twisting or bowing in (4,4′-Me2bipy)PtCl2 
compared to the minimal distortions found for the three LPtCl2 complexes (Figure 2.7). 
 
 
Figure 2.7 In-plane views of the two rings in bipyPtCl2 (left) and LPtCl2 (right). 
 
2.3.1.2 Structure of [(pyPh2t)2Pt](BF4)2 (8) 
• Coordination Parameters. The ORTEP drawing for 8 appears in Figure 2.4. The Pt–
N(py) bond length (2.050(3) Å) in 8 is similar to the Pt–N(py) bond length (2.032(3) Å) in [(4,4′-
Me2bipy)2Pt](BF4)2 (work in progress), but it is significantly longer than the Pt–N(t) bond 
distance (2.019(3) Å) in 8 (Table 2.2). The reason for the shorter Pt–N(t) bond distance was 
suggested above. The N–Pt–N bite angle in 8 is similar to that in [(4,4′-Me2bipy)2Pt](BF4)2. 
These N–Pt–N bite angles are slightly smaller than those for LPtCl2 (Table 2.2). The Pt–N bond 
distances in 8 are larger than the corresponding bond distances in 3. 
• Relative Bidentate Ligand Relationships. The ligand distortion due to in-plane bending 
for [(pyPh2t)2Pt](BF4)2 (8) was less than that for [(4,4′-Me2bipy)2Pt](BF4)2 but comparable with 
those of LPtCl2 (Table 2.2). For bipyridine complexes with ~2 Å M–N distances, the strain 
induced by the close approach of the hydrogen atoms of opposing ligands can be reduced by two 
different types of distortions. First, a tetrahedral deformation at the metal can occur, resulting in 
the ligands being canted relative to each other (Figure 2.8). Second, the ligand rings can be 
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bowed away from the ring directly across (Figure 2.8).32,33,36 The opposing ligands in [(4,4′-
Me2bipy)2Pt](BF4)2 are bowlike distorted (Figure 2.9), while canting of the two ligands occurs in 
[(2,2′-bipy)2Pt](NO3)2.33 In contrast, for [(pyPh2t)2Pt](BF4)2 (8) the platinum lies on an 
inversion center, and the coordination geometry is totally planar and symmetrical (Figure 2.9).  In 
[(4,4′-Me2bipy)2Pt](BF4)2 the distances found between the H6 (H on the C ortho to the N, Figure 
2.5) and the opposing C6 of the other ligand are 2.557 and 2.597 Å. For [(pyPh2t)2Pt](BF4)2 (8), 
in contrast, the distance between the related pyridyl proton (H(8), Figure 2.4) and the opposing 
triazine non-bonded N(2) of the other ligand is 2.160 Å. The unusually small distance suggests a 
possibility of two weak favorable H⋅⋅⋅N interactions between the two opposing pyPh2t ligands of 
8. Thus, the metal center exhibits no distortion. 
 
 
Figure 2.8 Canting (a) and bowing (b) of the two bipyridyl ligands with respect to each other in 
[(bipy)2Pt]X2. 
 
 
 
Figure 2.9 Side view of [(bipy)2Pt]X2 (left) and [(pyt)2Pt]X2 (right). 
 34 
2.3.2 NMR Spectroscopy 
As mentioned, both the reaction of ferene with cis-Pt(Me2SO)2Cl2 and the resulting 
products are difficult to assess by 1H NMR spectroscopy because of many overlapping signals. 
Also, simpler 3-(pyridin-2′-yl)-1,2,4-triazines (L) analogues which form LPtCl2 and [L2Pt]2+ 
complexes with less complicated spectra have not been studied. Hence, we have investigated by 
1H NMR spectroscopy the formation and properties, such as degree of solvolysis, of these 
simpler ptt compounds. We use the standard numbering system for these L (Figure 2.1). 
Reactions of L (20 mM) with cis-Pt(Me2SO)2Cl2 (5 mM) in DMSO-d6 were monitored 
with time until no further changes were observed. The H6′ doublet was usually observed between 
~9.3 to 9.6 ppm within ~1 h of mixing. After ~1 day, a weaker doublet appeared farther 
downfield (~10.0 to 10.2 ppm). (These findings are consistent with the ferene results: H6′ 
doublet at ~9.6 ppm for [(ferene)PtCl2]2- and at ~10.7 ppm for [(ferene)2Pt]2-).13 Addition of 
[NEt4]Cl caused an increase in the intensity of the doublet between 9.3 and 9.6 ppm, and the 
disappearance of the more downfield doublet (~10 to 10.2 ppm), indicating that these are signals 
of LPtCl2 and [L2Pt]2+, respectively. 
For all L, [L2Pt]2+ did not form completely and was less abundant than LPtCl2 in DMSO-
d6, even with a threefold excess of L. In order to form bis product exclusively, D2O (10% by 
volume) was added to a separate solution of L and cis-Pt(Me2SO)2Cl2 (in a 4:1 ratio). After ~1 h 
the [L2Pt]2+ signals were the only bound L signals present. The greater solvation of the chloride 
ions in D2O compared to that in DMSO-d6 facilitates the formation of bis complexes. The 
reaction of pyMe2t with cis-Pt(Me2SO)2Cl2 described in the Supporting Information provides a 
detailed set of results that are representative of studies with other L. 
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2.3.2.1 [(MepyMe2t)Pt(Guo)2]2+ Characterization. Within 30 min of mixing 
(MepyMe2t)PtCl2 and Guo in a 1:2 molar ratio in a D2O/DMSO-d6 solution at pH = 4.60 at 25 
°C, the [(MepyMe2t)Pt(Guo)2]2+ adduct was formed. The adduct has H8 signals at ~8.7 to 8.9 
ppm, downfield from the free Guo H8 signal at 8.11 ppm, indicating that Guo is bound to Pt via 
N7. Two guanine base arrangements HH (Head-to-Head) and HT (Head-to-Tail) are possible for 
[LPt(Guo)2]2+ type adducts. Three rotamers (HH, ∆HT, ΛHT) may be observed when L = a 
symmetrical bidentate ligand, whereas four rotamers (HHa, HHb, ∆HT, ΛHT) are possible when 
L = an unsymmetrical bidentate ligand (Figure 2.10).  
 
Figure 2.10 Possible base orientations of two cis guanine bases coordinated to Pt. Each arrow 
represents a guanine base (bottom). The platinum carrier ligand is to the rear; when it is 
unsymmetrical (N1 ≠ N2), there are two HH conformers. Rotation of one base about the Pt–N7 
bond leads to another conformer, but in each case the base orientation changes from HT to HH 
and vice-versa. When the carrier ligand has unsymmetrical bulk, it is possible that on the NMR 
time scale the base next to the bulky side of the carrier ligand does not rotate quickly, whereas 
the other base rotates rapidly. For example, the ∆HT conformer would interchange rapidly with 
the HHa conformer if the base next to N1 rotated slowly while the base next to N2 rotated 
readily. In contrast, the ∆HT conformer would form the HHb conformer only slowly. 
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The symmetry of the carrier ligand influences not only the number of conformers but also 
the number of sets of Guo signals detectable for each [LPt(Guo)2]2+ rotamer. For a non-bulky L, 
rotation about the Pt–N7 Guo bond is very fast on the NMR time scale; the rapid equilibration of 
rotamers in this case leads to one set or two sets of Guo NMR signals for [LPt(Guo)2]2+ adducts 
with symmetrical and unsymmetrical L, respectively. Bulky carrier ligands restrict the rotation of 
Guo about the Pt–N7 bond sufficiently to allow detection of different rotamers by NMR 
spectroscopy.21,37-43 Because the Guo H8 signals are downfield, they can be particularly 
informative for assessing the nature and distribution of rotamers. For an [LPt(Guo)2]2+ adduct 
with an unsymmetrical L, the four rotamers should give two and eight H8 signals for rapidly and 
slowly exchanging conformers, respectively. 
For [(MepyMe2t)Pt(Guo)2]2+, three bound Guo H8 signals were present (Figure 2.11): 
two H8 signals of comparable intensity at 8.90 and 8.87 ppm (integrating to a total of one proton) 
and another larger H8 signal upfield at 8.75 ppm (integrating to a single proton). The observation 
of three H8 signals (not two for fast or eight for slow isomerization) suggests the occurrence of a 
complicated equilibration process between rotamers and/or an intermediate exchange rate. 
The most likely process accounting for the three signals is rapid rotation of a Guo in one 
of the coordination positions and slow rotation of the other Guo. This situation would give two 
pairs of HT and HH conformers that interchange within the pair but not between pairs. In this 
case, the presence of three H8 signals with one large (the upfield H8) signal requires an overlap 
of two of the four expected H8 signals. The upfield Guo H8 signal could not be resolved, even at 
-4.0 °C. However, when the pH was raised to 7.75, four distinct H8 peaks of comparable 
intensity were observed at 8.88, 8.86, 8.71 and 8.68 ppm (Figure 2.11). At this pH the N1H of 
coordinated Guo is deprotonated, resulting in greater dispersion of H8 signals, but less dispersion 
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for the H1' signals, which all overlap. However, at pH 4.60 there are two H1' signals.  One H1' 
signal (at 6.06 ppm, for one Guo) is one-third as large as the other, overlapped H1' signal (at 6.04 
ppm, for three Guo). Thus, results for both H8 and H1' signals at both pH’s support the presence 
of four different Guo’s in two sets of similarly abundant HT/HH pairs. 
 
 
Figure 2.11 Aromatic and H1′ signals of the 1H NMR spectrum of the [(MepyMe2t)Pt(Guo)2]2+ 
adduct in D2O/DMSO-d6 solution at pH 4.60 (top) and pH 7.75 (bottom) at 25 °C. Numbers are 
taken from the numbering system in Figure 2.1 for L and are shown in Figure 2.10 for Guo. 
 
Extensive studies in which both the symmetrical carrier ligand and the guanine derivative 
(G) were varied systematically indicate that, for a given adduct, the HT rotamers (in total) are 
favored over the HH rotamer(s) (in total).44 Although the reasons for this observation are not 
fully understood, the most compelling explanations are that base dipole-dipole alignment favors 
the HT over the HH arrangement of guanines and that clashes between the exocyclic O6 on each 
guanine in the HH arrangement disfavor the HH rotamer. When G is a GMP, additional 
 38 
complications arise, increasing the abundance of the HH form in some cases, but in general Guo 
adducts have a particularly low amount of the HH rotamer.21,41,43 In a previous study of 
[LPtG2]2+ adducts with an unsymmetrical L, 2-aminomethylpiperidine (pipen), four H8 signals 
were observed for each adduct,45,46 as found here. The results were interpreted as indicating that 
each pair of H8 signals arose from a rapidly interchanging pair of conformers, ∆HT/HHa and 
ΛHT/HHb (Figure 2.10), with the HT form dominating.  In the pipen case, the amino group 
allows rapid rotation of the cis G, whereas the piperidine ring hinders rotation of the cis G.45,46 
The properties of the [(MepyMe2t)Pt(Guo)2]2+ adduct at pH 7.75 were explored further 
by using 2D NMR spectroscopy. An additional equivalent of Guo was added to ensure that all 
the Pt compound was consumed prior to a ROESY experiment, which allows us to probe the 
exchange processes and the through-space interactions between Guo and the MepyMe2t ligand. 
Neither NOE nor EXSY cross-peaks were observed between the H8 signals.  An HH conformer 
would give an H8-H8 NOE cross-peak, and even for a rapid HT/HH equilibrium, a cross-peak 
would be found if either HT/HH pair had a significant amount of the HH conformer. The four 
[(MepyMe2t)Pt(Guo)2]2+ H8 signals thus reflect mainly the two HT conformers, ∆HT and ΛHT, 
present in a nearly 1:1 ratio. The H8 NMR signals of the HH conformer were not detectable, 
indicating a more rapid rate of rotation about the Pt–N7 bond for one Guo in 
[(MepyMe2t)Pt(Guo)2]2+, a result more similar to that found for (pipen)PtG2 adducts45,46 than 
for (5,5′-Me2bipy)PtG2 adducts21 and (Me2ppz)PtG2 adducts41 (Me2ppz = N,N′-
dimethylpiperazine).  
NOE cross-peaks in the [(MepyMe2t)Pt(Guo)2]2+ ROESY spectrum between the Guo H8 
at 8.86 ppm and the pyridyl H6′ doublet at 7.96 ppm and between the Guo H8 singlet at 8.88 
ppm and the pyridyl H6′ doublet at 7.94 ppm indicate that the two most downfield H8 signals 
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belong to the Guo bound cis to the pyridyl ring. The more upfield H8 signals, at 8.71 and 8.68 
ppm, belong to the Guo bound cis to the triazine ring. 
Compared to the signals of [(MepyMe2t)Pt(Me2SO-d6)Cl]+ in D2O/DMSO-d6 at pH 4.60, 
the H5′ (7.76 ppm) and H3′ (8.60 ppm) signals of the [(MepyMe2t)Pt(Guo)2]2+ adduct at pH 
4.60 shifted only slightly upfield and downfield, respectively. In contrast, the H6′ doublets at 
8.04 and at 8.00 ppm (integrating to a total of one proton) for this adduct were shifted upfield by 
~1.26 ppm from the H6′ signal at 9.28 ppm of [(MepyMe2t)Pt(Me2SO-d6)Cl]+. The anisotropy 
of the cis-coordinated guanine base is responsible for these large upfield shifts. These shifts and 
the H8-H6′ NOE cross-peaks leave no doubt that the guanine in the adduct is positioned very 
close to H6′. Two considerations [a) the pyridyl H6′ proton is known to hinder the rate of 
rotation about the Pt–N7 Guo bond,21 and b) two upfield-shifted H6′ signals are resolved for the 
[(MepyMe2t)Pt(Guo)2]2+ adduct] leave no doubt that the slowly rotating Guo is cis to the pyridyl 
ring and that the Guo cis to the triazine ring is in fast rotation. Otherwise, the H6′ doublets would 
probably be time averaged. 
2.4 Conclusions 
Regardless of the presence of various exocylic groups, 3-(2′-pyridyl)-1,2,4-triazine 
ligands are excellent bidentate sp2 N-donors and form both LPtCl2 and [L2Pt]2+ complexes. The 
juxtaposition of the pyridyl H6′ proton and the triazine lone pair of electrons in [L2Pt]X2 allows 
formation of a planar structure. Also, this juxtaposition favors the trans arrangement of the 
bidentate ligands in [L2Pt]X2.  The ligands prefer to bind via only the N2 of the triazine ring. No 
evidence was found for isomers having N4 coordinated to Pt. Very likely this result arises from 
the effect of the group ortho to the bound N. For a given bidentate ligand, the interactions 
between the juxtaposed groups on the two rings ortho to the bridging carbons and on the 
 40 
periphery of the bidentate ligand are favorable for 3-(2′-pyridyl)-1,2,4-triazine ligands but 
unfavorable for 2,2′-bipyridines. This favorable factor would be present if the triazine ring binds 
to metals via either N2 or N4. For N2 binding, the N1 lone pair is readily accommodated 
sterically, but the substituent on C5 would create steric clashes if metal binding were to occur via 
N4. Thus, the observation that only N2 binding was detected can be understood. When combined 
with the X-ray structural results, the H6′ NMR spectral shifts of the complexes containing the 
L’s examined here establish that the structures of virucidal ptt compounds containing ferene 
proposed earlier were correct.13 
The dynamic properties of the[(MepyMe2t)Pt(Guo)2]2+ adduct indicate that the lone pair 
on the non-bonded nitrogen, N1, of the triazine ring is not sterically demanding. This lone pair 
does not strongly impede the rotation of Guo about the Pt–N7 bond, whereas the equivalently 
placed CH group of the pyridyl ring does impede rotation. This behavior and the structural data 
all point to a lower overall steric effect of the N2-metal-bound triazine ring compared to the 
metal-bound pyridine ring. Dynamic behavior similar to that of the [(MepyMe2t)Pt(Guo)2]2+ 
adduct has been well documented previously only in the case of pipen complexes.45,46 
Our result that Guo did not add to [(MepyMe2t)2Pt]2+ suggests the possibility that the 
virucidal activity of the LPtCl2 and the [L2Pt]2+ ptt agents arises, respectively, from covalent and 
non-covalent (possibly intercalative nucleic acid interactions favored by [L2Pt]2+ planarity) 
binding to biomolecular targets. These results suggest that the relatively neglected 3-(2′-pyridyl)-
1,2,4-triazine ligands should be examined more widely in coordination chemistry. 
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CHAPTER 3. NEGLECTED BIDENTATE sp2 N-DONOR CARRIER LIGANDS WITH 
TRIAZINE NITROGEN LONE PAIRS. PLATINUM COMPLEXES RETROMODELING 
CISPLATIN GUANINE NUCLEOBASE-ADDUCTS* 
 
3.1 Introduction 
Cisplatin (cis-Pt(NH3)2Cl2) is one of the most widely used anticancer drugs.1,2 Cisplatin 
and its analogues, LPtX2 models (L = one bidentate or two cis-unidentate N-donor carrier 
ligands), interact with DNA by forming a 1,2-intrastrand N7–Pt–N7 crosslink between two 
adjacent guanines of d(GpG) sequences in DNA.1-6 The cross-links formed by cisplatin (and its 
analogues) have been investigated and identified from X-ray structures,1,3 NMR spectroscopy,1,3 
and enzyme digestion studies.2,3,5  
Within the cross-link adduct, hydrogen bonding between the NH3 ligands of the cis-
Pt(NH3)2 moiety and residues in or near the cross-link has been an important component of 
hypotheses concerning both the mode of stabilization of distorted DNA induced by drug 
binding.7-12 However, examination of an X-ray structure of an HMG-bound 16-oligomer13 and an 
X-ray/NMR-derived model of a duplex 9-oligomer,14 both of which contain an intrastrand 
cisplatin lesion, suggests that hydrogen-bonding interactions involving the NH3 ligands are weak 
or even nonexistent. If the NH3 ligands are replaced by L carrier ligands having sp3 N atoms 
bearing two or more alkyl groups, modeling with the 9-mer structure suggests that clashes will 
occur.14 These results on duplex models have led to the hypothesis that the small size of the NH 
group, not its hydrogen-bonding ability, facilitates the anticancer activity of Pt compounds 
bearing multiple NH groups.15  
A degree of uncertainty exists in defining the structure of duplexes bearing Pt drug 
lesions.15,16 Relatively few X-ray structures are available,13,15,17 and NMR characterization is  
____________________________________________________________________________ 
* Contents of this chapter are under review by American Chemical Society. 
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because the carrier ligands in cisplatin are not bulky enough to impede the rotation of N7-bound 
guanine about the Pt–N7 bond.16,18 Thus, cisplatin adducts with nucleic acids and their 
constituents exist as a fluxional mixture of conformers, making elucidation of the structures in 
the solution state difficult; this complication is termed the dynamic motion problem.14,16,18,19 
 
 
Figure 3.1. Line drawing and numbering scheme for 5,5′-dimethyl-2,2′-bipyridine (5,5′-
Me2bipy) (top), 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine) (MepyMe2t) (bottom 
left), and bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) (bottom right) ligands. 
 
 
 
Figure 3.2. Possible base orientations of two cis guanine bases coordinated to Pt. Each arrow 
represents the base with the H8 atom at its head. In all cases, two HT conformers are possible. 
Two HH conformers are possible when L (to the rear) is unsymmetrical (N′ ≠ N, e.g., as in 
MepyMe2t, N′ = pyridyl N and N = triazine N, see below), but only one HH conformer is 
possible when L is symmetrical (N′ = N). Each rotation of one base about the Pt–N7 bond leads 
to changes in the relative base orientation from HT to HH, or vice-versa. 
 46 
To overcome the dynamic motion problem, a retro-modeling approach can be used by 
introducing features in the carrier ligand to make the spectral properties more informative.14,19-22 
Retro models are essentially analogues of cisplatin with carrier ligands designed to reduce the 
dynamic motion by destabilizing the transition state for Pt–N7 rotation, but having bulk in or 
near the coordination plane, thereby allowing the coexistence of multiple conformers. In this 
study, we compare the LPt(GMP)2 adducts containing the L depicted in Figure 3.1. For an LPtG2 
adduct (G = guanine derivative not linked by a phosphodiester group), the G bases can have 
head-to-tail (HT) or head-to-head (HH) orientations (Figure 3.2). The untethered G’s normally 
adopt preferentially an HT orientation,16,23 whereas the bases in d(GpG) cross-links having a 
sugar phosphate backbone are found most often in the HH orientation, especially when a 5′ 
residue is present.6,19,24-31  
In order to gain a better understanding of a number of fundamental factors influencing 
properties of LPtG2 adducts, we must know the effect of the carrier-ligand interactions with the 
nucleic acid constituents (bases, sugars, etc.). These interactions, present in very small adducts, 
also occur in larger models, including duplexes. However, they can be more difficult to assess in 
the larger adducts, particularly because larger adducts manifest additional interactions involving 
both flanking residues in the cross-link strand and residues in the complementary strand. Retro 
models with sp3 N-donor ligands have been investigated more often16,19-21,32 than those with sp2 
N-donor heterocyclic chelating ligands.  
Studies of LPt(Guo)2 complexes (L = 2,9-dimethyl-1,10-phenanthroline,33 
MepyMe2t;34 Guo = guanosine) and (5,5′-Me2bipy)Pt(d(GpG))22 have demonstrated the 
coexistence of different rotamers exchanging slowly relative to the NMR time scale. In cisplatin 
intrastrand cross-linked DNA adducts, the dominant conformer appears to have the guanines in a 
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HH orientation.21 For most LPtG2 adducts, the HH conformers are minor conformers, when 
compared to the HT conformers, and are favored more in the 5′-GMP adduct than in the 
corresponding 3′-GMP adduct.19,20,30,31,35 When the L carrier ligand is unsymmetrical, two HH 
conformers are possible (Figure 3.2). However, in all previous work, even with the 5′-GMP 
adducts, it was not possible to assign the HHa and HHb conformers (Figure 3.2). The 
(MepyMe2t)Pt(5′-GMP)2 adduct studied here allowed, for the first time, the determination of the 
conformation of two such HH conformers.  
3.2 Experimental Section 
3.2.1 Starting Materials 
 
 
Figure 3.3 Synthesis of bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) ligands. 
 
5′-GMP, 3′-GMP (Sigma), and 5,5′-Me2bipy (Aldrich) were used as received. cis-
Pt(Me2SO)2Cl2 was prepared as described in the literature.36 The syntheses of (5,5′-
Me2bipy)PtCl2 and (MepyMe2t)PtCl2 are described elsewhere.22,34,37 Bis-3,3′-(5,6-dialkyl-1,2,4-
triazine) (R4dt, R = Me or Et) ligands were prepared by a known method38 (Figure 3.3). 
Elemental analyses (C,H,N) were performed by Atlantic Microlabs, Atlanta, GA. 
3.2.2 NMR Measurements 
1H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz. We used 
the values of 0.00, 4.78, and 4.98 ppm to reference signals to TMS in DMSO-d6 solutions at 25 
°C and to the residual HOD signal at 25 °C and 5 °C in D2O/DMSO-d6 solutions, respectively. A 
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presaturation pulse to suppress the water peak was used when necessary. 2D ROESY 
experiments39 were performed at 5 °C by using a 500 ms mixing time (128 scans per t1 
increment). ROESY and 1D NMR data, processed with XWINNMR or Mestre-C software, were 
used to assign signals and (along with CD data) to assess the conformation of the adducts under 
various pH conditions. DNO3 and NaOD solutions (0.1 M in D2O) were used to adjust the pH of 
D2O/DMSO-d6 solutions, especially during the reactions in which the pH decreased with time.  
3.2.3 Circular Dichroism (CD) Spectroscopy 
All samples used for CD experiments were prepared from the respective NMR samples 
by diluting to ~0.025 mM Pt with deionized water. Spectra were recorded from 400 to 200 nm at 
a scan speed of 50 nm/min on a JASCO J-600 CD spectropolarimeter. Six scans were recorded 
and averaged for each sample. 
3.2.4 Synthesis of (R4dt)PtCl2 Complexes 
The (R4dt)PtCl2 complexes were obtained as yellow precipitates upon heating a methanol 
solution (10 mL) of  cis-Pt(Me2SO)2Cl2 (42.2 mg, 0.1 mmol) and the desired R4dt ligand (0.1 
mmol) at 60 °C for 6 h. The precipitates were collected, washed with diethyl ether, followed by 
chloroform, and then dried in vacuo. 
3.2.4.1 (Me4dt)PtCl2. The method described above afforded a yellow precipitate; yield, 
26.5 mg (55%). 1H NMR (ppm) in DMSO-d6 : 2.62 (s, 5-CH3), 2.81 (s, 6-CH3). Anal. Calcd for 
C10H12Cl2N6Pt·1/3(H2O): C, 24.58; H, 2.59; N, 17.21. Found: C, 24.66; H, 2.69; N, 16.91. 
3.2.4.2 (Et4dt)PtCl2. The product was obtained as a yellow powder; yield, 36.1 mg 
(67%). 1H NMR (ppm) in DMSO-d6: 3.20 (quartet, 6-CH2), 2.96 (quartet, 5-CH2), 1.30-1.41 (m, 
5,6-CH3). X-ray quality crystals were obtained by mixing equal volumes of 10 mM solutions of 
cis-Pt(Me2SO)2Cl2 (8.44 mg, 10 mM) and the Et4dt ligand (5.44 mg) in 2 mL of acetonitrile and 
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allowing this solution to stand at 25 °C. Thin yellow needles of (Et4dt)PtCl2 were obtained in 
~25% yield after 24 h. The structure was determined by X-ray diffraction.  
3.2.5. Formation of LPt(GMP)2 (L = 5,5′-Me2bipy, MepyMe2t, Me4dt, Et4dt and GMP = 5′- 
and 3′-GMP) 
A typical preparation of LPt(GMP)2 involved mixing a solution containing ~2 equiv of 
GMP dissolved in 350 µL of D2O at pH ~4 and a solution containing 1 equiv (~5 mM) of LPtCl2 
complex in 250 µL of DMSO-d6 to give a 1:2 ratio of Pt:GMP, and the mixture (pH ~4) was kept 
at 25 °C. The mixture of D2O and DMSO-d6 solutions was employed to improve the solubility of 
the LPtCl2 complex. The solution was monitored by 1H NMR spectroscopy until no change in 
the bound vs. free H8 signal intensity was observed. The LPtCl2 complex in a D2O/DMSO-d6 
mixture forms a solvated complex that always remained in small amounts, along with some free 
GMP.   
3.3 Results and Discussion 
3.3.1 Conformational Assignments and Conformer Properties  
The asymmetry of the G ribose residue and the local symmetry of the LPt moiety 
influence the number of NMR signals that can be observed for each LPtG2 conformer. 1H NMR 
spectra in the ribose region are very crowded and complex, especially for adducts with 
unsymmetrical carrier ligands. The downfield G H8 signals, in a less crowded, more disperse 
region of the spectra, are particularly useful for assessing the nature and distribution of 
conformers (Figure 3.2). Because the G bears a chiral ribose moiety, LPtG2 adducts with C2-
symmetrical carrier ligands (e.g., Me4dt, Et4dt) have one HH and two HT (∆HT and ΛHT) 
NMR-distinguishable conformers (maximum total of four H8 signals), and models with 
unsymmetrical carrier ligands (e.g., MepyMe2t) have two HH (HHa and HHb) and two HT (∆HT 
and ΛHT) conformers (maximum total of eight H8 signals). The conformation and signal 
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assignments of the HH atropisomers are based on the presence of NOE cross-peaks between the 
two H8 signals. 
At pH 6-7 for LPt(GMP)2 adducts, the phosphate group is deprotonated and N1 is 
protonated,40,41 creating the possibility of H-bonding between the phosphate group and the imino 
hydrogen (N1H) of the cis GMP. This interligand interaction is called “second-to-second sphere 
communication” (SSC) because the interacting groups are at the periphery of the cis 
nucleotides.21,42,43 Such SSC interactions have been identified as important factors stabilizing the 
ΛHT and ∆HT conformers of the Pt adducts of 5′-GMP and 3′-GMP, respectively.35 The CD 
signal shape provides a definitive means for assigning the chirality of the major HT form of 
LPtG2 complexes when that form clearly dominates. A CD signal shape having a positive feature 
at ~290 nm and a negative feature at ~256 nm is characteristic of the ΛHT LPtG2 
conformer,21,31,32,42,44 whereas a CD signal shape having a negative feature at ~290 nm and a 
positive feature at ~256 nm is characteristic of the ∆HT conformer of LPtG2 adducts.31,32,42,45 
The CD signal of HH conformers is generally weak, a feature attributable to the inherent 
symmetry of the base chromophore, with the two bases having a pseudo mirror relationship in 
HH conformers. 
3.3.2 H8 Shifts and Base Canting 
In addition to the HH or HT G base orientation, G base canting is another significant 
structural parameter of LPtG2 conformers. A given base is generally not oriented with its plane 
exactly perpendicular to the coordination plane, but is canted. The canting can be either left-
handed (L) or right-handed (R) (Figure 3.4). Useful indications for assessing the degree of G 
base canting are provided by the G H8 signal shifts.14 The H8 shift is influenced by the 
positioning of the H8 atom with respect to the shielding cone of the cis G base. In an HT 
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arrangement, the canting may move the six-membered rings either closer to the midpoint 
between the N7 atoms (‘6-in’ form) or farther from this midpoint (‘6-out’ form). The canting of 
the bases in the direction (‘6-out’ form) that moves each H8 toward the cis G will lead to greater 
H8 shielding and, hence, an upfield H8 signal relative to the average H8 signal. The minor HT 
conformer typically is ‘6-out’. In contrast, the canting of the base that moves its H8 away from 
the cis G will lead to less H8 shielding or perhaps deshielding in the HT form26 and thus a more 
downfield H8 signal. The major HT conformer typically is ‘6-in’. 
 
 
Figure 3.4 Shorthand representation for left-handed (L) (a, c) and right-handed (R) (b, d) canting 
for LPtG2 adducts. In the ∆HT conformer shown (a, b), L and R canting have the six-membered 
ring far from the C2 axis for L canting (‘6-out’) and close to the axis for R canting (‘6-in’). For 
the ΛHT conformer (not shown), the arrows are all rotated by 180°. The HH conformer can be 
left-handed (c), right-handed (d) or not canted (e). 
 
For the HH orientation, one base is typically more canted, with its H8 toward the other cis 
base, which is less canted.19,30,31 The H8 atom of the more canted G is closest to the shielding 
region of the cis G and has a relatively upfield H8 signal (HHu). The H8 signal of the less canted 
base is relatively downfield (HHd) because this H8 is farthest from the cis G base shielding 
region and may be in the deshielding region of this base.31,43 Typically the HHu and HHd H8 
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signals are separated by ~1 ppm and straddle the HT H8 signals. In less common cases, the HH 
bases are not canted and the two signals are relatively downfield. 
3.3.3. (5,5′-Me2bipy)Pt(5′-GMP)2 
 
 
Figure 3.5 Aromatic region of 1H NMR spectra of (5,5′-Me2bipy)Pt(5′-GMP)2 (top) and (5,5′-
Me2bipy)Pt(3′-GMP)2 (bottom) at pH ~ 4.0 and 25 °C. The H8 signals for the conformers are 
designated by the conformation. (Pyridyl H6′ signals attributed to the solvated Pt complex are 
indicated by asterisks.)  
 
Four new H8 signals of the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct downfield from the free 
5′-GMP H8 signal at 8.22 ppm were observed at 25 °C (Figure 3.5). When the pH was raised 
from 4.0 to 7.5, the H8 signal at 8.81 ppm shifted slightly upfield by 0.02 ppm and became the 
most dominant signal. The CD signal shape observed for this adduct at pH 7.5 is characteristic of 
the ΛHT conformer (Figure 3.6). For the 5′-GMP adducts, the ΛHT conformer is more favored 
by SSC upon phosphate deprotonation;16 therefore, the dominant H8 signal of the (5,5′-
Me2bipy)Pt(5′-GMP)2 adduct was assigned to the ΛHT conformer. The intensity of the H8 
signals at 9.11 and 9.01 ppm (pH 4.0) remained comparable throughout the pH titration. These 
H8 signals shifted downfield by ~0.11-0.14 ppm when the pH was increased to 7.5. The two H8 
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signals were connected through an NOE cross-peak in a ROESY spectrum collected at 5 °C and 
were thus assigned to the HH conformer. The signal at 8.77 ppm was assigned to the ∆HT 
conformer, the only remaining possible conformer. The H8 chemical shifts at pH 4.0 and 7.5 are 
listed in Table 3.1. From pH 4.0 to 7.5, the distribution of the ΛHT, ∆HT and HH conformers 
changed from 42%, 29%, and 29% to 58%, 23%, and 18%, respectively.  
 
 
Figure 3.6 CD spectra of (5,5′-Me2bipy)Pt(5′-GMP)2 and (5,5′-Me2bipy)Pt(3′-GMP)2 at 25 °C. 
 
The H8 signals of the HH conformer of the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct have low 
dispersion (0.10 ppm) and both are relatively downfield when compared to the HT H8 signals. A 
similar unusual H8 shift pattern was reported for the HH conformer of the (Me2ppz)Pt(5′-GMP)2 
adduct (Me2ppz = N,N′-dimethylpiperazine) and was attributed to a low degree of base canting.21 
The H8 signals of the (5,5′-Me2bipy)Pt(5′-GMP)2 HH conformer have a downfield shift because 
the two bases have relatively little canting, and as a result H8 experiences less shielding by the 
cis G and possibly greater deshielding by the anisotropic Pt atom.35,46-48 For the (5,5′-
Me2bipy)Pt(5′-GMP)2 adduct, the H8 signal of the major ΛHT conformer is downfield to that of 
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the minor ∆HT conformer. In typical cases for the HT conformers, the ‘6-in’ form is favored.20,49 
The H8 signal of the ‘6-in’ form is downfield because the H8 atoms are positioned away from the 
cis base, while the H8 signal of the ‘6-out’ form is upfield because the H8 signals of the two 
bases are shielded by the cis base. For the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct, the major ΛHT 
conformer is the ‘6-in’ form, thus L canted, and the minor ∆HT conformer is the ‘6-out’ form 
with L canting (Figure 3.4).  
Table 3.1 Chemical Shifts of the H8 Signals of LPt(GMP)2 Adducts  (L = 5,5′-Me2bipy, Et4dt, 
Me4dt) at 5 °C a 
complex pH ∆HT ΛHT HHd HHu 
(5,5′-Me2bipy)Pt(5′-GMP)2b 4.0 8.77 8.81 9.11 9.01 
 7.5 8.72 8.79 9.25 9.12 
(5,5′-Me2bipy)Pt(3′-GMP)2b 4.0 8.88 8.76 c c 
 7.5 8.87 8.75 c c 
(Et4dt)Pt(5′-GMP)2 4.0 9.06 8.96 9.18 8.83 
 7.5 9.04 8.99 9.37 8.96 
(Et4dt)Pt(3′-GMP)2 4.0 9.01 8.87 c c 
 7.5 9.01 8.88 c c 
(Me4dt)Pt(5′-GMP)2 4.0 9.08 8.96 9.10 8.66 
 7.0 9.06 8.95 9.27 8.74 
(Me4dt)Pt(3′-GMP)2 4.0 8.85 8.83 c c 
 7.0 8.89 8.92 c c 
a
 Subscripted letters d and u are used to distinguish the downfield and the upfield H8 signals, 
respectively. Signal assignments are based on the 2D NMR and pH titration studies. b NMR 
spectrum recorded at 25 °C. c Signal not detected. 
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The absence of H8–H8 EXSY cross-peaks in the ROESY spectrum of (5,5′-
Me2bipy)Pt(5′-GMP)2 indicates that interconversion between the rotamers is slow. Rotation is 
probably impeded by the steric effect of the pyridyl H6/H6′ atoms of 5,5′-Me2bipy, which are the 
pyridyl ring atoms closest to the cis 5′-GMP’s, as evident from models and from the observation 
of H8–H6/H6′ NOE cross-peaks. During rotation, the G O6 clashes with the pyridyl ring C6H. A 
further indication of this proximity is the finding that the pyridyl H6/H6′ signals of the (5,5′-
Me2bipy)Pt(5′-GMP)2 adduct are shifted upfield by 1.0-1.4 ppm, when compared to the H6/H6′ 
signals (9.19 and 8.81 ppm) of the solvated Pt precursor. The anisotropy of the cis-coordinated G 
base is responsible for these large upfield shifts. A similar upfield shift was observed for the 
H6/H6′ signal of the [(MepyMe2t)Pt(Guo)2]2+ adduct34 and for the signals of the similarly 
positioned phenanthroline (phen) protons in the [(phen)Pt(Guo)2]2+ adduct.33  
3.3.4. (5,5′-Me2bipy)Pt(3′-GMP)2 
Two H8 signals downfield to the free 3′-GMP H8 signal at 8.11 ppm were observed at 25 
°C and were assigned to the HT conformers of the (5,5′-Me2bipy)Pt(3′-GMP)2 adduct (Table 3.1 
and Figure 3.5). From pH 4.0 to 7.5, the intensity of the H8 signal at 8.88 ppm increased, while 
that for the H8 signal at 8.76 ppm decreased. The CD signal shape at pH 7.5 was characteristic of 
the ∆HT conformer (Figure 3.6). For the 3′-GMP adducts, the ∆HT conformer is known to be 
stabilized by SSC upon phosphate deprotonation (pH ~7.0).19,32,35,45 Therefore, this major H8 
signal was assigned to the ∆HT conformer. The H8 signal at 8.76 ppm was assigned to the ΛHT 
conformer. From pH 4.0 to 7.5, the conformation distribution of the ∆HT and ΛHT conformers
 
changed from 73% and 27% to 80% and 20%, respectively. The H8 signal of the major ∆HT 
conformer is 0.17 ppm downfield from that of the minor ΛHT conformer. From this relationship, 
 56 
the ‘6-in’ major form is ∆HT R, and the ‘6-out’ minor form is ΛHT R (cf. Figure 3.4). Neither 
NOE nor EXSY cross-peaks were observed between the H8 signals of the (5,5′-Me2bipy)Pt(3′-
GMP)2 adduct. Strong H8–H6/H6′ NOE cross-peaks at 8.06, 8.88 ppm for the ∆HT conformer 
and at 7.79, 8.76 ppm were observed for the ΛHT conformer. Of particular note, the HH 
conformer was not detected for this adduct, even at 5 °C, thus reinforcing the general finding that 
the 5′-phosphate group stabilizes the HH conformer more than the 3′-phosphate group does.35,43 
When conformer interchange is slow, the HH conformer is usually found for LPt(3′-GMP)2 
adducts. For example, at pH 3.3 for the (Me2ppz)Pt(GMP)2 adducts, the amount of HH 
conformer observed for the 3′-GMP adduct was small (~8%), in comparison to ~24% HH 
conformer for the 5′-GMP adduct.21 The (5,5′-Me2bipy)Pt(3′-GMP)2 adduct, in fact, presents the 
first case in which no HH conformer is found for a 3′-GMP adduct with slowly interchanging 
rotamers. 
3.3.5. (MepyMe2t)Pt(5′-GMP)2 
Within two hours of mixing (MepyMe2t)PtCl2 with 5′-GMP in a 1:2 molar ratio at pH 
∼4.0 at 25 °C, four pairs of new H8 signals downfield from the free 5′-GMP H8 signal were 
present. As the pH was varied from 2.5 to 7.5, the H8 signals at 8.96 and 8.78 ppm became the 
most dominant signals (Figure 3.7). A CD signal shape characteristic of the ΛHT conformer was 
observed for (MepyMe2t)Pt(5′-GMP)2 at pH 7.5 and below (Figure 3.8). The CD signal intensity 
was stronger at pH 7.5 than at pH 2.5, consistent with the higher stability of the ΛHT conformer 
caused on phosphate deprotonation resulting from SSC.21,42,43 Thus, the larger H8 signals (at 8.96 
and 8.78 ppm at pH 2.5) were assigned to the ΛHT conformer. 
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Figure 3.7 Aromatic region of 1H NMR spectra of (MepyMe2t)Pt(5′-GMP)2 at pH 2.5 (bottom) 
and pH 7.5 (top) at 25 °C. The H8 signals for the conformers are designated by the conformation. 
(Pyridyl signals attributed to the solvated Pt complex are indicated by asterisks.) 
 
 
 
Figure 3.8 CD spectra of (MepyMe2t)Pt(5′-GMP)2 at pH 2.5 and pH 7.5 at 25 °C. 
 58 
 
 
Figure 3.9 ROESY spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct in the aromatic region at 
pH 2.5 and 25 °C. The cross-peak labeled as HHa is an NOE between the two H8 signals of the 
HHa conformer. The other labeled cross-peaks are EXSY peaks between the H8 signals of two 
different conformers.  
 
Table 3.2 Chemical Shifts of the H8 Signals of (MepyMe2t)Pt(GMP)2 Adducts at 25 °C a 
complex pH ∆HT ΛHT HHa HHb 
  ∆HTd 
(py) 
∆HTu 
(t) 
ΛHTd 
(py) 
ΛHT
u 
(t)
 
HHad 
(t)
 
HHau 
(py)
 
HHbd 
(t)
 
HHbu 
(py)
 
(MepyMe2t)Pt(5′-GMP)2 2.5 8.96 8.83 8.96 8.78 9.08 8.71 8.94 8.88 
 7.5 8.962 8.814 8.958 8.807 9.31 8.91 9.23  9.10 
(MepyMe2t)Pt(3′-GMP)2 4.5 8.95 8.84 8.89 8.74 b  b  
 7.5 8.89 8.81 8.89 8.74 b  b  
a The py and t notations designate G's cis to the pyridyl and triazine rings, respectively. 
Subscripted letters d and u are used for downfield and upfield H8 signals, respectively. Third 
decimal place subscripted numbers are used to distinguish signals with very similar chemical 
shifts. Signal assignments are based on the 2D NMR and pH titration studies. b Signal not 
detected. 
 
In a ROESY spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct at pH 2.5 (where the H8 
signals of this adduct were most widely dispersed), a weak NOE cross-peak present between the 
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two comparably sized H8 signals at 9.08 and 8.71 ppm establishes the HH conformation (Figure 
3.9 and Table 3.2). This HH conformer (assigned as HHa, see below) is the second most 
abundant conformer of the (MepyMe2t)Pt(5′-GMP)2 adduct. These two HH H8 signals are well 
dispersed and straddle the signals of the HT conformers, the usual H8 chemical shift 
pattern.19,30,31 The remaining two pairs of H8 signals must belong to the ∆HT and HHb 
conformers. However, because of the unusual properties of these conformers and the 
unsymmetrical nature of the carrier ligand, we turned to a pH study to make the assignment of 
conformation. 
From pH 2.5 to pH 7.5 the H8 signals for the (MepyMe2t)Pt(5′-GMP)2 HHa rotamer 
shifted significantly downfield by 0.23 and 0.20 ppm (Figure 3.7). Typically, a ca. 0.2 ppm 
downfield shift was observed for HH rotamers20,21 upon phosphate deprotonation; this effect may 
be explained by the “wrong-way shift” attributed to the higher deshielding effect of the 
deprotonated phosphate group as it is positioned in the HH conformer.20,50 However, the H8 
signals of the HT conformers do not shift significantly in the pH ~2-7 range.21,35,43 Consistent 
with this pattern, the H8 signals of the (MepyMe2t)Pt(5′-GMP)2 ΛHT conformer shifted very 
little (Table 3.2, Figure 3.7), whereas a ca. 0.2 ppm downfield shift occurred for the H8 signal of 
the HH conformer of the (R4dt)Pt(5′-GMP)2 adducts discussed below.  
One of the two pairs of H8 signals of the (MepyMe2t)Pt(5′-GMP)2 adduct (at 8.94 and 
8.88 ppm) not assigned above shifted downfield by more than 0.2 ppm from pH 2.5 to 7.5 (Table 
3.2, Figure 3.7); this pair is assigned to HHb. However, because of the low abundance of the 
HHb conformer, no H8 to H8 NOE cross-peak was observed in the ROESY spectrum for the 
(MepyMe2t)Pt(5′-GMP)2 adduct. The remaining pair of H8 signals shifted only slightly upfield 
(Table 3.2, Figure 3.7), consistent with an assignment to the only other possible conformer, ∆HT. 
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For the (MepyMe2t)Pt(5′-GMP)2 adduct, the H8 to pyridyl H6′ NOE cross-peaks can be 
used to determine which H8 signal belongs to the 5′-GMP cis to the pyridyl ring and by default 
which H8 signal belongs to the 5′-GMP cis to the triazine ring. Because the ∆HT and ΛHT 
conformers are assigned, the orientation of the G bases relative to these ligand rings is 
established for the HT conformers.  The pyridyl H6′ signals of the (MepyMe2t)Pt(5′-GMP)2 
adduct (overlapping at 8.0-8.1 ppm) have NOE cross-peaks to the downfield H8 signals of the 
ΛHT and ∆HT conformers (overlapping at 8.96 ppm) and to the upfield H8 signals of the HHa 
conformer (at 8.71 ppm) and the HHb conformer (at 8.88 ppm). These H8 signals are assigned to 
the 5′-GMP cis to the pyridyl ring.  
As can be seen from Figure 3.2, where N′ represents the pyridyl ring, the base next to this 
ring has an orientation with respect to the coordination plane that is the same in the ΛHT and 
HHa pair. Likewise, the orientation of this base is the same in the ∆HT and HHb pair. The 
rotation of the 5′-GMP cis to the pyridyl ring is expected to be slow; thus, conformer interchange 
involving such rotation will be too slow to generate detectable EXSY cross-peaks. (Slow 
interconversion between rotamers is depicted by short arrows in this figure.) Each HT conformer 
can exchange rapidly (depicted by long arrows) with only one HH conformer because only the 
base cis to the triazine ring can rotate rapidly. For example, the H8 signal of the G in the ∆HT 
rotamer cis to the triazine ring at 8.83 ppm has an EXSY cross-peak with the downfield H8 
signal of the HHb rotamer at 8.94 ppm; this H8 signal of the HHb rotamer belongs to the 5′-GMP 
cis to the triazine ring. Such EXSY cross-peaks between the H8 signals of the 5′-GMP cis to the 
triazine ring of the HH and HT rotamers were used for the unambiguous assignment of the HH 
conformers as HHa and HHb because the ∆HT and the ΛHT H8 signals of the 5′-GMP cis to the 
pyridyl ring overlap at 8.96 ppm.  
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We apply the foregoing reasoning to all four H8-H8 EXSY cross-peaks in the ROESY 
spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct at 25 C (Figure 3.9). The EXSY cross-peaks 
observed are between the H8 signals of the HHa and the ΛHT rotamers (9.08 and 8.78 ppm (cis 
to the triazine ring) and 8.71 and 8.96 ppm (cis to the pyridyl ring)) and between the H8 signals 
of the HHb and the ∆HT rotamers (8.94 and 8.83 ppm (cis to the triazine ring) and 8.88 and 8.96 
ppm (cis to the pyridyl ring)).  
For the (MepyMe2t)Pt(5′-GMP)2 adduct, as the pH was increased from 2.5 to 7.5, the 
population of the ΛHT, HHa, ∆HT, and HHb conformers changed from 40%, 30%, 20%, and 
10% to 65%, 10%, 20%, and 5%, respectively (Figure 3.7). For this
 
adduct, the combined 
abundance of the HT conformers is greater than the combined abundance of the HH conformers, 
a typical situation.49 It is also typical for the percentage of the HH conformers to decrease with 
increasing pH.20  
At pH 7.5 and below, the HHa conformer of (MepyMe2t)Pt(5′-GMP)2 is more abundant  
and has more H8 to H8 signal dispersion (0.37 ppm) than the HHb conformer (0.06 ppm). For 
HHa, the 5′-GMP cis to the pyridyl ring has the upfield shift so the base is canted with its H8 
atom projecting toward the shielding region of the 5′-GMP cis to the triazine ring. This 5′-GMP 
is either not canted or only slightly canted. Canting in the HHa conformer (Figure 3.2, where N′ 
represents the pyridyl ring) is right-handed (R). However, the small H8 signal dispersion for the 
HHb conformer of the (MepyMe2t)Pt(5′-GMP)2 adduct is associated with a low degree of 
canting,21,22 similar to that observed for the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct. The orientation 
of the two 5′-GMP bases in HHb may be nearly perpendicular to the Pt coordination plane or 
may be slightly canted. Alternatively, the two bases may be “wagging”, rapidly changing the 
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canting direction between the R- and L-canted orientations, leading to shift averaging and thereby 
accounting for the small HH H8 signal dispersion.  
3.3.6. (MepyMe2t)Pt(3′-GMP)2 
Qualitatively, for G derivatives the rate of rotation about the Pt–N7 bond increases in the 
order, 5′-GMP < 3′-GMP < Guo < 9-EtG (9-EtG = 9-ethylguanine).19,31,32,46,51 Previously we 
observed
 
only four H8 signals for  (MepyMe2t)Pt(Guo)2.34 We attributed this finding to fast 
interchange within each of the pairs (ΛHT, HHa and ∆HT, HHb), a process involving G base 
rotation for the Guo cis to the triazine ring (Figure 3.2). Also, rotation of the Guo cis to the 
pyridyl group was postulated to be a slow process, as now confirmed for the (MepyMe2t)Pt(5′-
GMP)2 adduct, which exhibited no interchange (no EXSY peaks) between the two pairs.  
 
 
Figure 3.10 Aromatic region of 1H NMR spectra of (MepyMe2t)Pt(3′-GMP)2 at pH 4.5 (bottom) 
and pH 7.5 (top) at 25 °C. The H8 signals for the conformers are designated by the conformation. 
 
Two pairs of H8 signals in a 2:1 ratio were observed for the (MepyMe2t)Pt(3′-GMP)2 
adduct at pH 4.5 and 25 °C (Figure 3.10). Neither NOE nor EXSY cross-peaks were observed 
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between these H8 signals; an NOE cross-peak is expected for an HH conformer. Therefore, even 
for a rapid HT/HH equilibrium, an NOE cross-peak would be found if either HT/HH pair had a 
significant amount of the HH conformer. The H8 NMR signals of the HH conformer were not 
detectable even at low temperature (0 °C), a result similar to that found for the (pipen)Pt(3′-
GMP)245 (pipen = 2-aminomethylpiperidine) and [(MepyMe2t)Pt(Guo)2]2+ adducts. Thus, the H8 
signals of the (MepyMe2t)Pt(3′-GMP)2 adduct arising from two sets of rapidly interchanging 
pairs of conformers, ∆HT/HHa and ΛHT/HHb, reflect primarily a dominant HT conformer, as 
discussed previously.34 The two pairs of HT and HH conformers interchange within the pair but 
not between pairs. The four H8 signals for the (MepyMe2t)Pt(3′-GMP)2 adduct thus reflect 
mainly the two HT conformers, ∆HT and ΛHT. From the order of rotation rates for the various G 
derivatives it was uncertain what pattern of behavior to expect, but now it is clear that 
(MepyMe2t)Pt(3′-GMP)2 has dynamic properties more similar to those of (MepyMe2t)Pt(Guo)2 
than to those of (MepyMe2t)Pt(5′-GMP)2.  
 
 
Figure 3.11 CD spectra of (MepyMe2t)Pt(3′-GMP)2 at pH 4.5 and 7.5 at 25 °C. 
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From 4.5 to 7.5, the more downfield of the two H8 signals of the major HT rotamer of 
(MepyMe2t)Pt(3′-GMP)2 (at 8.95 ppm) shifted slightly upfield, overlapping with the downfield 
H8 signal of the minor HT rotamer at 8.89 ppm (Table 2). The other H8 signals showed no 
significant shift until pH 7.5. As the pH was increased from 4.5 to 7.5, the major HT rotamer 
became the almost exclusively observed atropisomer (Figure 3.10). The CD spectra collected at 
pH 4.5 and 7.5 are characteristic of the ∆HT conformer (Figure 3.11). Therefore, at pH 4.5, the 
H8 signals at 8.95 and 8.84 ppm belonging to the major HT conformer are assigned to the ∆HT 
conformer stabilized by SSC, while the H8 signals at 8.89 and 8.74 ppm are assigned to the ΛHT 
conformer (minor). This previously reported downfield relationship of the H8 signal of the major 
HT conformer to the respective H8 signal of the minor HT conformer19,23,30,31,43 is consistent 
with the major ∆HT conformer being ‘6-in’ (R canting) and the minor ΛHT conformer being ‘6-
out’ (L canting). 
The properties of the (MepyMe2t)Pt(3′-GMP)2 adduct at pH 4.5 were explored further in 
ROESY  studies. From the NOE cross-peaks, the H8 signals belonging to the 3′-GMP cis to the 
pyridyl ring of the HT conformers of the (MepyMe2t)Pt(5′-GMP)2 adduct were also downfield 
compared to those of the 3′-GMP cis to the triazine ring. For the (MepyMe2t)Pt(3′-GMP)2 
adduct, the H6′ doublets of the ∆HT and ΛHT conformers (Supporting Information) were shifted 
upfield by 1.01 and 1.24 ppm from the H6′ signal of the solvated Pt complex at 9.26 ppm (Figure 
3.10); similar behavior was observed for the H6′ signal of (5,5′-Me2bipy)Pt(3′-GMP)2 adduct. 
These large H6′ upfield shifts can be attributed to the anisotropic effect of the cis coordinated 
base but cannot easily be correlated with the degree of canting.  
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3.3.7 (Et4dt)Pt(5′-GMP)2 
 
 
Figure 3.12 H8 region of the 1H NMR spectra of (Et4dt)Pt(5′-GMP)2 at 5 °C.  
 
Four new H8 signals of comparable intensities were observed within 24 h of mixing 1 
equiv of (Et4dt)PtCl2 with 2 equiv of 5′-GMP at 25 °C (Figure 3.12). Sharp 1H NMR signals 
were observed at 25 °C for the (Et4dt)Pt(5′-GMP)2 adduct at pH ~4; however, in order to 
compare the data with the (Me4dt)Pt(5′-GMP)2 adduct (Supporting Information), 1D 1H NMR 
spectra and a ROESY spectrum were collected at 5 °C.  At 25 °C, the full width at half 
maximum (fwhm) of the H8 signals for (Et4dt)Pt(5′-GMP)2 was 6 Hz for all three rotamers, as 
compared to the fwhm of the H8 signals of (Me4dt)Pt(5′-GMP)2 of 11 (∆HT), 10 (ΛHT), 12 
(HHd) and 11 (HHu) Hz. These H8 signals of the (Et4dt)Pt(5′-GMP)2 adduct at 25 °C were even 
sharper than those of the (Me4dt)Pt(5′-GMP)2 adduct at 5 °C, where all fwhm values were ~7 
Hz. These comparisons clearly indicate that the rotation rate about the Pt–N7 bond is 
considerably slower for (Et4dt)Pt(5′-GMP)2 than for (Me4dt)Pt(5′-GMP)2, probably because of 
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steric clashes between the 5′-GMP O6 and the methyl group of the 6,6′ ethyl groups of the Et4dt 
ligand in the (Et4dt)Pt(5′-GMP)2 adduct as the G base rotates (Figure 3.13). 
 
 
Figure 3.13 Greater steric clashes between substitutents at the 6,6′ position of the R4dt carrier 
ligand and the G O6 for the Et4dt adduct compared to the Me4dt adduct. 
 
 
 
Figure 3.14 CD spectra of (Et4dt)Pt(5′-GMP)2 and (Et4dt)Pt(3′-GMP)2 at 25 °C. 
 
When the pH of solutions containing (Et4dt)Pt(GMP)2 adducts was raised from ~4 to 7.5 
(above pH 7.5 the adduct decomposed, as evidenced by an increase in the intensity of the free 
GMP H8 signal), the H8 signal at 8.96 ppm shifted slightly downfield to 8.99 ppm and became 
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the most dominant signal (Figure 3.12); this peak was assigned to the ΛHT conformer because 
the CD signal shape observed for this solution is characteristic of the ΛHT conformation (Figure 
3.14).31,32,35,44,45 SSC interactions stabilize the ΛHT conformer of LPt(5′-GMP)2 adducts at or 
near neutral pH.35,42,43 At pH 4.0, an NOE cross-peak was observed between the two dispersed, 
comparably sized H8 signals at 9.18 and 8.83 ppm (Figure 3.15). These characteristics allow 
unambiguous assignment of these H8 signals to the HH rotamer. The H8 signals of the HH 
rotamer for the (Et4dt)Pt(5′-GMP)2 adduct at both high and low pH values were ~0.08-0.22 ppm 
more downfield than those for the (Me4dt)Pt(5′-GMP)2 adduct (Table 3.1). The remaining H8 
signal of the (Et4dt)Pt(5′-GMP)2 adduct at 9.06 ppm (pH 4.0) was assigned to the ∆HT rotamer. 
From pH 4.0-7.5, no significant shift was observed for the H8 signals of the HT rotamers; 
however, the HHd and the HHu signals shifted downfield by 0.19 and 0.13 ppm, respectively. 
In contrast to the typical H8 chemical shift pattern of the major and the minor HT 
conformers,19,23,30,31,43 the H8 signal of the major HT conformer (ΛHT) of the (Et4dt)Pt(5′-
GMP)2 adduct (at pH 7.5) is upfield to that of the minor HT conformer (∆HT). Because the H8 
signals of the HT conformers are relatively more downfield and the difference in the chemical 
shifts is small (0.10 ppm), it is not clear if this unusual HT H8 signal shift pattern is because of a 
relatively more upfield ΛHT H8 signal or a more downfield ∆HT H8 signal. The H8 signals of 
the HT conformers of the (Et4dt)Pt(5′-GMP)2 adduct are positioned between the two H8 signals 
of the HH conformer. Thus, the H8 shifts of the HT conformers are not particularly unusual. 
Because of the symmetrical nature of the carrier ligand in (Et4dt)Pt(5′-GMP)2, the bases in HT 
conformers may ‘wag’ between R and L canting, causing the H8 signals of the conformers to 
have similar shifts. The H8 chemical shift pattern (separation of 0.35 ppm) for the HH conformer 
of (Et4dt)Pt(5′-GMP)2 is similar to that of the HH conformer of (MepyMe2t)Pt(5′-GMP)2. The 
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moderately large H8 signal dispersion (0.35 ppm) for the (Et4dt)Pt(5′-GMP)2 HH conformer is 
attributable to different canting of the two bases.  
 
 
Figure 3.15 H8 region of the ROESY spectrum of (Et4dt)Pt(5′-GMP)2 at pH 4.0 and 5 °C. The 
cross-peak labeled as HH is an NOE between the H8 signals of an HH conformer. The other 
labeled cross-peaks are EXSY peaks between the H8 signals of different rotamers.  
 
Five EXSY cross-peaks were observed in a ROESY spectrum of (Et4dt)Pt(5′-GMP)2, 
collected at 5 °C (Figure 3.15). The two H8 signals of the HH rotamer have cross-peaks with the 
H8 signals of both the ΛHT and ∆HT rotamers. Also, a weak EXSY cross-peak was observed 
between the H8 signals of the ΛHT and the ∆HT rotamers. Because both 5′-GMP’s are cis to the 
sterically less impeding triazine rings, Pt–N7 rotation is fast enough for the H8 signals of the 
rotamers to have EXSY cross-peaks. In contrast, interchange between rotamers is slower in 
ligands containing a pyridyl moiety, as evidenced by the absence of any H8-H8 EXSY cross-
peaks for (5,5′-Me2bipy)Pt(5′-GMP)2. In addition H8-H8 cross-peaks between the ΛHT and the 
∆HT conformers were absent for the (MepyMe2t)Pt(5′-GMP)2 adduct. The broad NMR signals 
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observed at 25 °C for the (Me4dt)Pt(5′-GMP)2 adduct can be attributed to exchange between 
conformers and provide further evidence for facile interchange between rotamers in the 
(R4dt)Pt(5′-GMP)2 adducts. 
For the (Et4dt)Pt(5′-GMP)2 adduct, increasing the pH from 4.0 to 7.5 changed the 
distribution of the HH, ΛHT and ∆HT rotamers from 50%, 25% and 25% to 40%, 37% and 23%, 
respectively (Figure 3.12). For both (Et4dt)Pt(5′-GMP)2 (Figure 3.12) and (Me4dt)Pt(5′-GMP)2 
(Supporting Information) at pH 4.0, the two HT conformers are almost equally abundant, and the 
HH conformer has a relatively high abundance; these features are unusual when compared to the 
other LPt(5′-GMP)2 adducts, including the (5,5′-Me2bipy)Pt(5′-GMP)2 and (MepyMe2t)Pt(5′-
GMP)2 adducts studied here. This larger abundance of the HH conformer of the (R4dt)Pt(5′-
GMP)2 adducts is attributable to the overall low steric effects of the R4dt (R = Me and Et) 
ligand.  
The chemical shift of the H8 signals and the HH rotamer abundance in (Et4dt)Pt(5′-
GMP)2, when compared to values for (Me4dt)Pt(5′-GMP)2 (Supporting Information), suggest 
some interaction between the ethyl groups of Et4dt and the bound 5′-GMP’s. As mentioned 
above, the 6,6′ ethyl groups impede G base rotation. However, at pH 4 the 50% abundance of the 
HH rotamer for the (Et4dt)Pt(5′-GMP)2 adduct was slightly higher than the 40% abundance 
observed for the (Me4dt)Pt(5′-GMP)2 HH rotamer. Thus, the greater bulk of Et vs. Me is 
reflected primarily in the G base rotation rate.    
 3.3.8 (Et4dt)Pt(3′-GMP)2 
The two H8 signals observed in a 2:1 ratio for the (Et4dt)Pt(3′-GMP)2 adduct (Figure 
3.16) did not shift when the pH was raised from 4.0 to 7.5. However, the signal at 9.01 ppm 
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became the dominant H8 signal. The CD signal shape at pH 7.5 (Figure 3.14) is characteristic of 
the ∆HT conformation.31,32,42,45 Thus, the 9.01 ppm signal was assigned to the ∆HT conformer, 
the conformer stabilized by SSC on phosphate deprotonation for 3′-GMP adducts.35,42,43 The 
other H8 signal (at 8.87 ppm) is assigned to the ΛHT conformer. The conformer distributions 
(respective amounts of ∆HT and ΛHT = 67% and 33% at pH 4.0 and 75% and 25% at pH 7)
 
are 
comparable with those for (Me4dt)Pt(3′-GMP)2 (Supporting Information).  
 
 
Figure 3.16. H8 region of the 1H NMR spectra of (Et4dt)Pt(3′-GMP)2 at 5 °C.  
 
The HH conformer was not detected for either (R4dt)Pt(3′-GMP)2 adduct. The dispersion 
of the two H8 signals of the (Et4dt)Pt(3′-GMP)2 adduct (Table 3.1) was sufficient for us to 
resolve an EXSY cross-peak between these H8 signals. The cross-peak confirms that the two 
observable HT signals are mainly from rapidly interchanging ∆HT and ΛHT conformers; 
interchange undoubtedly proceeds via the HH conformer (Figure 3.2). The same exchange 
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process obviously occurs for the (Me4dt)Pt(3′-GMP)2 adduct, but the H8 signals are not 
separated well enough for us to detect the EXSY cross-peak (Supporting Information). 
3.4 Conclusions 
  The bulk of the bidentate sp2 N-donor ligands is sufficient to impede the rotation of the 
GMP’s about the Pt–N7 bonds of the LPt(GMP)2 adducts; thus, H8 signals for conformers could 
be resolved and assigned. From NMR data (including EXSY results), the qualitative rates of 
conformer interconversion follow the order, Me4dt > Et4dt > MepyMe2t > 5,5′-Me2bipy. Thus, 
we conclude that the pyridyl H6′ atom strongly impedes the rotation of the cis G base about the 
Pt–N7 bond by clashing with G O6, whereas the equivalently placed lone pair of the relevant 
non-bonded N of the triazine does not so strongly impede G rotation. Thus, the triazine ring has a 
lower overall steric effect than the pyridyl ring.  The intermediate properties of MepyMe2t, with 
one triazine and one pyridyl ring led to EXSY data for the (MepyMe2t)Pt(5′-GMP)2 adduct that 
allowed us to unambiguously determine and assign the conformation of the two HH conformers, 
HHa and HHb.  
The nature of both the GMP and the carrier ligand in LPtG2 adducts influences the 
distribution of conformers and their characteristics. The LPtG2 adducts studied here have a 
higher abundance of the HH conformer when G = 5′-GMP’s than when G = 3′-GMP’s, 
supporting the general finding that the 5′-phosphate group stabilizes the HH conformer.35,43 
Typically, one HT conformer dominates over the other HT and the HH conformer at low pH 
(~4), especially at neutral pH. We have discovered that carrier ligands of the type, R4dt, lead to 
the HH having almost comparable abundance to the total of the two HT conformers for the 
(R4dt)Pt(5′-GMP)2 adduct at equilibrium at pH 4. We conclude that the sterically less demanding 
nature of the R4dt ligand allows ample space for the HH conformer to exist with less significant 
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clashes between the O6 atoms of the 5′-GMP’s. Normally, second-sphere communication raises 
the abundance of one HT conformer as the pH is raised to near neutrality. This trend was found 
for the (R4dt)Pt(5′-GMP)2 adducts. However, the abundance of the HH isomer remains high. 
Given the finding that carrier ligands favoring the HH conformer in the cross-link are associated 
with anticancer activity,16 Pt complexes of R4dt ligand should be tested for activity. 
In previous studies of LPt(5′-GMP)2 complexes, the CD and NMR spectroscopic data 
indicate that the ΛHT atropisomer predominates in solution at neutral pH.19,21,35,42,44,45 The 
distribution of conformers for the (5,5′-Me2bipy)Pt(5′-GMP)2 and (MepyMe2t)Pt(5′-GMP)2 
adducts agrees with the results for other LPt(5′-GMP)2 adducts. However, the two HT 
conformers of the (R4dt)Pt(5′-GMP)2 (R = Me or Et) adducts are unusual in having an 
approximately equal abundance at low pH and in having an H8 signal for the minor HT form 
(∆HT) downfield to that of the major HT form (ΛHT) near physiological pH. At this time the 
reason for these differences is not apparent, and additional studies are in progress in order to 
understand the unique features of (R4dt)PtG2 complexes. However, because R4dt ligands are 
sterically less demanding when compared to other sp2 N-donor ligands, it is possible that steric 
factors may limit the abundance of the minor HT conformer for LPt(GMP)2 adducts for other L. 
Nevertheless, we have made the surprising observation that placing greater bulk at the 6,6′ 
positions by changing R in R4dt from Me to Et has a clear effect on the G base rotation rate 
about Pt–N7 bond. We attribute this effect to clashes between the G O6 and the methyl group of 
the 6,6′ ethyl groups (Figure 3.13). 
Finally, our results indicate that adduct formation between LPtCl2 (L = 5,5′-Me2bipy and 
MepyMe2t) and 5′- and 3′-GMP does not go to completion, and residual solvated Pt complexes 
exist at equilibrium. Because the solutions contain DMSO, this solvent both complicates the 
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identification of the solvato species and probably is responsible for incomplete adduct formation. 
However, this situation presents a rare opportunity to compare the relative binding affinity of 3′-
GMP vs. 5′-GMP toward Pt(II) in cis bis adducts. The ratio of LPt(3′-GMP)2 : solvated Pt 
complex was 46:1 for L = 5,5′-Me2bipy and 38:1 for L = MepyMe2t, but the ratio of LPt(5′-
GMP)2 : solvated Pt complex was only 5:1 for L = 5,5′-Me2bipy and only 4:1 for L = 
MepyMe2t. This greater stability of LPt(3′-GMP)2 compared to LPt(5′-GMP)2 parallels the 
results observed for the fac-[Re(CO)3(H2O)(3′-GMP)2]- and fac-[Re(CO)3(H2O)(5′-GMP)2]- 
adducts.52 This difference in the binding propensity of 3′-GMP vs. 5′-GMP is very unlikely to be 
due to electronic effects because N7 should have very similar donor ability for both 3′-GMP and 
5′-GMP. Rather, the difference more likely arises from SSC effects involving the positioning of 
the phosphate groups. Perhaps the 3′-phosphate group is better positioned to form stabilizing H-
bonds with N1H of the cis 3′-GMP than is the 5′-phosphate group. Such stabilization of an HT 
conformer could also explain the generally observed low abundance of the HH conformer of 
LPt(3′-GMP)2 adducts.  The (5,5′-Me2bipy)Pt(3′-GMP)2 adduct studied presents an unusual 
case, in which no HH conformer was detected by using high-field NMR spectroscopy for a 3′-
GMP adduct that has rotamers interchanging relatively slowly on the NMR time scale. 
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CHAPTER 4. USE OF NEGLECTED BIS(TRIAZINE)-TYPE LIGANDS TO ASSESS 
COMPARATIVE CARRIER-LIGAND EFFECTS RELATIVE TO THE LIGANDS IN 
CLINICALLY USED Pt ANTICANCER DRUGS: d(GpG) AND OLIGONUCLEOTIDES 
CONTAINING THE N7–Pt–N7 CROSS-LINK 
 
4.1 Introduction 
Cisplatin (cis-Pt(NH3)2Cl2) and related analogues continue to enjoy expanding clinical 
use in the fight against cancer, even though the original discovery was made many years ago.1-8 
Although analogues of the type LPtX2 (L = one bidentate or two cis-unidentate N-donor ligands, 
X2 = anionic leaving ligands) are generally less active,2,5,9-12 there is evidence that the carrier 
ligand can modulate the anticancer and mutagenic properties. Oxaliplatin [(1R,2R-
diaminocyclohexane)oxalatoplatinum(II)] is a third generation Pt based anticancer agent that 
forms the same kind of intra- and interstrand DNA cross-links as cisplatin13-16 and has activity 
against some cisplatin-resistant tumor cells.13,17 An intrastrand DNA cross-link with Pt linking 
N7’s of adjacent guanines of DNA, Pt(d(G*pG*))  (G* = N7-platinated G linked by a 
phosphodiester backbone), is thought to be the critical lesion accounting for activity.5,15,18-23 The 
guanine base G* residues in such cross-links are generally accepted to have a head-to-head (HH) 
orientation, with the two G* residues maintaining the anti conformation characteristic of B-
DNA;24-32 this HH conformation is designated as HH1 (Figure 4.1). Virtually all reports on both 
single-stranded and duplex adducts indicate that the HH1 conformer predominates.27,30,33-35 
An implicit assumption in drug design is that the HH conformers are relevant to 
activity.36 It is hypothesized that the cisplatin anticancer activity involves specific recognition of 
kinked DNA adducts by proteins with an HMG domain.12,37-42 Tight binding to the HMG-
containing protein may be required for such recognition, which by inhibiting repair, leads to cell 
death. The most favorable protein-DNA contacts may require this HH1 conformation, and, 
indeed, even variations in the flanking sequence influence protein binding.41 However, carrier 
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ligands that favor a non-HH1 conformation for the cross-link could form DNA adducts with this 
different conformation (Figure 4.1). Such cross-link adducts might bind the HMG proteins less 
strongly, and thus may be readily repaired (repair diminishes activity).36,43 On the basis of this 
HMG protection mechanism, we hypothesize that understanding those factors that favor HH1 
over other conformers is important for designing new anticancer drugs. In turn, if we can force 
unusual conformations onto the cross-link, such conformers may be useful 'tools' for probing the 
mechanism of action, which has still not been fully elucidated. 
 
 
Figure 4.1. The possible base orientations (head-to-head, HH and head-to-tail, HT) of two G* 
bases coordinated to cis positions on Pt. The large arrows represent the G* base, with the 
arrowhead denoting the G* H8 (shown below the scheme). The small curved arrows connecting 
the G* base arrows indicate the direction of propagation of the sugar-phosphodiester backbone. 
G* coordination sites are forward, and the carrier ligand (not shown except for N-donor atoms) is 
to the rear. The four recognized conformers are shown. Interconversion between these 
conformers requires base rotation about the Pt–N7(G*) bond. Slow isomerization from the two 
HH conformers to the ΛHT conformer is depicted by short counter-parallel arrows.  
 
In simple LPtG2 adducts (boldface G indicates a guanine derivative not linked to another 
nucleoside by a phosphodiester group), the bases favor the head-to-tail (HT) arrangement,44,45 
whereas the adducts with single-stranded d(G*pG*) cross-links are thought to favor the HH1 
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conformation.32,33,46-48 In the absence of an X-ray structure, the observation of only one set of 1H 
NMR signals33,46 for the simplest cross-link adduct, cis-Pt(NH3)2(d(G*pG*)) has been taken to 
imply that the presence of the backbone favors the HH base arrangement over the otherwise 
favored HT arrangement.33,43,46,47,49-52 We believe that the observation of only one set of 1H 
NMR signals for the cis-Pt(NH3)2(d(G*pG*)) adduct is best attributed to dynamic interchange 
between multiple conformers. Because of these conflicting interpretations, the cis-
Pt(NH3)2(d(G*pG*)) model of the cisplatin-DNA intrastrand adduct is said to suffer from the 
‘dynamic motion problem'.23,43,44,50,53,54  
To overcome this dynamic motion problem, a retro-modeling approach has been 
employed. In this approach, the carrier ligands are designed to reduce the dynamic motion by a 
billion-fold compared to cis-Pt(NH3)2 adducts, thereby permitting the coexistence of multiple 
conformers and leading to more informative spectral properties.23,36,55-57 The study of the reaction 
of chiral enantiomers of [BipPt(H2O)2]2+ (Bip = 2,2′-bipiperidine) with d(GpG) provided the first 
definitive evidence for the existence of LPt(d(G*pG*)) non-HH1 conformers.43,50 For (S,R,R,S)-
BipPt(d(G*pG*)), conformers of comparable stability, HH1 and HH2, were found (the 2 
indicates that the direction of propagation of the sugar-phosphodiester backbone is opposite to 
that in B-DNA, Figure 4.1);50 these conformers are designated as HH1 R and HH2 R to indicate 
that the canting is right-handed for both HH conformers. For (R,S,S,R)-BipPt(d(G*pG*)), the 
HH1 L conformer and the ∆HT conformer (with an anti-5′-G* and a syn-3′-G*, Figure 4.1) were 
abundant.43 After the initial discovery of these conformers, retro-models with the N,N′-
dimethylpiperazine (Me2ppz)58 and 5,5′-dimethyl bipyridine (5,5′-Me2bipy)23 ligands allowed 
the simultaneous detection of both the HH2 and the ∆HT conformers, in addition to the well-
known HH1 conformer. 
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The antiparallel alignment of the base dipole and the minimal O6 clash of the two G 
bases favor the HT over the HH arrangement. To observe the conformers in solution, the carrier 
ligand must be made bulky. In early work, no HH conformer was found when the carrier ligand 
had two sp3 N's and no NH groups.59,60 Later, less bulky ligands of the type used in the 
retromodeling approach, but with one hydrogen on each of the two sp3 N's, revealed that the HH 
form could be observed.45,55,56,61-63 With such models, it was found that the nature of the G 
derivative influenced the distribution. The percentage of HH conformer generally increases along 
the series, Guo < 3'-GMP < 5'-GMP. The reason for this order is not totally clear, but it was 
found that the phosphate groups of one G interacted with the base of the other G in the cis 
position. This interaction favors a particular HT chirality and may be stronger in 3'-GMP than in 
5'-GMP. If such is the case, the higher abundance of the HH conformer in 5'-GMP adducts is 
explained.58,62,64  
 
 
Figure 4.2. Numbering scheme for 5,5′-dimethyl bipyridine (5,5′-Me2bipy) and bis-3,3′-(5,6-
disubstituted-1,2,4-triazine) (R4dt) ligands. 
 
The abundance for the HT conformers was similar for some LPtG2 adducts having in-
plane ligand bulk (L = 5,5′-Me2bipy and 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-
triazine)).65 However, we have discovered that carrier ligands of the type, bis-3,3′-(5,6-dialkyl-
1,2,4-triazine) (R4dt, Figure 4.2), led to almost comparable abundance of HH and HT 
conformers for the (R4dt)Pt(5′-GMP)2 adduct.65 The overall low steric effects of the R4dt ligand, 
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with two N + N lone pair groupings, allow enough space for the HH conformer to exist without 
significant clashes between the O6 atoms of the 5′-GMP’s.65 The R4dt ligand is unique in that it 
has the in-plane bulk needed to reduce the Pt–N7(G) rotation, but at the same time it is sterically 
less demanding, enough to allow a high abundance of the HH conformer. Given the finding that 
carrier ligands favoring the HH conformer in the cross-link are associated with anticancer 
activity,44 we evaluate here the (R4dt)Pt(d(G*pG*)) adduct for the distribution and the 
characteristics of its conformers.  
Earlier studies with the LPt(d(G*pG*)) adduct having L = the sp2 N-donor 5,5′-Me2bipy 
achiral carrier ligand was particularly informative. The 5,5′-Me2bipy H6/H6′ protons (Figure 
4.2), which project toward the cis G*, were used as probes to elucidate conformer structures.23 
We have now investigated (R4dt)Pt(d(G*pG*)) (R4dt = Me4dt, Et4dt) (Figure 4.2) adducts 
containing another sp2 N-donor achiral carrier ligand. This ligand has in-plane bulk that is 
expected to destabilize the transition state for rotation about both Pt–N7(G*) bonds and thus 
eliminate the dynamic motion problem. Nevertheless, the presence of the sterically less 
demanding lone pairs on the N1/N1′ atoms in R4dt (positioned in the same location as the 
H6/H6′ protons of 5,5′-Me2bipy, Figure 4.2) pointing toward the 5′-G* and the 3′-G* alters the 
steric properties.  
We begin with our results on (R4dt)Pt(d(G*pG*)) adducts, followed by the 
(R4dt)Pt(oligo) adducts (oligo = GGT, TGG, TGGT), in which 5′- and 3′-flanking residues are 
introduced. The flanking residues can be viewed as substituents on the Pt(d(G*pG*)) chelate 
ring. The oligos examined have T residues because GGT and TGG are a part of the repetitive 
sequence found in telomeres, a potential cisplatin single-strand (ss) DNA target,66,67 and also 
because T residues were used in the (Me2ppz)Pt(oligo) studies.68 Comparison of results obtained 
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for (R4dt)Pt(oligo) with (Me2ppz)Pt(oligo)68 will allow us to understand the effect of carrier 
ligands on conformer distribution and their characteristics. A comparative study for 
LPt(d(G*pG*)) and LPt(oligo) is presented here for the first time for L = sp2 N-donor carrier 
ligand to assess the effect of a flanking residue on the conformer distribution in DNA cross-link 
adducts. 
4.2 Experimental Section 
4.2.1 Starting Materials 
2′-Deoxyguanyl(3′→5′)-2′-deoxyguanosine (d(GpG)) from Sigma was used as received. 
Bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) ligands (Figure 4.2) were synthesized by a known 
method.69 (Me4dt)PtCl2 (Me4dt = bis-3,3′-(5,6-dimethyl-1,2,4-triazine)) and (Et4dt)PtCl2 (Et4dt 
= bis-3,3′-(5,6-diethyl-1,2,4-triazine)) were prepared as described elsewhere.65 d(TGG), d(GGT), 
and d(TGGT) oligonucleotides, obtained from the Microchemical Facility at Emory University, 
were purified by ÄKTA FPLC (Amersham Biosciences). Failure sequences were removed by 
using ion exchange chromatography on an Amersham Biosciences Mono Q HR 10/10 anion 
exchange FPLC column (A = 2 M NaCl, B = H2O, 0-50% A over ~50 min). Collected fractions 
were desalted on an Amersham Biosciences HiTrap desalting FPLC column (A = H2O, 3.5 
mL/min for 20 min), taken to dryness by rotary evaporation, and then dissolved in ~0.5-1.0 mL 
of D2O.  
4.2.2 Reaction of (R4dt)PtCl2 with d(GpG) 
A 5 mM and a 7 mM solution containing an equimolar ratio of Pt:d(GpG) were prepared 
by mixing a DMSO-d6 solution of (Me4dt)PtCl2 (1.32 mg, 200 µL) and (Et4dt)PtCl2 (2.07 mg, 
400 µL), respectively, with a D2O solution of d(GpG) (1.70 mg, 350 µL and 2.38 mg, 150 µL, 
respectively). Because of low solubility of (R4dt)PtCl2 in D2O, the reaction was carried out in a 
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mixture of D2O and DMSO-d6 (64:36 by volume when R = Me and 27:73 by volume when R = 
Et). The solutions were maintained at pH 4.0 and 5° C and carefully monitored for two days by 
1H NMR spectroscopy until no free d(GpG) signals were observed. For comparison, 275 µL of 
the (Et4dt)Pt(d(G*pG*)) solution was diluted with 275 µL of D2O, to obtain a 64:36 ratio of D2O 
and DMSO-d6, the same ratio as that used for (Me4dt)Pt(d(GpG)). The final concentration of Pt 
in the (Et4dt)Pt(d(GpG)) solution was 3.5 mM. The (R4dt)Pt(d(GpG)) solutions were monitored 
by 1H NMR spectroscopy every 24 h for the initial 6 days and then weekly up to 4 months until 
no change in the H8 signal intensity was observed. 
4.2.3 Reaction of (R4dt)PtCl2 (R4dt = Me4dt, Et4dt) with Oligonucleotides 
The concentration of the FPLC purified oligos (dissolved in 500 µL of D2O) was 
determined by using UV spectroscopy. (Oligo ε260 values were calculated70 to be 30.0, 29.1 and 
37.6 cm-1mM-1 for d(GGT), d(TGG) and d(TGGT), respectively.) A 1:1 molar Pt:oligo solution 
was prepared (~1.5 mM) in 550 µL of a 64:36 mixture of D2O:DMSO-d6. A solution of the 
desired (R4dt)PtCl2 complex was dissolved in 200 µL of DMSO-d6 and mixed with the 
appropriate volume of the oligo in D2O. The volume of the solution was brought to 550 µL by 
adding the required amount of D2O. The pH of the solution was maintained at 4.0 and the 
solution was kept at 5 °C. The solution was carefully monitored by 1H NMR spectroscopy until 
no free oligo signals were observed and then weekly up to 2 months to monitor any change in the 
H8 signal intensity. 
4.2.4 NMR Measurements 
1H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz or a 
Varian spectrometer at 700 MHz. We used a value of 4.78 ppm to reference signals to the 
residual HOD signal in D2O/DMSO-d6 solutions. A presaturation pulse to suppress the water 
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peak was used when necessary. 31P NMR spectra were referenced to external trimethyl phosphate 
(0 ppm) in a 64:36 mixture of D2O:DMSO-d6. DNO3 and NaOD solutions (0.1 M in D2O) were 
used to adjust the pH of D2O/DMSO-d6 solutions. NMR data were processed with XWINNMR 
or Mestre-C software. 
1H-1H COSY and ROESY spectra were recorded in order to assign the signals of the 
products. Matrixes (512 x 2048) were collected for COSY and (500 ms delay) ROESY 
experiments, both conducted at 25 °C with a spectral window of ~6000 Hz, and a presaturation 
pulse of ~1 s to reduce the HOD signal. Typically, 32 scans were collected per block. An 
exponential apodization function with a line broadening of 0.2 Hz and a phase-shifted 90° sine 
bell function were used to process the ROESY t2 and t1 data, respectively. 
4.2.5 Circular Dichroism (CD) Spectroscopy 
All samples used for CD experiments were prepared from the respective NMR samples 
by diluting to ~0.025 mM Pt with deionized water. The concentration of the CD samples was 
determined by measuring the absorption at 260 nm on a UV-vis spectrometer (d(GpG) ε260 = 21.6 
cm-1mM-1). Spectra were recorded from 400 to 200 nm at a scan speed of 50 nm/min on a 
JASCO J-600 CD spectropolarimeter. Six scans were recorded and averaged for each sample. 
4.2.6 High Performance Liquid Chromatography (HPLC) 
Chromatograms were obtained on a Varian ProStar HPLC instrument with a PDA 
detector operating at 254 nm. Separations employed a Microsorb 100-5 C8 150 x 4.6 mm 
reverse-phase column. Eluants A and B both contained 0.02 M ammonium acetate buffer, pH 
5.5. Solvent A was water and solvent B was a 2:1 methanol:water mixture. A flow rate of 0.70 
mL/min was maintained over the course of a 40 min linear gradient (0 min = 95% A and 5% B, 
40 min = 48% A and 52% B) for the (R4dt)Pt(d(G*pG*)) adducts. The NMR sample was diluted 
to obtain a 1.7 mM solution. Each eluted fraction was collected, concentrated to a small volume 
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(200 µL), and stored at 25 °C to see if equilibration occurred. An aliquot of each fraction was re-
injected after 2 h and then after intervals of 24 h for 7 days, and finally at weekly intervals for 
two months. The percentage of each product separated by HPLC was measured by integration of 
the corresponding peak area. 
4.3 Results 
4.3.1 Conformer Assignment and Conformational Features 
For the (R4dt)Pt(d(G*pG*)) adducts 1H-1H ROESY and COSY data were used to assign 
H8 and sugar proton signals. Structural features were assessed by standard methods. The S- and 
N-sugar pucker conformations were identified from the characteristic H1′ coupling patterns and 
the existence of H8-H3′ NOE cross-peaks for N-sugars.71,72 For all conformers of LPtd(G*pG*) 
adducts, the sugar residue of the 5′-G* typically adopts an N-pucker conformation, while the 3′-
G* sugar has the S-pucker.43,44,50,54 The anti or syn G* nucleotide conformations can be assessed 
by strong intraresidue H8-H2′/H2′′ NOE cross-peaks and weak (or unobservable) H8-H1′ cross-
peaks for the anti conformation and stronger H8-H1′ NOE cross-peaks for the syn conformation 
.
72-74
 Because the G* H8 atoms are closer to each other in the HH conformers than in the HT 
conformers, the observation of an H8-H8 cross-peak is characteristic of an HH conformer, 
whereas the absence of such a cross-peak is indicative of an HT conformer.43,75 HH and ∆HT 
conformers of LPt(d(G*pG*)) complexes often give rise to characteristic NMR shift changes 
compared to free d(GpG); more downfield H8 and 31P signals indicate HH 
conformers,27,29,33,46,48,76 whereas more upfield H8 and 31P NMR signals indicate a ∆HT 
conformer.43,53 Such observations are used below to assign conformations of 
(R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) adducts.  
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4.3.2 (Me4dt)Pt(d(G*pG*)) 
 
 
Figure 4.3. 1H NMR spectra (400 MHz) in the H8 region for (Me4dt)Pt(d(G*pG*)) collected at 
room temperature after 1 week (bottom) and after 8 weeks (top) (pH 4.0, in D2O/DMSO-d6). The 
H8 signals for the various conformers are labeled. 
 
Within ~30 min of mixing (Me4dt)PtCl2 and d(GpG) in a 1:1 molar ratio in 64:36 
D2O:DMSO-d6 solution at pH ∼4.0 at 5 °C, the (Me4dt)Pt(d(G*pG*)) adduct was fully formed. 
This reaction was repeated several times with similar results; however, small variations in 
conditions, such as the ratio of D2O:DMSO-d6 in the reaction solvent mixture due to adventitious 
water and the temperature in the various NMR probes used, eight H8 signals for the 
(Me4dt)Pt(d(G*pG*)) adduct were resolved in some cases (Supporting Information, Figure C2) 
while some H8 signals overlapped in other cases (Figure 4.3). In the spectrum in Figure 4.3, six 
new peaks downfield from the free d(GpG) H8 signals at 8.06 and 7.83 ppm, indicating that the 
adduct consisted of several species with both bases of d(GpG) bound to Pt via N7. The intensity 
of these peaks and the spectrum in Supporting Information (Figure C2) indicate that some peaks 
contain overlapping signals. Indeed the G* H8 peak at 9.03 ppm in 1H 400 MHz NMR spectra 
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can clearly be interpreted as three overlapped signals (Figure 4.3). However, for the same sample 
at 700 MHz this peak was slightly better resolved to give two distinct G* H8 peaks at 9.03 and 
9.02 ppm, with ROESY and COSY data indicating that two G* H8 signals still overlapped to 
give the peak at 9.03 ppm.  
 
 
Figure 4.4. 1H-1H ROESY spectrum (700 MHz, 600 ms mixing time) of a 1-week-old 
(Me4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks.  
 
The NOE cross-peaks (not shown) in the ROESY spectrum between H8 signals at 9.02 
and 8.98 ppm and at 9.23 and 9.03 ppm (most abundant and next most abundant conformers, 
respectively) indicate that both are HH conformers (Table 4.1 and 4.2). For the more abundant 
HH conformer, the G* H8-H2′/H2′′ cross-peaks were stronger than the H8-H1′ cross-peaks 
(Figure 4.4), indicating a predominantly anti conformation for both the 5′-G* and 3′-G* residues. 
Because the 5′-G* and 3′-G* H1′ resonances overlap, the coupling patterns could not be 
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determined. However, the presence of an NOE cross-peak between the H8 signal at 8.98 ppm and 
that of H3′ confirms the N-sugar pucker (Figure 4.4). This signal is therefore assigned to the 5′-
G* residue, which typically has an N-pucker in such cross-links.21,27,43,50,54,76 The H8 signal at 
9.02 ppm, which must be the 3′-G* H8 signal, has no H8-H3′ cross-peak, thus indicating an S-
sugar pucker. Therefore, the dominant (Me4dt)Pt(d(G*pG*)) conformer is one of the anti,anti-
HH conformers (either HH1 or HH2).   
Table 4.1. 1H and 31P NMR Signal Assignments (ppm) for the (R4dt)Pt(d(G*pG*)) Adducts at 
pH ~4 and 25 °C a 
adduct conformer G*/T H8 H1′ H2′ H2′′ H3′ H4′ base  
sugara 
31P 
(Me4dt)Pt(d(G*pG*)) HH1 5′ 8.98 6.44 2.60 2.89 5.00 4.16 anti -3.43 
  3′ 9.02 6.46 2.69 2.60 4.70 4.25 anti  
(Et4dt)Pt(d(G*pG*)) HH1 5′ 9.04 6.39 2.55 2.80 4.92 4.08 anti -3.41 
  3′ 8.97 6.43 2.61 2.53 4.64 4.22 anti  
(Me4dt)Pt(d(G*pG*)) HH2 5′ 9.03 6.42 3.19 2.91 4.96 4.14 anti -2.76 
  3′ 9.23 6.40 2.51 2.82 4.74 4.50 anti  
(Et4dt)Pt(d(G*pG*)) HH2 5′ 9.10 6.37 3.15 2.88 5.01 4.08 anti -2.51 
  3′ 9.23 6.32 2.32 2.72 4.65 4.41 anti  
(Me4dt)Pt(d(G*pG*)) ∆HT 5′ 8.24 6.40 3.22 2.49 4.74 4.19 anti -5.01 
  3′ 8.31 6.24 3.48 2.66 4.81 4.12 syn  
(Et4dt)Pt(d(G*pG*)) ∆HT 5′ 8.32 6.35 3.52 2.65 4.76 4.02 anti -4.72 
  3′ 8.29 6.19 3.35 2.61 4.88 4.10 syn  
(Me4dt)Pt(d(G*pG*)) ΛHT 5′ 9.03 6.57 3.04 2.90 4.13 4.99 anti -4.09 
  3′ 8.65 5.84 2.40 2.84 4.83 4.69 anti  
(Et4dt)Pt(d(G*pG*)) ΛHT 5′ 8.99 6.50 2.82 2.78 4.59 b anti -4.01 
  3′ 8.66 5.98 2.39 2.72 b b anti  
(Me4dt)Pt(d(TG*G*T)) HH1 5′ 8.98 6.49 2.84 2.66 4.87 4.32 anti  
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(table 4.1 continued) 
  3′ 9.40 6.42 2.77 2.91 4.06 4.45 anti  
  5′-T 7.52 6.09 2.15 2.51 3.67 4.08   
  3′-T 7.84 6.40 2.42 2.35 4.64 4.19   
(Me4dt)Pt(d(TG*G*)) HH1 5′ 8.97 6.51 2.50 2.78 4.72 4.28 anti  
  3′ 9.41 6.44 2.98 2.58 4.60 4.25 anti  
  5′-T 7.48 6.05 2.15 2.55 4.75 3.50   
(Me4dt)Pt(d(G*G*T)) HH1 5′ 8.98 6.45 2.57 2.89   anti -3.49 
  3′ 9.03 6.41 2.73 2.62   anti  
 HH2 5′ 9.02 6.39 3.18 2.93 4.96  anti -2.64 
  3′ 9.25 6.41 2.41 2.96   anti  
 ∆HT 5′ 8.21 6.41 3.12 2.44   anti  
  3′ 8.31 6.24 3.47 2.83   syn  
 ΛHT 5′ 8.86 6.60 3.12 2.86   anti  
  3′ 8.59 6.10 2.44 2.81   anti  
a Conformational assignment (anti/syn) based on the relative strength of NOE cross-peaks 
between H8 resonances and H1′ or H2′/H2′′ signals in the ROESY spectrum. b Signals not 
detected.  
 
For the other HH conformer of the (Me4dt)Pt(d(G*pG*)) adduct, the G* H8 signal at 
9.03 ppm has a strong H8-H3′ cross-peak, indicating a 5′-G* N-sugar pucker, and the H8 signal 
at 9.23 ppm has no H8-H3′ NOE cross-peak, indicating a 3′-G* S-sugar pucker (Figure 4.4). The 
observation of stronger 5′-G* H8-H2′/H2′′ cross-peaks than the H8-H1′ cross-peak is consistent 
with an anti conformation.19,23,43,49,54 For the 3′-G*, weak H8-H2′ and H8-H1′ NOE cross-peaks 
were observed (Figure 4.4). Thus, the minor HH conformer adopts an anti,anti conformation. The 
distances between the H8 atom and sugar protons determined by molecular mechanics/dynamics 
computations on the HH conformers of (Me2ppz)Pt(d(G*pG*)) indicated that observable H8-
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sugar NOEs are unlikely for the 3′-G* residue of the HH2 conformer.54 The observation of weak 
3′-G* H8-to-sugar cross-peaks for the minor HH conformer and strong 3′-G* H8-to-sugar cross-
peaks for the major HH conformer led us to assign the minor and the major HH conformers to 
the HH2 and HH1 conformers, respectively. Our results for the minor and the major HH 
conformers are consistent with the HH2 and HH1 conformers of (R,S,S,R)-BipPt(d(G*pG*))50 
and (Me2ppz)Pt(d(G*pG*)).54  
Table 4.2. H8 Chemical Shifts of the (R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) Adducts at pH ~4 
at 25 °C 
H8 shifts (ppm) 
adduct G* 
HH1 HH2 ∆HT ΛHT 
5′ 8.98 9.03 8.24 9.03 
(Me4dt)Pt(d(G*pG*)) 
3′ 9.02 9.23 8.31 8.65 
5′ 8.98 9.02 8.21 8.86 
(Me4dt)Pt(d(G*G*T)) 
3′ 9.03 9.25 8.31 8.59 
5′ 8.97    
(Me4dt)Pt(d(TG*G*)) 
3′ 9.41    
5′ 8.98    
(Me4dt)Pt(d(TG*G*T)) 
3′ 9.40    
5′ 9.04 9.10 8.32 8.99 (Et4dt)Pt(d(G*pG*)) 
 3′ 8.97 9.23 8.29 8.66 
5′ 9.07 9.17 8.36  (Et4dt)Pt(d(G*G*T)) 
 3′ 9.11 9.33 8.35  
5′ 9.04    (Et4dt)Pt(d(TG*G*)) 
 3′ 9.59    
 
For the (Me4dt)Pt(d(G*pG*)) adduct, there are two other pairs of H8 signals at 8.31 and 
8.24 ppm and at 8.65 ppm and within the 9.03 ppm peak; except for the overlapped signal, these 
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signals are upfield to the G* H8 signals of the HH1 and HH2 conformers. These two pairs of 
signals, which indicate the presence of two conformers, showed no H8-H8 NOE cross-peaks, in 
the ROESY spectra collected for the 1-week-old as well as for the 3-months-old 
(Me4dt)Pt(d(G*pG*)) sample indicating that the bases of these conformers adopt the HT 
arrangement.23,43,50,53 
On the basis of the relative intensity of the H8 signals and the 31P NMR signals, the H8 
signals at 8.31 and 8.24 ppm and the 31P NMR signal at -5.01 ppm were assigned to one HT 
conformer. Such an upfield 31P NMR shift is characteristic of the ∆HT conformer and is 
consistent with the shift values of the ∆HT conformer of both (5,5′-Me2bipy)Pt(d(G*pG*)) (-
4.74 ppm) and (Me2ppz)Pt(d(G*pG*)) (-5.12 ppm). For the (Me4dt)Pt(d(G*pG*)) ∆HT 
conformer, the G* H8 signal at 8.24 ppm exhibits an intraresidue H8-H3′ NOE cross-peak 
(Figure 4.4) consistent with a 5′-G* N-sugar pucker. A strong 5′-G* H8-H2′′ cross-peak and a 
weak H8-H1′ cross-peak indicate an anti 5′-G* conformation (Figure 4.4). For the H8 signal at 
8.31 ppm, the absence of an H8-H3′ NOE and the observation of a doublet of doublets coupling 
pattern for the H1′ signal (6.24 ppm) are indicative of a 3′-G* S-sugar pucker. Strong 3′-G* H8-
H1′ NOE and weak H8-H2′′ cross-peaks indicate a syn 3′-G* conformation. Thus, the ∆HT 
conformer adopts an anti,syn conformation, as has been found previously.23,43,53,54 
The intensity of the H8 signals for the other HT conformer (a fourth conformer at 8.65 
and 9.03 ppm remained relatively unchanged for ∼3 weeks after initiation of the reaction. 
However, these signals increased slowly over a period of ~3 months, finally becoming the most 
dominant. Thus, this HT conformer, which is thermodynamically favorable, could possibly be the 
elusive ΛHT conformer. The distribution of the HH1, HH2, ∆HT, and the putative ΛHT 
conformers changed from 42%, 37%, 11% and 10% (after 1 week) to 36%, 18%, 6% and 40% 
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(after ~3 months), respectively (Supporting Information Figure C2). The CD signal shape 
provides a definitive means for assigning the chirality of the major HT conformer when that 
conformer clearly dominates.54 For the (Me4dt)Pt(d(G*pG*)) sample, 8 weeks after initiation of 
the reaction, the distribution of the HH1, HH2, ∆HT, and the putative ΛHT conformers was 40%, 
25%, 10% and 25%. A positive feature at ~290 nm (Figure 4.5) in the CD spectrum for this 
sample is characteristic of the ΛHT conformer of LPtG2 adducts.36,53,57,58,61,77 This feature is 
consistent with the suggestion that the slowly forming HT conformer is the elusive ΛHT 
conformer.  
 
 
Figure 4.5. CD spectra of an (Me4dt)Pt(d(G*pG*)) sample recorded in water at pH ~ 4 and 25 
°C. The positive feature at ~290 nm is indicative of a ΛHT conformation.  
 
For the putative ΛHT conformer of the (Me4dt)Pt(d(G*pG*)) adduct, the G* H8 signals 
at 8.65 and 9.03 ppm have H8-H2′/H2′′ cross-peaks stronger than the H8-H1′ cross-peak (Figure 
4.4), indicating an anti conformation for both G* resdiues. The H8-H3′ NOE cross-peak (9.03-
4.13 ppm) and an H1′ doublet for this residue are consistent with a 5′-G* N-sugar pucker. The 
absence of an observable H8-H3′ cross-peak (8.65-4.83 ppm) and the doublet of doublets 
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coupling pattern for the H1′ signal indicate a 3′-G* S-sugar pucker for the putative ΛHT 
conformer.  
EXSY cross-peaks were absent in the ROESY spectrum of the (Me4dt)Pt(d(G*pG*)) 
adduct, indicating that interconversion between the rotamers is very slow. These slowly 
interconverting rotamers were separated and analyzed by HPLC (see below).  
 
 
Figure 4.6. 31P NMR spectrum (400 MHz) of (Me4dt)Pt(d(G*pG*)) after 6 days (bottom) and 
after 8 weeks (top) in D2O/DMSO-d6 at pH 4.0 and 25 °C.  
 
4.3.2.1 31P NMR Spectroscopy. Compared to the -4.2 ppm value of the unstrained 
d(GpG) phosphodiester group, the 31P NMR signal of HH conformers is downfield and that for 
the ∆HT conformer is upfield. From their relative intensities, 31P NMR signals at -2.76, -3.43 and 
-5.01 ppm for the (Me4dt)Pt(d(G*pG*)) adduct were assigned to the HH2, HH1, and the ∆HT 
conformers, respectively (Figure 4.6). In addition, a fourth peak at -4.09 ppm slowly increased 
with time, indicating that this signal belongs to the putative ΛHT conformer of the 
(Me4dt)Pt(d(G*pG*)) adduct (Figure 4.6). The 31P NMR chemical shifts for the ∆HT and the 
two HH conformers are more upfield than those reported for (5,5′-Me2bipy)Pt(d(G*pG*))23 (-
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2.23 (HH2), -2.64 (HH1) and -4.74 (∆HT) ppm) and more comparable to those of 
(Me2ppz)Pt(d(G*pG*)).54  
4.3.2.2 HPLC Analysis. The rate of interconversion between the (R4dt)Pt(d(G*pG*)) 
rotamers is considerably slower than that for the adducts lacking the sugar-phosphodiester 
backbone (e.g., (R4dt)Pt(GMP)265), thus permitting the separation of the (R4dt)Pt(d(G*pG*)) 
conformers by HPLC.  
 
 
Figure 4.7. HPLC chromatograms of a week-old (Me4dt)Pt(d(G*pG*)) sample (bottom), an 8-
week-old (Me4dt)Pt(d(G*pG*)) sample (middle), and a week-old (Et4dt)Pt(d(G*pG*)) sample 
(top).  
 
For the (Me4dt)Pt(d(G*pG*)) adduct at 25 °C, three fractions were collected with 
retention times (RT) of 10.8, 15.7 and 20.3 min and present in 28%, 52% and 20% abundance, 
respectively (Figure 4.7). The percent population of each product was determined by calculating 
the area under each peak. An aliquot of each fraction when re-injected gave a chromatogram with 
four peaks (RT = 11.3, 12.2, 16.0 and 20.9 min). The small difference in the retention times of 
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the products at equilibrium and those found upon re-injecting the fractions can be attributed to 
the presence of ammonium acetate in the fractions after initial collection. Because of very similar 
retention times, the two products eluting at 11.3 min and 12.2 min came together at 10.8 min 
when the (Me4dt)Pt(d(G*pG*)) adduct was first injected into the column. Because the product in 
each fraction equilibrated with time to give all four product peaks, each peak must belong to one 
of the four (Me4dt)Pt(d(G*pG*)) conformers. The intensity of the peak at RT = 20.3 min 
increased with time, suggesting that this fraction contains the ΛHT conformer (Figure 4.7). 
For the (Me4dt)Pt(d(G*pG*)) adduct, the fraction eluted at 15.7 min, after 1 day, gave a 
chromatogram with peaks at 11.3 (16%), 12.2 (12%), and 16.0 (72%) min. After four days, upon 
re-injecting an aliquot of the same fraction, the conformers redistributed [11.3 min (14%), 12.2 
min (32%), and 16.0 min (51%)]. Also, a small peak (~3%, RT = 20.9 min) was detected. The 
fraction that eluted at 10.8 min after one day gave a chromatogram with three peaks at 11.3, 12.2 
and 16.0 min. After four days the distribution of these products changed from 42%, 40% and 
18% to 21%, 30% and 48%. A very small peak at RT = 20.9 min (1%) was also observed after 
four days. The fraction collected at 20.3 min redistributed very slowly into the other conformers. 
The peaks at smaller retention times were not detected when this fraction was injected even after 
2 days. Re-injection of this fraction after four days revealed four product peaks at 11.3 min (5%), 
12.2 min (27%), 16.0 min (9%) and 20.9 min (59%). Clearly, the conformers eluting at 11.3, 12.2 
and 16.0 min interconvert more rapidly than the one eluting at 20.9 min. A correlation of the 
intensities of the H8 signals in the NMR spectrum with the product peaks in the HPLC 
chromatograms suggests that the fraction eluting at 16.0 min contains the most abundant HH1 
conformer, and the fraction at 20.9 min contains the fourth form of the (Me4dt)Pt(d(G*pG*)) 
adduct. The HPLC data suggest that the fourth form seen by 1H NMR spectroscopy could be the 
elusive ΛHT conformer. The rotation of one base about the Pt–N7 bond leads to changes in the 
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relative base orientation from HH to HT, or vice-versa. The HH1 conformer with RT = 16.0 min 
converts to the ∆HT conformer (RT = 11.3 min), which rapidly interconverts to the HH2 
conformer (RT = 12.2 min). The postulated ΛHT conformer eluting at 20.9 min converts first to 
the HH2 conformer, which then equilibrates to give the ∆HT and HH1 conformers. The rate of 
interconversion for the HH1, HH2 and ∆HT conformers is faster than that of the ΛHT conformer. 
4.3.3 (Et4dt)Pt(d(G*pG*)) 
Four new pairs of G* H8 signals, downfield of the H8 signals of free d(GpG), were 
observed within minutes after mixing (Et4dt)PtCl2 and d(GpG) solutions. After 1 day no free 
d(GpG) signals were observed, indicating complete reaction. A 275-µL aliquot of this solution 
was diluted with D2O to obtain a ratio of 64:36 for D2O:DMSO-d6 (as used for the 
(Me4dt)Pt(d(G*pG*)) reaction). Signal assignments and conformational features were 
determined by established methods using ROESY and COSY data.23,43 The H8 peaks at 9.23 and 
9.10 ppm and 8.97 and 9.04 ppm were connected by H8-H8 NOE cross-peaks, indicating two 
HH conformers. The 2D NMR data indicate that the two HH conformers have an anti,anti HH 
conformation, with a 3′-G* S-sugar and a 5′-G* N-sugar (Table 4.1 and Supporting Information). 
NOE cross-peaks between the H8 signals at 8.66 and 8.99 ppm and at 8.29 and 8.32 ppm were 
absent, indicating HT conformers (Tables 4.1 and 4.2). The 31P NMR signals for the 
(Et4dt)Pt(d(G*pG*)) adduct were observed at -3.41, -2.51, -4.72 and -4.01 ppm. On the basis of 
the characteristic shifts of the 31P NMR signals and the relative intensities of the 
(Et4dt)Pt(d(G*pG*)) H8 signals and their similarity to the shifts of the (Me4dt)Pt(d(G*pG*)) H8 
signals, the more downfield H8 signals belonging to the minor HH conformer were assigned to 
the HH2 conformer and those at 8.97 and 9.04 ppm were assigned to the major HH1 conformer 
(Table 4.1). For HT conformers, the most upfield H8 signals were assigned to the ∆HT 
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conformer, and the H8 signals at 8.66 and 8.99 ppm were assigned to the ΛHT conformer (Table 
4.1). The ∆HT conformer has an anti,syn HT conformation and the ΛHT conformer has an 
anti,anti HT conformation with a 3′-G* S-sugar and a 5′-G* N-sugar (Supporting Information). 
 
 
Figure 4.8. H8 region of the 1H NMR spectrum (400 MHz) of (Et4dt)Pt(d(G*pG*)) after 1 week 
(bottom) and after 8 weeks (top) in D2O/DMSO-d6 at pH 4.0 and 25 °C.  
 
For (Et4dt)Pt(d(G*pG*)), the distribution of the HH1, HH2, ∆HT and ΛHT conformers 
changed from 42%, 37%, 11%, and 10%, respectively, at one week after initiation of the reaction 
to 41%, 33%, 9% and 17%, respectively, after another seven weeks (Figure 4.8). The abundance 
of the ΛHT conformer increased slowly with time, as found for the (Me4dt)Pt(d(G*pG*)) adduct. 
However, at equilibrium the 17% relative abundance of the ΛHT conformer of the 
(Et4dt)Pt(d(G*pG*)) adduct was considerably less than the 40% observed for the 
(Me4dt)Pt(d(G*pG*)) adduct. Evidently, the ΛHT conformer for (Et4dt)Pt(d(G*pG*)) adduct is 
less favored than for (Me4dt)Pt(d(G*pG*)) adduct because of the bulk of the Et group, a result 
suggesting that in-plane bulk does not disfavor the ΛHT conformer.  
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In a ROESY spectrum of (Et4dt)Pt(d(G*pG*)), NOE cross-peaks were observed between 
the G* H8 signals and the Et4dt methyl signals, which overlap in the 0.90 to 1.10 ppm region. 
NOE cross-peaks were observed between these methyl signals and the H8 signals of the 3′-G* of 
the HH2 conformer, the 3′- and the 5′-G* of the HH1 conformer and the 3′-G* of the ΛHT 
conformer. Also, NOE cross-peaks between the methyl signals and the H1′ sugar signals were 
observed. No such NOE cross-peaks were observed in the ROESY spectrum of the 
(Me4dt)Pt(d(G*pG*)) adduct. The NOE cross-peaks between the G* residue and the carrier 
ligand clearly indicate that the substituents at the 6/6′ position in a bis-3,3′-(1,2,4-triazine) can 
interact with the Pt-bound guanine derivatives, and thus affect the rate of rotation of G* bases 
about the Pt–N7 bond. 
4.3.3.1 HPLC Analysis. For the (Et4dt)Pt(d(G*pG*)) adduct, the three fractions 
collected, with retention times of 27.2 (42%), 29.5 (44%), and 31.9 (14%) min (Figure 4.7), 
followed a pattern  similar to that for (Me4dt)Pt(d(G*pG*)). The HH1 conformer eluted at 29.5 
min, the HH2 and ∆HT conformers eluted together at 27.2 min, and the ΛHT conformer eluted at 
31.9 min. Because of the more hydrophobic ethyl group, the retention times for the 
(Et4dt)Pt(d(G*pG*)) peaks were longer than those for (Me4dt)Pt(d(G*pG*)) peaks.  
Each product upon re-injecting into the HPLC column as observed for 
(Me4dt)Pt(d(G*pG*)), redistributed to give four product peaks (RT = 27.7, 28.4, 30.0 and 32.5 
min). Because of very similar retention times, the two products eluting at 27.7 min and 28.4 min 
came together at 27.2 min when the (Et4dt)Pt(d(G*pG*)) adduct at equilibrium was first injected 
into the column. Again, as we found for the R = Me analogue, the results indicate that each peak 
belongs to one of the four (Et4dt)Pt(d(G*pG*)) conformers. For reasons given above, these 
HPLC observations provide compelling evidence that the four forms detected by NMR spectra 
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must be conformers that re-equilibrate. However, each fraction, upon re-injecting, redistributed 
significantly only after two days, indicating that the rate of interconversion between the 
conformers was slower than that observed for the (Me4dt)Pt(d(G*pG*)) conformers, which 
interconvert after ~1 day.  
For (Et4dt)Pt(d(G*pG*)), each isolated fraction when injected after 1 day, gave a 
chromatogram with ~99% of the peak of the fraction injected, the peaks for other conformers 
were observed only after two days indicating slow redistribution in comparison to 
(Me4dt)Pt(d(G*pG*)). After four days, substantial conformer redistribution was observed for 
each isolated fraction. The fraction that eluted at 27.2 min redistributed to give four peaks [27.7 
min (18 %), 28.4 (50%), 30.0 (21%) and 32.5 (11%)]. Likewise, four conformer peaks were 
observed for the fractions for the HH1 conformer eluting at 29.5 min (27.7 min (10 %), 28.4 
(19%), 30.0 (63%), and 32.5 (8%) and for the ΛHT conformer eluting at 31.9 min (27.7 min 
(7%), 28.4 (38%), 30.0 (26%), and 32.5 (29%)). In contrast to the slowly redistributing ΛHT 
conformer of (Me4dt)Pt(d(G*pG*)), the ΛHT conformer of (Et4dt)Pt(d(G*pG*)) redistributed 
somewhat faster than the other conformers. This provides further support to the NMR finding 
that the ΛHT conformer is less favored for the more bulky Et4dt ligand than for the Me4dt ligand 
in the (R4dt)Pt(d(G*pG*)) adducts. 
The sequence of conformer interconversion for (Et4dt)Pt(d(G*pG*)) was similar to that 
observed for (Me4dt)Pt(d(G*pG*)). The HH1 conformer with RT = 30.0 min converts to the 
∆HT conformer (RT = 27.7 min), which rapidly interconverts to the HH2 conformer (RT = 28.4 
min). The postulated ΛHT (RT = 32.5 min) converts first to the HH2 conformer, which then 
equilibrates to give the ∆HT and HH1 conformers. 
 
 100 
4.3.4 (Me4dt)Pt(d(TG*G*T)) 
Within 1 h after mixing a 2.2 mM solution of d(TGGT) in D2O (350 µL) with a 3.9 mM 
solution of (Me4dt)PtCl2 in DMSO-d6 (200 µL) solution, four new pairs of G* H8 signals were 
observed downfield to the H8 signals of the free d(TGGT). The reaction was complete after ~1 
day, as indicated by the disappearance of the free d(TGGT) signals. After 1 day only one pair of 
G* H8 signals remained, and thus the short-lived H8 signals were from intermediates or unstable 
conformers.  
 
 
Figure 4.9. H8 region of the 1H NMR spectra (400 MHz) of (a) (Me4dt)Pt(d(G*G*T)), (b) 
(Me4dt)Pt(d(G*pG*)), (c) (Me4dt)Pt(d(TG*G*)), and (d) (Me4dt)Pt(d(TG*G*T)) after 7 days in 
D2O/DMSO-d6 at pH ~4 and 25 °C. 
 
For the (Me4dt)Pt(d(TG*G*T)) adduct, the two G* H8 signals at 9.40 and 8.98 ppm 
(Figure 4.9) were connected by an NOE cross-peak, which is consistent with an HH arrangement. 
A weak H8-H1′ and a strong H8-H2′/H2′′ NOE cross-peak indicated that both G* residues of the 
HH conformer are anti. The 3′- and 5′-T H6 signals were observed at 7.52 and 7.84 ppm, 
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respectively. NOE data were used to assign the sugar signals for the G* and T residues (Table 
4.1). The H1′ coupling patterns indicated an S- and N-sugar for the 3′- and 5′-G* residues, 
respectively, and an S-sugar for both the 3′- and 5′-T residues. The (Me4dt)Pt(d(TG*G*T)) 
adduct at equilibrium existed as ~100% HH1 conformer. The 31P NMR signals for the HH1 
conformer of the (Me4dt)Pt(d(TG*G*T)) adduct were observed at -4.24, -4.30 and -4.52 ppm. 
The signal for the phosphate group between the adjacent G* residues is ~1 ppm upfield to that of 
the HH1 conformer of the (Me4dt)Pt(d(G*pG*)) adduct. 
4.3.5. (Me4dt)Pt(d(TG*G*)) 
Within two hours after mixing a 1.9 mM solution of d(TGG) in D2O (350 µL) with a 3.3 
mM solution of (Me4dt)PtCl2 in DMSO-d6 (200 µL), a new set of signals was observed (Figure 
4.9) in addition to those of free d(TGG) signals (8.09 (3′-G H8), 7.92 (5′-G H8) and 7.41 (5′-
TH6) ppm). These free d(TGG) signals disappeared after a day, indicating that the reaction was 
complete. The two G* H8 signals (at 9.41 and 8.97 ppm) of the adduct were connected by an 
NOE cross-peak, indicating an HH conformation. The ROESY data indicate that this dominant 
conformer has a normal anti,anti-HH conformation. The 5′-G* has an H8-H3′ NOE (a finding 
typical for an N-sugar), while the absence of an H8-H3′ NOE indicated an S-sugar for the 3′-G*. 
The H1′ coupling pattern of the signals at 6.44 and 6.51 ppm for the 3′-G* and the 5′-G*, 
respectively, was also consistent with this sugar pucker assignment. The H6 signal of the 5′-T 
was observed at 7.48 ppm. The doublet of doublets coupling pattern of the 5′T H1′ signal (6.05 
ppm) indicated an S-sugar. The (Me4dt)Pt(d(TG*G*)) adduct at equilibrium existed as ~100% 
HH1 conformer. The 31P NMR signals for the HH1 conformer at -4.51 and -4.66 ppm are ~1 
ppm upfield from the 31P NMR signal (at -3.43 ppm) for the HH1 (Me4dt)Pt(d(G*pG*)) 
conformer. 
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4.3.6 (Et4dt)Pt(d(TG*G*)) 
For (Et4dt)Pt(d(TG*G*)), one new set of signals downfield to the free d(TGG) signals 
was observed when a 1.4 mM solution of d(TGG) in D2O (350 µL) was treated with a 2.5 mM 
solution of (Et4dt)PtCl2 in DMSO-d6 (200 µL). The three singlets at 9.59, 9.04 and 7.41 ppm 
belonged to the 3′-G* and 5′-G* H8 signals and the 5′-T H6 signal, respectively. The H1′ signals 
at 6.51, 6.53, and 5.98 ppm belonged to 3′-G*, 5′-G* and 5′-T, respectively. From the H1′ 
coupling pattern, the 5′-G* has an N-sugar, and the 3′-G* and the 5′-T have an S-sugar. The 
presence of exclusively one conformer for the (Et4dt)Pt(d(TG*G*)) adduct (Figure 4.10), as 
found for the (Me4dt)Pt(d(TG*G*)) adduct, led us to assign these signals to the HH1 conformer. 
The 31P NMR signals for the HH1 conformer of the (Et4dt)Pt(d(TG*G*))  adduct were observed 
at -4.58 and -4.86 ppm. 
 
 
Figure 4.10. H8 region of 1H NMR spectra (400 MHz) of (a) (Et4dt)Pt(d(G*G*T)), (b) 
(Et4dt)Pt(d(G*pG*)), and (c) (Et4dt)Pt(d(TG*G*)) after 7 days in D2O/DMSO-d6 at pH ~4 and 
25 °C.  
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4.3.7 (Me4dt)Pt(d(G*G*T)) 
Three new pairs of G* H8 signals, downfield to the H8 signals of the free d(GGT) (8.15 
(3′-G H8), 7.98 (5′-G H8) and 7.74 (5′-TH6) ppm), were observed within ~15 min of treating a 
1.7 mM solution of d(GGT) in D2O (350 µL) with a 3.0 mM solution of (Me4dt)PtCl2 in DMSO-
d6 (200 µL). After ~2 days, no free d(GGT) signals were observed, indicating complete reaction. 
For (Me4dt)Pt(d(G*G*T)), the relative intensities and shifts of the G* H8 signals were very 
similar to the values observed for the (Me4dt)Pt(d(G*pG*)) adduct (Table 4.1 and Figure 4.9). 
The H8 signals at 9.03 and 8.98 ppm and at 9.25 and 9.02 ppm were respectively connected with 
NOE cross-peaks, indicating an HH conformation. The two G* residues of both the HH 
conformers are anti, with an N-sugar for the 5′-G* and an S-sugar for the 3′-G*. The G* H8 
signals mentioned above were assigned to the HH1 and HH2 conformers, respectively. The 
signal assignment was based on the similarity in the H8 chemical shifts of (Me4dt)Pt(d(G*G*T)) 
with those of the (Me4dt)Pt(d(G*pG*)) adduct. The 31P NMR signal shifts at -3.49 and -2.64 
ppm for (Me4dt)Pt(d(G*G*T)) were similar to those of the HH1 and HH2 conformers of the 
(Me4dt)Pt(d(G*pG*)) adduct, respectively. The T H6 signals at 7.83 and 7.90 ppm were 
respectively assigned to the HH1 and HH2 conformers. 
The absence of an NOE cross-peak between the H8 signals at 8.31 and 8.21 ppm 
indicated an HT conformer for the (Me4dt)Pt(d(G*G*T)) adduct. The NMR data indicated an 
anti,syn conformation, with an N- and S-sugar for the 5′- and 3′-G* bases, respectively. The 
similarity of these H8 shifts to those of the ∆HT conformer of the (Me4dt)Pt(d(G*pG*)) adduct 
allowed us to assign these signals to the ∆HT conformer of the (Me4dt)Pt(d(G*G*T)) adduct. 
The T H6 signal at 7.93 ppm was assigned to the ∆HT conformer; the G*pG* 31P NMR signal in 
the ∆HT conformer could not be identified because of the overlapping G*pT signals in the -4 to -
 104 
4.6 ppm region of all the conformers. A very small fourth pair of G* H8 signals (at 8.59 and 8.86 
ppm) was observed 4 days after initiation of the reaction but was not evaluated further because of 
the low abundance (3%).The chemical shift pattern was similar to the ΛHT conformer (8.65 and 
9.03 ppm) of the (Me4dt)Pt(d(G*pG*)) adduct. The final distribution of conformers for the 
(Me4dt)Pt(d(G*G*T)) adduct was 48% HH2, 32% HH1, 17% ∆HT, and 3% ΛHT conformer 
(Figure 4.9).  
4.3.8 (Et4dt)Pt(d(G*G*T))  
Three new pairs of G* H8 signals, downfield to the H8 signals of the free d(GGT), were 
observed within ~20 min of mixing a 1.3 mM solution of d(GGT) in D2O (350 µL) with a 2.2 
mM solution of (Et4dt)PtCl2 in DMSO-d6 (200 µL). After ~7 days, no free d(GGT) signals were 
observed, indicating complete reaction. Assignments were based on the relative intensities and 
the characteristic shifts of the G* H8 signals, as determined above for the (Et4dt)Pt(d(G*pG*)) 
and the (Me4dt)Pt(d(G*G*T)) adducts. The H8 signals of the (Et4dt)Pt(d(G*G*T)) adduct at 
9.33 and 9.17 ppm and at 9.11 and 9.07 ppm were assigned to the HH1 and HH2 conformers, 
respectively. The two most upfield G* H8 signals at 8.36 and 8.35 ppm were assigned to the 
∆HT conformer of the (Et4dt)Pt(d(G*G*T)) adduct. The downfield 31P NMR signals at -3.25 
and -2.46 ppm are characteristic of the HH1 and HH2 conformers, respectively; these shifts are 
consistent with the shifts of the respective HH conformers of the (Et4dt)Pt(d(G*pG*)) adduct. 
However, the 31P NMR signal for the ∆HT conformer could not be identified because the G*pT 
phosphate group signals overlapped in the -3.8 to -4.5 ppm region. The T H6 signals at 7.85, 
7.91, and 7.78 ppm were assigned to the HH1, the HH2 and the ∆HT conformers, respectively. 
Although observed for (Et4dt)Pt(d(G*pG*)), the signals for the ΛHT conformer of 
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(Et4dt)Pt(d(G*G*T)) were not detected, even two weeks after initiation of the reaction (final 
distribution of the conformers was 43% HH2, 35% HH1, and 22% ∆HT, Figure 4.10).   
4.4 Discussion 
To understand the effect of the carrier ligand, we compare the properties of the 
(R4dt)Pt(d(G*pG*)) adducts with the results reported for other LPt(d(G*pG*))  (L = 5,5′-
Me2bipy,23 Me2ppz,54 and Bip43,53) adducts. Both Me2ppz and Bip are sp3 N-donor ligands with 
the bulk of the ligand lying out of the Pt coordination plane. However, R4dt and 5,5′-Me2bipy 
are planar, aromatic sp2 N-donor ligands with significant bulk located in the coordination plane. 
For the (5,5′-Me2bipy)Pt(d(G*pG*)) adduct, the H6/H6′ atoms of the carrier ligand point toward 
the cis G* residues, restricting the rate of rotation about the Pt–N7 bond.23 In contrast, it was our 
hypothesis that the sterically less demanding N lone pair on each triazine ring in the 
(R4dt)Pt(d(G*pG*)) adducts is expected to provide space for the cis G* residue to seek a more 
favorable position and to undergo rotation. We tested this hypothesis by assessing conformer 
distribution for (R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) adducts. Fortunately, the observation of 
the previously elusive ΛHT conformer provided both a novel observation as well as evidence 
suggesting that the hypothesis was correct.   
4.4.1 Distribution of (R4dt)Pt(d(G*pG*)) (R4dt = Me4dt, Et4dt) Conformers 
In addition to the HH1, HH2, and ∆HT conformers commonly observed in 
LPt(d(G*pG*)) adducts, for the first time, a fourth form of an LPt(d(G*pG*)) adduct was 
observed at low pH. This unusually abundant and slowly forming species appears to be the 
elusive ΛHT conformer.  
By monitoring HPLC traces and NMR signals, the now well-established HH, HH2, and 
∆HT conformers were identified and found to be present in the HPLC peak with the shortest 
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retention time (contains ∆HT and HH2) and the peak with an intermediate retention time (HH1). 
The fourth form, which became abundant only very slowly, was present in the peak with the 
longest retention time (Figure 4.7). The isolation of the peaks, followed by re-injection after 
various time periods, led to better separation (probably related to the residual HPLC buffer from 
the initial separation). The HPLC analysis of the re-injected peaks gave evidence that the ∆HT, 
HH2, and HH1 conformers interchanged relatively quickly. Considering the dilute conditions and 
the fact that the adducts were formed prior to separation, the interconversion of these conformers, 
which involves rotation of the G* bases and in some cases backbone rearrangement, is expected. 
Of particular importance, the peaks with the common conformers on re-injection gave 
evidence for formation of the peak with the long retention time. In turn, re-injection of this peak, 
isolated by HPLC from the reaction solution in which the adduct was formed, led to the 
formation of the well-known conformers. These findings are compelling evidence that this fourth 
form is the elusive ΛHT conformer, the only conformer previously not present in an abundant 
amount under conditions where the d(G*pG*) moiety is in the normal protonation state with N1 
of both guanines protonated. 
We can suggest with reasonable confidence that the ΛHT conformer, despite the normally 
favorable HT base arrangement, which avoids base-base clashes and which benefits from 
antiparallel base dipole - base dipole interactions, may be a sterically large conformer unable to 
fit easily into the cavity provided by the typical L carrier ligand. Other results, in addition to the 
previous failure to detect any such abundant species, support this viewpoint. In particular, the 
amount of the ΛHT conformer was considerably less (17%) for R = Et than the 40% observed 
for R = Me in (R4dt)Pt(d(G*pG*)) adducts. This increase means that low bulk favors the ΛHT 
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conformer. In addition, whereas the 3′-T flanking a crosslink normally has no effect, the ΛHT 
conformer becomes much less abundant in adducts with a 3′-residue. 
Although our study was not designed to assess mechanism, the results provide a 
particularly good indication of the likely processes involved in conformer interchange. As 
mentioned, the interchange from one conformer to another involves at the very least rotation of a 
G* base. Rotation of the 5′-G* base could in theory convert HH1 to ΛHT, and vice versa. We 
cannot rule out this process completely, but we see no evidence for this isomerization. Because 
the backbone propagation direction differs for these two conformers, (1) for HH1 and (2) for 
ΛHT, both base rotation and backbone rearrangement are required. This combination of 
processes may be extremely slow. 
 
 
Figure 4.11. Scheme relating the conformers of an (R4dt)Pt(d(G*pG*)) adduct modified from 
Figure 1 to show fast interconversion (depicted by long counter-parallel arrows) between the two 
HH conformers and the ∆HT conformer and slow interconversion (depicted by short counter-
parallel arrows) between the HH2 conformer and the ΛHT conformer. The interconversion 
between the HH1 and ΛHT conformer requires both backbone rearrangement and base rotation (a 
process expected to be extremely slow) while the interconversion between the HH2 and ΛHT 
conformer requires only a simple rotation of the 3′-G* base (a process expected to be relatively 
fast) 
 
On the other hand, HH2 could convert to ΛHT without backbone rearrangement by 
simple rotation of the 3′-G* base. However, our data suggest that whatever process leads to 
ΛHT, the interconversion between the now more commonly identified conformers is relatively 
 108 
much faster (although not fast in the normal sense of the word). Thus, it could be rather difficult 
to decide which of the conformers produced ΛHT by using results obtained starting with these 
conformers. 
Fortunately, under the solution conditions dictated by the isolation of the HPLC peaks, 
the data using the peak for the uncommon fourth conformer are rather informative. The rates of 
interconversion are such that ΛHT preferentially forms the HH2 conformer. Thus we can modify 
the general scheme relating the conformers as shown in figure 4.11.   
For the (5,5-Me2bipy)Pt(d(G*pG*)) adduct, a fourth set of signals was detected but was 
not evaluated further because of the low abundance (~4%).23 The first evidence for a ΛHT 
conformer (called ΛHT2) was reported for the (R,S,S,R)-BipPt(G*pG*) adduct at pH ~10.53 
However, this conformer was not detected for the (Me2ppz)Pt(d(G*pG*)) adduct. Apparently, 
the ΛHT conformer forms more slowly than the other conformers in LPt(d(G*pG*)) adducts. At 
equilibrium, the distribution of the HH1, HH2, ∆HT, and ΛHT conformers was 36%, 18%, 6%, 
and 40%, respectively, for the (Me4dt)Pt(d(G*pG*)) adduct and 41%, 33%, 9%, and 17%, 
respectively, for the (Et4dt)Pt(d(G*pG*)) adduct. Evidently at equilibrium, the HH2 conformer 
is more favored and the ΛHT conformer is less favored for (Et4dt)Pt(d(G*pG*)) than for 
(Me4dt)Pt(d(G*pG*)).  
At equilibrium, a relatively large percentage of the HH2 conformer was obtained for the 
(Et4dt)Pt(d(G*pG*)) adduct when compared to the (5,5′-Me2bipy)Pt(d(G*pG*))23 and 
(Me2ppz)Pt(d(G*pG*))54 adducts (Table 4.3). During the early stages of the formation reaction 
for (Me4dt)Pt(d(G*pG*)), a large abundance (37%) of the HH2 conformer was observed, which 
redistributed with other conformers to give a final distribution of 18%. The large abundance of 
the HH conformers can be attributed to the overall low steric effects of the R4dt ligand, allowing 
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ample space for the HH conformers to exist without significant clashes between the O6 groups of 
the d(G*pG*) moiety. (A triazine ring N atom + N lone pair grouping is sterically less impeding 
than the C6 atom + H atom grouping in the sp2 N-donor 5,5′-Me2bipy ligand studied earlier.)  
Table 4.3. Conformer Distribution (%) for LPt(d(G*pG*)) and LPt(oligo) Adducts at 
equilibrium. 
adduct HH1 HH2 ∆HT ΛHT 
(Me4dt)Pt(d(G*pG*)) 36 18 6 40 
(Me4dt)Pt(d(G*G*T)) 48 32 17 3 
(Me4dt)Pt(d(TG*G*)) 99    
(Me4dt)Pt(d(TG*G*T)) 99    
(Et4dt)Pt(d(G*pG*)) 41 33 9 17 
(Et4dt)Pt(d(G*G*T)) 43 35 22  
(Et4dt)Pt(d(TG*G*)) 99    
(5,5-Me4bipy)Pt(d(G*pG*))23 52 10 34  
(Me2ppz)Pt(d(G*pG*))54 50 20 30  
 
In Table 4.3, the conformer distributions of (R4dt)Pt(oligo) adducts are compared to 
those for the respective (R4dt)Pt(d(G*pG*)) adducts. For the (R4dt)Pt(d(G*G*T)) adducts, the 
three HH1, HH2 and ∆HT conformers were abundant, but the distribution of these conformers 
was different from that for the (R4dt)Pt(d(G*pG*)) adducts (Table 4.3). A low abundance of the 
ΛHT conformer (3%) was observed four days after initiation of the reaction for the 
(Me4dt)Pt(d(G*G*T)) adduct. However, for (Et4dt)Pt(d(G*G*T)) the H8 signals of this 
conformer were not detected even 4 weeks after initiation of the reaction. This finding is 
consistent with the slow isomerization to the ΛHT conformer for the (Et4dt)Pt(d(G*pG*)) 
adducts. The ΛHT conformer is less favored for the (R4dt)Pt(d(G*G*T)) adducts when R = Et 
than when R = Me. The number of conformers and the H8 signal shifts for the 
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(R4dt)Pt(d(G*G*T)) and (R4dt)Pt(d(G*pG*)) adducts were very similar. Thus, it can be inferred 
that the 3′-T residue does not influence the structure of the d(G*pG*) cross-link.   
In contrast, for the (Me4dt)Pt(d(TG*G*)),  (Et4dt)Pt(d(TG*G*)) and 
(Me4dt)Pt(d(TG*G*T))  adducts, the HH1 L conformer was ~100% favored at equilibrium 
(Figures 4.8 and 4.9). The remaining three possible conformers were not detected for these 
adducts. A preference for the HH1 conformer was also observed for (Me2ppz)Pt(d(TG*G*)) and 
(Me2ppz)Pt(d(TG*G*T)).54 Thus, the presence of a 5′-flanking T residue highly favors the HH1 
conformer, and this propensity is not affected by the addition of a 3′-T residue. The 5′-substituent 
remains the key factor in influencing the distribution and H8 shifts of the cross-link moiety. 
4.4.2 Sugar-phosphodiester Backbone of (R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) 
Conformers 
 
The observation of a 5′-G* H8-H3′ NOE cross-peak indicated that the 5′-G* residue of all 
the conformers of (R4dt)Pt(d(G*pG*)) (R4 = Me4 and Et4) adopts the N-sugar pucker universally 
found for the 5′-G* sugar in LPt(d(G*pG*)) cross-link adducts.27,50,51,54,76 Thus, the favored N-
pucker observed for the 5′-G* sugar appears to be independent of the carrier ligand. The absence 
or weakness of the 3′-G* H8-H3′ cross-peak indicated that the 3′-G* sugar for all the four 
conformers of the (R4dt)Pt(d(G*pG*)) adduct has the S-sugar pucker. The S-pucker is favored 
by the 3′-G* in free d(GpG) and also for the conformers of (5,5′-Me2bipy)Pt(d(G*pG*))23, 
(Me2ppz)Pt(d(G*pG*))54 and BipPt(d(G*pG*)).43,50,53 Moreover, the shifts of the sugar proton 
signals of the commonly observed HH1, HH2 and ∆HT conformers of the (R4dt)Pt(d(G*pG*)) 
adduct were very similar to those of the (5,5′-Me2bipy)Pt(d(G*pG*))23 and the 
(Me2ppz)Pt(d(G*pG*)) adducts.54 Such similarity in the chemical shifts indicates that the sugar-
phosphodiester backbone has a similar structure in all adducts.  
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The similarity in the structure-sensitive 31P NMR chemical shifts of the 
(R4dt)Pt(d(G*pG*)) conformers and the respective conformers of the previously studied 
LPt(d(G*pG*)) adducts (L = 5,5′-Me2bipy,23 Me2ppz,54 (S,R,R,S)-Bip,43 and (R,S,S,R)-Bip50) 
provides further evidence that the carrier ligand has little influence on the structure of the sugar-
phosphodiester backbone for all conformers of LPt(d(G*pG*)) adducts.  
The 31P NMR shifts (for the HH conformers) and the H8 chemical shifts for the 
d(G*pG*) moiety of the (R4dt)Pt(d(G*G*T)) adduct are very similar to those of the respective 
(R4dt)Pt(d(G*pG*)) adduct (Figure 4.9 and 4.10) indicating that the 3′-T residue is positioned 
far from the 3′-G* residue and has little effect on the structure of the G*pG* sugar-
phosphodiester backbone. The 3′-T flanking a crosslink normally has no effect, the ΛHT 
conformer becomes much less abundant in adducts with a 3′-residue. These results are in 
agreement with those for HH and ∆HT conformers of the (Me2ppz)Pt(d(G*G*T)) adduct68 as 
well as for the HH conformers of the dynamic LPt(d(GGTT)) adducts (L = ethylenediamine and 
(MeNH2)2).25  
For LPt(oligo) adducts (L = sp3 N-donor ligands) having a 5′-T residue, a downfield 31P 
NMR signal ~-2.5 to -3.2 ppm was observed, a characteristic shift of the HH1 conformation of 
the G*pG* cross-link.25 The structure sensitive 31P NMR signal for the exclusively formed HH1 
conformer of both the (R4dt)Pt(d(TG*G*)) and the (R4dt)Pt(d(TG*G*T) adducts is ~1 ppm 
upfield from the 31P NMR shift of the HH1 conformer of the respective (R4dt)Pt(d(G*pG*)) 
adduct. The 31P NMR signal shifts for the HH1 conformer of these (R4dt)Pt(oligo) adducts were 
very similar to the shifts for unstrained phosphodiester groups in oligos (~-4 ppm).25 This may be 
attributed to the overall low steric effects of the R4dt ligand, with two N + N lone pair groupings 
which allow more space for the HH conformer to exist65 resulting in a less distorted backbone 
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structure. Thus, it can be said that a 5′-T residue in a (R4dt)Pt(oligo) may slightly affect the 
conformation of the sugar-phosphodiester backbone.    
4.4.3 Base Canting 
 
 
Figure 4.12. HH1, HH2, ∆HT and ΛHT conformers, showing variants with left-handed and 
right-handed canting. 
 
Besides the HH or HT orientation and backbone propagation direction, the other 
significant structural feature is base canting. The bases are not exactly perpendicular to the 
coordination plane, and the degree and the direction (left- or right-handed, Figure 4.12) of 
canting differ depending on a number of factors and particularly the carrier ligand, the presence 
or absence of a link between the bases, the sugar (ribo or deoxyribo), and the single-stranded or 
duplex character of the DNA. Fortunately, the G* H8 signals are a good probe for assessing the 
degree of base canting.43 Typically, H8 signals of the HH conformers of LPt(d(G*pG*)) adducts 
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have chemical shifts of ~7.8-8.1 ppm (canted base) and ~8.8-9.2 ppm (less canted base), 
respectively.43 For the HH orientation, often only one base is significantly canted, such that the 
H8 atom is positioned toward the other cis base, which is less canted.55,61,63 The H8 atom of the 
canted base is within the shielding region of the less canted base and has a relatively upfield H8 
signal. The H8 signal of the less canted base is relatively downfield because this H8 is far from 
the cis base shielding region.61,62 The HH H8 signals can be dispersed by as much as ~1 ppm.43  
4.4.3.1 (R4dt)Pt(d(G*pG*)). According to the H8 shift method43 for assessing base 
canting in the HH conformers of d(G*pG*) adducts with sp3 N-donor ligands, an H8 signal shift 
of ~9.0 (3′-G*) and ~8.7 (5′-G*) ppm is associated with less canted bases.43 The 
(Me2ppz)Pt(d(G*pG*)) G* H8 shifts reported for the HH1 conformer at 8.93 (3′-G*) and 8.51 
(5′-G*) ppm and for the HH2 conformer at 8.78 (3′-G*) and 8.71 (5′-G*) ppm indicate low base 
canting.54 Also, the G* bases in the HH conformers of the (5,5′-Me2bipy)Pt(d(G*pG*)) adduct 
were relatively less canted, with H8 signals at 9.14 and 8.76 ppm for the HH1 L conformer and at 
9.07 and 8.83 ppm for the HH2 R conformer.23 The relatively downfield H8 signals of the (5,5′-
Me2bipy)Pt(d(G*pG*)) adduct were attributed to the greater inductive effect of Pt because of the 
relatively poor electron-donating ability of the aromatic 5,5′-Me2bipy ligand compared to that of 
the Me2ppz ligand.23 The even more downfield H8 signals for the (R4dt)Pt(d(G*pG*)) adduct 
can be attributed to the presence of six nitrogen atoms in the aromatic rings, making this ligand a 
poorer electron donor than the 5,5′-Me2bipy ligand. We have experimental evidence that the 
presence of DMSO in the solvent mixture also causes the signals to have a more downfield shift 
than in water. The H8 signals for the (R4dt)Pt(d(G*pG*)) solutions containing ~36% DMSO 
were ~0.15 ppm more downfield than when the solution contained ~10% DMSO.  
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For the HH1 and the HH2 conformers of the (R4dt)Pt(d(G*pG*)) adducts, only HH2 
gives sufficient dispersion to assess the canting direction. The 5′-G* is slightly canted toward the 
cis 3′-G*, hence a more upfield 5′-G* H8 signal compared to the 3′-G* H8 signal. The bases in 
the HH2 conformer of (Me4dt)Pt(d(G*pG*)) and (Et4dt)Pt(d(G*pG*)) adducts are right-hand 
canted (Figure 4.12). The H8 chemical shifts and the small dispersion between the H8 signals of 
the HH conformers of the (Me4dt)Pt(d(G*pG*)) and (Et4dt)Pt(d(G*pG*)) adducts (Table 4.2) 
suggest relatively less canted bases in all cases. 
Shift relationships to canting are not so easily interpreted for the ∆HT conformer.23,54 For 
the (R4dt)Pt(d(G*pG*)) adduct, both 3′- and 5′-G* H8 signals are upfield (Table 4.2) but are 
comparatively more downfield than the H8 signals of 3′-G* (8.01 ppm) and the 5′-G* bases (8.18 
ppm) of the ∆HT conformer of the 5,5′-Me2bipyPt(d(G*pG*)) adduct. However, allowing for 
the poor electron-donating effect of the R4dt ligand and the solvent effect (discussed above), the 
bases in the ∆HT conformer for (R4dt)Pt(d(G*pG*)) and (5,5′-Me2bipy)Pt(d(G*pG*)) will most 
likely cant in almost identical manner.23 
For the ΛHT conformer of the (R4dt)Pt(d(G*pG*)) adduct, the small separations of H8 
shifts, 0.38 ppm for the (Me4dt)Pt(d(G*pG*)) adduct and 0.33 ppm for the (Et4dt)Pt(d(G*pG*)) 
adduct, suggest the conformer has relatively small base canting.  
4.4.3.2 Influence of Flanking T Residues on Base Canting. In order to use chemical 
shifts to assess the influence of the flanking residue (T) on the base canting, it is important to 
allow for the possible through-space and inductive effects of the T residue on the chemical shifts. 
These effects can alter the shifts of the G* H8 and sugar proton signals of the respective parent 
(R4dt)Pt(d(G*pG*)) adduct. First, the anisotropic effect of the phosphate group can deshield the 
nearest H8 atom. The presence of a 5′-p group was found to cause a downfield shift of the 5′-G 
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H8 signal.25,46,78 When this group is on the 3′-carbon, it is too far from the G* H8 to have much 
direct influence on the H8 shift. Second, the anisotropy of the T base might also influence the H8 
signals. 
• Influence of the 3′-T on G* Base Canting. The conformers of the 
(R4dt)Pt(d(G*G*T)) adduct with a 3′-flanking T residue have 5′- and 3′-G* H8 signal shifts very 
similar to the respective signals of the (R4dt)Pt(d(G*pG*)) adduct (Table 4.2). The 3′-residue 
has no significant influence on the H8 chemical shifts or the degree of canting for the d(G*pG*) 
moiety.68 These results are consistent with those reported for the (Me2ppz)Pt(d(G*G*T)) 
adduct.68 Because the 3′-T residue is far from the 3′-G* residue, it has little or no effect on the 
direction or degree of canting.  
• Influence of the 5′-T on G* Base Canting. For the (R4dt)Pt(d(TG*G*)) HH1 
conformer, the 5′-G* H8 signals are slightly upfield from the 5′-G* H8 signals of the respective 
(R4dt)Pt(d(G*pG*)) adduct; however, the 3′-G* H8 signals were considerably downfield [0.38 
ppm for (Me4dt)Pt(d(TG*G*)) and 0.62 ppm for (Et4dt)Pt(d(TG*G*))] from the 3′-G* H8 
signal of the respective (R4dt)Pt(d(G*pG*)) adduct (Table 4.2). A very downfield 3′-G* H8 
signal compared to the 5′-G* H8 signal indicates L canting in the HH1 conformer.44,47,68 The 
doublet of doublets coupling pattern of the 5′-T H1′ signal indicates an S-sugar for the HH L 
conformer of (R4dt)Pt(d(TG*G*)) adducts. From X-ray structural data of cis-
Pt(NH3)2(d(pG*pG*) and cis-Pt(NH3)2(d(CG*G*), the ammine cis to the canted 5′-G* in L-
canted, single-stranded (ss) cross-links always has an H-bond to the oligo,24,49 and the 5′-flanking 
residue has an S-sugar.24 Because R4dt ligands cannot form H-bonds, we conclude that the 
degree of L canting is a consequence of the steric effects of the 5′ residue, and the H-bonding 
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interactions are inconsequential. Our results are in agreement with the findings for 
(Me2ppz)Pt(d(TG*G*)) and (Me2ppz)Pt(d(TG*G*T)) showing that any 5′-substituent, including 
the 5′-p group, favors the HH1 L conformer.68  
4.5 Conclusions  
We report here the first evidence of formation of a substantial amount of a fourth form of 
an LPt(d(G*pG*)) adduct. HPLC data suggest that this is the elusive ΛHT conformer of the N7–
Pt–N7 d(G*pG*) cross-link adduct. The putative ΛHT conformer of (R4dt)Pt(d(G*pG*)) is 
kinetically less favored when compared to the HH1, HH2 and ∆HT conformers and becomes 
abundant slowly (~8 weeks) by conformer isomerization. It is possible that this ΛHT conformer 
was not detected in the previously reported less dynamic adducts, even after long time periods, 
because of its slow rate of formation. However, for the (R4dt)Pt(d(G*pG*)) adduct all four 
expected conformers could be identified and characterized by 1H NMR spectroscopy. Our results 
with (R4dt)Pt(5′-GMP)2 revealed that the R4dt carrier ligand is sterically less demanding and 
allows a less restricted rotation of G about the Pt–N7 bond. The detection of all four conformers 
and absence of any EXSY cross-peaks for the (R4dt)Pt(d(G*pG*)) adduct provides the first clear 
evidence that the sugar-phosphodiester backbone between two adjacent G’s slows the exchange 
between the conformers. 
 From the distribution of conformers for (R4dt)Pt(d(G*pG*)), (5,5′-
Me2bipy)Pt(d(G*pG*)),23 BipPt-(d(G*pG*))43,50 and Me2ppzPt(d(G*pG*))54 adducts, 
regardless of the carrier ligand the HH1 conformer is most abundant. However, the 
thermodynamically favored putative ΛHT conformer for (Me4dt)Pt(d(G*pG*)) was almost as 
abundant as the HH1 conformer at equilibrium. NMR results in this study also show that the 
structure of the sugar-phosphodiester backbone differ from conformer to conformer, but the 31P 
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NMR data for the (R4dt)Pt(d(TG*G*)) adduct, for the first time indicated that for a given 
conformer, the backbone structure may depend on the carrier ligand. The low steric effects of the 
N lone pairs of the R4dt ligand allow more space for the HH conformer to exist resulting in a less 
distorted backbone for the HH1 conformer.  
For all the (Et4dt)Pt(d(G*pG*)) conformers (except for ∆HT conformer present in 9% 
abundance only), weak NOE cross-peaks (comparable in size) between the 3′-G* H8 and the 
methyl peaks of the carrier ligand indicated that the substituents at the 6/6′ position in a bis-3,3′-
(1,2,4-triaizine) are close to the cis G*. The (Et4dt)Pt(d(G*pG*)) conformers isolated by HPLC, 
upon re-injection, redistributed slowly (~2 days) compared to the (Me4dt)Pt(d(G*pG*)) 
conformers, which interconverted significantly after ~1day.  Also, in contrast to the 
(Me4dt)Pt(d(G*G*T)) adduct, the ΛHT conformer does not form for the (Et4dt)Pt(d(G*G*T)) 
adduct. These evidences in addition to the results from the (R4dt)Pt(5′-GMP)2 studies65 suggest 
that placing greater bulk at the 6,6′ positions by changing R in R4dt from Me to Et has a clear 
effect on the G* base rotation rate about Pt–N7 bond. 
Because of the symmetrical nature of the carrier ligand in (R4dt)Pt(d(G*pG*)), the two 
bases of the HH and HT conformers may ‘wag’ between R and L canting, causing the H8 signals 
of the conformers to have relatively similar shifts. However, the H8 shifts also indicate that the 
base canting in (R4dt)Pt(d(G*pG*)) conformers is small. These results agree with the low base 
canting observed for the (5,5′-Me2bipy)Pt(d(G*pG*)) conformers. However, the presence of a 
5′-flanking T residue on the d(GpG) sequence introduces L canting of the bases in the HH1 
conformer. Unless a carrier ligand such as (R,S,S,R)-Bip (which favors right-handed canting) is 
present,44,79 all single-stranded N7–Pt–N7 cross-links regardless of oligonucleotide length are 
left-handed.20,54,68 The highly L nature of the ss adducts with a 5′-T residue is chiefly a 
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consequence of the bulk of the 5′ substituents; factors such as H-bonding are inconsequential. 
Also, the 5′-T residue maintains an S-sugar pucker in the ss adducts even in the absence of H-
bonding, providing further support to the finding that the N-pucker of this residue in the Lippard 
bp step of duplexes is related to stacking and Watson-Crick H-bonding and not to the 
insignificance of ammine H-bonding.68 
Several important points have emerged from a comparison of the (R4dt)Pt(oligo) adducts 
with (R4dt)Pt(d(G*pG*)). For (R4dt)Pt adducts at equilibrium, d(G*pG*) and d(G*G*T) 
uniquely have all the four conformers (except for the (Et4dt)Pt(d(G*G*T)) ΛHT conformer 
which does not form), but, in contrast, d(TG*G*) has only the HH1 conformer. The ΛHT 
conformer becomes much less abundant in adducts with a 3′-residue. The structure sensitive 31P 
NMR shifts were similar for the HH conformers of (R4dt)Pt(d(G*G*T)) and 
(R4dt)Pt(d(G*pG*)), however, for the HH1 conformer of (R4dt)Pt(d(TG*G*)) the signals were 
~1 ppm upfield to that for the respective (R4dt)Pt(d(G*pG*)). Evidently, the 3′-flanking T 
residue has little or no effect, but the 5′-flanking T residue has a dramatic effect on the conformer 
distribution and the d(G*pG*) cross-link structure.  
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CHAPTER 5. LIGAND AND COORDINATION-PLANE DISTORTIONS IN Pt(II) 
COMPLEXES OF ISOMERS OF DIMETHYL-2,2′-BIPYRIDINE* 
 
5.1 Introduction 
Rosenberg’s serendipitous discovery of the anticancer activity of cisplatin, cis-
Pt(NH3)2Cl2,1 has stimulated extensive interest in the interaction of Pt complexes with nucleic 
acids. Pt compounds can bind to DNA by either covalent or non-covalent interactions. Cisplatin 
and several other Pt anticancer drugs interact with nucleic acids by forming 1,2-intrastrand cross-
links having covalent Pt−N7 bonds with two adjacent guanines.2,3 Dichloro Pt(II) complexes of 
aromatic sp2 N-donor ligands such as 5,5′-dimethyl-2,2′-bipyridine (5,5′-Me2bipy),4 2,9-
dimethyl-1,10-phenanthroline (2,9-Me2phen)5 and 3-(4-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-
triazine (MepyMe2t)6 (Figure 5.1) also form adducts with Pt−N7 bonds to two guanine ligands. 
From these adducts it is possible to gain insight into structure by using NMR methods, because 
the dynamic motion around the Pt−N7 bonds is decreased compared to adducts of active drugs. 
A Pt(II) complex having aromatic ligands can not only bind to nucleobases but can also 
intercalate into DNA.7-14 Aromatic ring stacking between nucleobases and the intercalating 
molecule is considered to be one of the driving forces leading to binding; the extent of binding is 
expected to depend on the planarity of the complex.11,15 
Because of the planar nature of bipyridine ligands, intercalation of Pt bipyridine 
complexes has been the focus of considerable interest.9,11,16,17 The cation, [(bipy)2Pt]2+ (bipy = 
2,2′-bipyridine), was reported to intercalate into DNA through only one of the bipy ligands.9  
____________________________________________________________________________ 
* Reproduced with permission from International Union of Crystallography: Maheshwari, V.; 
Carlone, M.; Fronczek, F. R.; Marzilli, L. G., "Ligand and Coordination-Plane Distortions in 
Pt(II) Complexes of Isomers of Dimethyl-2,2′-bipyridine," Acta Crystallographica, Section B: 
Structural Science, 2007, B63, 603-611. Copyright 2007 International Union of Crystallography. 
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Figure 5.1 Stick representations and numbering schemes for coordinated (a) dimethyl-2,2′-
bipyridine (Me2bipy) and (b) 3-(4′-substituted pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine 
(R1pyR2R3t) ligands. 
 
For [(R2bipy)M(en)](ClO4)2  (M = Pt or Pd, R = H or CH3 and en = ethylenediamine) 
complexes, the binding constant value was found to be higher for R = CH3 when M = Pd.11 
Previously we speculated that the antiviral activity of the [(pyPh2t)2Pt](BF4)2 (pyPh2t = 3-
(pyridin-2-yl)-5,6-diphenyl-1,2,4-triazine) complex18 could arise from intercalation of the highly 
planar [trans-(pyPh2t)2Pt](BF4)2 complex into nucleic acids.6 
Because the uncoordinated 2,2′-bipyridine ligand is essentially planar with an anti 
conformation,19,20 the H3 to H3′ repulsion is avoided. However, except in rare, unusual cases, 
coordinated bipyridines have a syn conformation (Figure 5.1) leading to the possibility that the 
H3 to H3′ repulsion will explain distortions from planarity found in the coordinated ligand.21 In 
this study we have synthesized and crystallized such dimethyl-2,2′-bipyridine platinum 
complexes as (Me2bipy)PtCl2 and [(Me2bipy)2Pt]X2. Structural analysis of these Me2bipy 
complexes has allowed us to evaluate the effect of having methyl groups at the 4,4′, 5,5′, and 6,6′ 
positions on distortions from planarity of these complexes. The extent of distortion of 
coordinated bipyridine ligands is characterized by parameters in Figure 5.2, defined by Hazell 
(2004). We also discuss the extent of distortions by using the following dihedral angles: θdi, 
between the best planes through the two pyridyl rings in a bipyridine ligand; and θS, between the 
coordination plane (defined by the best plane through the four donor atoms surrounding the 
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metal) and the plane of the aromatic portion of the bipyridine ligand (defined by NCC′N′ atoms) 
(Figure 5.3).22 The structural features and coordination parameters of I-IV are compared with 
those of published Pt/Pd complexes with bipyridine or 3-(pyridin-2′-yl)-5,6-disubstitued-1,2,4-
triazine (R1pyR2R3t) ligands (Figure 5.1). The latter have no H3 to H3′ repulsive interactions.6 
 
 
Figure 5.2 Distortions in bipyridine ligands: (a) twist angle (θT), (b) bowing (θB), (c) S-shaped 
distortion (ds), (d) in-plane bending (θP). θT, θB and θP are the angles between the best straight 
lines (ax + c = z) through each pyridyl ring of the bipyridine ligand in the yz, xz and xy 
projections, respectively. ds is the perpendicular distance between the best straight lines through 
each pyridyl ring in the xz projection.21 
 
 
Figure 5.3 The dihedral angles: θdi between the best planes through the two pyridyl rings in a 
bipyridine ligand; and θS, between the metal coordination plane and the plane containing the 
NCC′N′ atoms of the bipyridine ligand. 
 
5.2 Experimental  
5.2.1 Starting Materials  
4,4′-Dimethyl-2,2′-bipyridine (4,4′-Me2bipy), 5,5′-dimethyl-2,2′-bipyridine (5,5′-
Me2bipy), and 6,6′-dimethyl-2,2′-bipyridine (6,6′-Me2bipy) were used as received (Aldrich). 
cis-Pt(Me2SO)2Cl2 was prepared as described in the literature.23 
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5.2.2 NMR Measurements 
  
1H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz. TMS 
was used to reference the signals.  
5.2.3 General Synthesis of Dichloro Bipyridine Platinum Complexes 
Two methods were employed to obtain (Me2bipy)PtCl2 complexes. Method A involved 
heating a methanol solution (30 mL) of cis-Pt(Me2SO)2Cl2 (0.101 g, 0.24 mmol) and the desired 
Me2bipy ligand (0.044 g, 0.24 mmol) at 60 °C for 12 h. The yellow solid that precipitated was 
collected, washed with diethyl ether followed by chloroform, and dried in vacuo. This method 
produced high yields of powdered (Me2bipy)PtCl2 complexes that required no further 
purification. Method B, employed to obtain X-ray-quality crystals, involved mixing equal 
volumes of 10 mM solutions of cis-Pt(Me2SO)2Cl2 and the ligand in acetonitrile (total volume ~2 
mL) and allowing this mixture to stand at 25 °C. Yellow to orange colored crystals of the 
(Me2bipy)PtCl2 complex were collected after 24 h. 
5.2.3.1 Dichloro(4,4′-dimethyl-2,2′-bipyridyl)platinum(II) ((4,4′-Me2bipy)PtCl2, I). 
Method A gave a yellow precipitate: yield, 73.5 mg (68%). Method B afforded thin yellow 
needles. C12H12Cl2N2Pt: yield, 1.7 mg (38%).1H NMR (ppm) in DMSO-d6: 9.27 (d, H6/6'), 8.44 
(s, H3/3'), 7.66 (d, H5/5'), 2.48 (s, 4/4'-CH3).  
5.2.3.2 Dichloro(5,5′-dimethyl-2,2′-bipyridyl)platinum(II) ((5,5′-Me2bipy)PtCl2, II). 
Method A resulted in a yellow powder: yield, 75.8 mg (70%). Yellow plates were obtained by 
method B. C12H12Cl2N2Pt: yield, 1.9 mg (42%).1H NMR (ppm) in DMSO-d6: 9.28 (s, H6/6'), 
8.42 (d, H3/3'), 8.23 (d, H4/4'), 2.49 (s, 5/5'-CH3).  
5.2.3.3 Dichloro(6,6′-dimethyl-2,2′-bipyridyl)platinum(II) ((6,6′-Me2bipy)PtCl2, III). 
The complex was obtained as a yellow solid by method A: yield, 48.6 mg (45%). Slow 
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evaporation of an acetonitrile solution of (6,6'-Me2bipy)PtCl2 (~10.0 mg in 1 mL) produced X-
ray quality orange needle-shaped crystals. The Pt(6,6′-Me2bipy)Cl2 complex co-crystallized with 
a molecule of acetonitrile. C12H12N2Cl2Pt•C2H3N: yield, 1.1 mg (25%).1H NMR (ppm) in 
(CD3)2CO: 7.55 (d, H(5/5'), 8.15 (t, H4/4'), 8.22 (d, H3/3'), 2.99 (s, 6/6'-CH3).  
5.2.3.4 Bis(4,4'-dimethyl-2,2'-bipyridyl)platinum(II) Tetra-fluoroborate ([(4,4'-
Me2bipy)2Pt](BF4)2, IV). cis-Pt(Me2SO)2Cl2 (42.22 mg, 0.1 mmol) was added to a methanol 
solution of 4,4'-Me2bipy (73.69 mg, 0.4 mmol, 10 mL), and the resulting suspension became a 
solution when stirred at 60 °C for 24 h. The mixture was allowed to cool to room temperature. 
Any precipitate that formed was removed by filtration. Crystals were obtained from the clear 
filtrate by dropwise addition of a methanol solution of NaBF4 (10 mM, ~500 µL) to 10 mL of 
filtrate. Thin, colorless, needle-shaped crystals of [(4,4'-Me2bipy)2Pt](BF4)2 co-crystallized with 
uncomplexed ligand on allowing the solution to stand undisturbed for 24 h. A set of upfield 
signals in the NMR spectrum of the crystals provided evidence of the free 4,4'-Me2bipy ligand. 
C24H24N4B2F8Pt•C12H12N2: yield, 15 mg (21%). 1H NMR (ppm) in DMSO-d6: for [(4,4'-
Me2bipy)2Pt](BF4)2: 8.85 (d, H6/6'), 8.66 (s, H3/3'), 7.82 (d, H5/5'), 2.63 (s, 4/4'-CH3) and for 
4,4'-Me2bipy: 8.49 (d, H6/6'), 8.19 (s, H3/3'), 7.24 (d, H5/5'), 2.38 (s, 4/4'-CH3). 
5.2.4 X-ray Data Collection and Structure Determination  
Single crystals were placed in a cooled nitrogen gas stream at 105 or 110 K on a Nonius 
Kappa CCD diffractometer fitted with an Oxford Cryostream cooler with graphite-
monochromated Mo Kα (0.71073 Å) radiation. Data reduction included absorption corrections 
by the multi-scan method, using HKL Denzo and Scalepack.24 All X-ray structures were 
determined by direct methods and difference Fourier techniques. SIR9725 and SHELXL9726 
programs were used to solve and refine the crystal structures.  
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All H atoms were visible in difference maps, but were placed in idealized positions, with 
C−H = 0.95-1.00 Å, depending on atom type. A torsional parameter was refined for each methyl 
group. Displacement parameters for H were assigned as Uiso = 1.2Ueq of the attached atom (1.5 
for methyl groups). All non-hydrogen atoms were refined anisotropically. For all structures, 
maximum residual densities were located near the Pt positions. 
5.3 Results and Discussion  
Structures of I-IV are reported here (Figure 5.4). Crystal data and structure refinement 
parameters are listed in Table 5.1.  
 
 
Figure 5.4 ORTEP plots of (4,4′-Me2bipy)PtCl2 (I); (5,5′-Me2bipy)PtCl2 (II); (6,6′-
Me2bipy)PtCl2 (III); and [(4,4′-Me2bipy)2Pt](BF4)2 (IV). The solvent molecule in III and the 
uncomplexed 4,4′-Me2bipy ligand and the counter ion (BF4) in IV are not shown for clarity. 
Thermal ellipsoids are drawn with 50% probability. 
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Table 5.1 Crystal Data and Experimental Details for (4,4′-Me2bipy)PtCl2 (I), (5,5′-
Me2bipy)PtCl2 (II), (6,6′-Me2bipy)PtCl2 (III), and [(4,4′-Me2bipy)2Pt](BF4)2 (IV). 
 I II III IV 
Crystal data         
Chemical formula C12H12Cl2N2Pt C12H12Cl2N2Pt C12H12Cl2N2Pt• 
C2H3N 
[Pt(C12H12N2)2](BF4)2• 
C12H12N2 
Mr 450.23 450.23 491.28 921.42 
Cell setting, space 
group 
Monoclinic, P21/n Monoclinic, C2/c Triclinic, 1P  Triclinic, 1P  
Temperature (K) 110 105 105 110 
a, b, c (Å) 6.7739 (10), 10.755 
(2), 17.312 (3) 
13.162 (3), 9.088 
(2), 12.125 (3) 
8.1049 (10), 8.7028 
(10), 12.005 (2) 
7.3395 (10), 10.580 (2), 
12.093 (2) 
α, β, γ (°) 90, 93.80 (2), 90 90, 121.110 (11), 
90 
73.863 (5), 73.919 
(5), 77.132 (6) 
70.602 (9), 87.384 (12), 
79.978 (12) 
V (Å3) 1258.5 (4) 1241.8 (5) 771.78 (18) 872.1 (2) 
Z 4 4 2 1 
Dx (Mg m–3) 2.376 2.408 2.114 1.754 
Radiation type Mo Kα Mo Kα Mo Kα Mo Kα 
µ (mm–1) 11.55 11.71 9.43 4.10 
Crystal form, 
colour 
Needle, yellow Plate, yellow Needle, orange Needle, colorless 
Crystal size (mm) 0.22 × 0.10 × 0.10 0.11 × 0.10 × 0.04 0.15 × 0.05 × 0.05 0.15 × 0.05 × 0.03 
          
Data collection         
Diffractometer KappaCCD (with 
Oxford 
Cryostream) 
KappaCCD (with 
Oxford 
Cryostream) 
KappaCCD (with 
Oxford 
Cryostream) 
KappaCCD (with 
Oxford Cryostream) 
Data collection 
method 
ω scans with κ 
offsets 
ω scans with κ 
offsets 
ω scans with κ 
offsets 
ω scans with κ offsets 
Absorption 
correction 
Multi-scan (based 
on symmetry-
related 
measurements) 
Multi-scan (based 
on symmetry-
related 
measurements) 
Multi-scan (based 
on symmetry-
related 
measurements) 
Multi-scan (based on 
symmetry-related 
measurements) 
 Tmin 0.150 0.341 0.380 0.578 
 Tmax 0.315 0.626 0.624 0.887 
No. of measured, 
independent and 
observed 
reflections 
16686, 7208, 5830 15159, 2482, 2283 34009, 6114, 5654 19893, 6773, 6435 
Criterion for 
observed 
reflections 
I > 2σ(I) I > 2σ(I) I > 2σ(I) I > 2σ(I) 
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(table 5.1 continued)    
Rint 0.039 0.025 0.022 0.045 
θmax (°) 40.7 33.7 33.7 33.7 
          
Refinement         
Refinement on F2 F2 F2 F2 
R[F2 > 2σ(F2)], 
wR(F2), S 
0.037, 0.085, 1.04 0.026, 0.056, 1.06 0.023, 0.045, 1.06 0.043, 0.082, 1.06 
No. of relections 7208 2482 6114 6773 
No. of parameters 157 80 193 245 
H-atom treatment Constrained to 
parent site 
Constrained to 
parent site 
Constrained to 
parent site 
Constrained to parent 
site 
Weighting scheme w = 1/[σ2(Fo2) + 
(0.0235P)2 + 
6.6393P] where P 
= (Fo2 + 2Fc2)/3 
w = 1/[σ2(Fo2) + 
(0.0176P)2 + 
3.5799P] where P 
= (Fo2 + 2Fc2)/3 
w = 1/[σ2(Fo2) + 
(0.0062P)2 + 
1.4431P] where P 
= (Fo2 + 2Fc2)/3 
w = 1/[σ2(Fo2) + 
(0.0253P)2 + 1.6231P] 
where P = (Fo2 + 
2Fc2)/3 
(∆/σ)max 0.001 0.001 0.002 <0.0001 
∆ρmax, ∆ρmin (e Å–3) 2.84, –3.50 1.59, –2.48 1.23, –2.26 1.42, –1.87 
Extinction method SHELXL SHELXL SHELXL SHELXL 
Extinction 
coefficient 
0.00231 (17) 0.00066 (8) 0.0073 (2) 0.0013 (4) 
Computer programs: COLLECT ;30 HKL Scalepack;24 HKL Denzo and Scalepack;24 SIR97;25 SIR97;25 SHELXL-
97;26 ORTEP-3 for Windows.31 
 
The X-ray structures of (6,6′-Me2bipy)PdCl2 and (6-Mebipy)PdCl2 complexes were 
reported at room temperature by Newkome et al. (1982). The deformation calculations were 
done using X-ray data at T = 100 K.27 The structure of II at room temperature was first reported 
by Miskowski (1993) with Z′ = 1 in space group Cc. Marsh (1997), revisiting the perils of Cc, 
pointed out that the structure can be better described with the molecule lying on a twofold axis in 
C2/c.29 Our refinement using low-temperature data confirms Marsh’s assessment. In the structure 
of IV, both the Pt complex and uncomplexed ligand lie on inversion centers. The acetonitrile 
molecule in III is disordered into two orientations with populations 0.720(5):0.280(5), with a 
common methyl site. 
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5.3.1 Out-of-Plane Distortions  
5.3.1.1 Dichloro Pt(II)/Pd(II) Complexes. Hazell noted that bipyridines are not planar 
in metal complexes that have M−N distances within the typical range of ~2.0 to 2.2 Å.32 The out-
of-plane distortions that these complexes display can be described in terms of bowing, twisting, 
and S-shaped deformation (Figure 5.2).21 Hazell examined distortions for 551 metal complexes 
containing 2,2′-bipyridine (bipy) or substituted 2,2′-bipyridines from the Cambridge Structural 
Database33 and calculated that the twist angle (θT) ranges from 0.0 to 26.1° and the bow angle 
(θB) ranges from 0.0 to 19.8°.21  
Table 5.2 Ligand deformation in platinum and palladium complexes.a 
Compound Twist 
angle 
(θT) 
Bow 
angle 
(θB) 
S-shaped 
distortion 
(ds) 
In-plane 
distortion 
(θP) 
M−N 
distance 
(Å) 
Dihedral 
angles 
(θdi) 
Cl−M−Cl 
 
 
(4,4′-Me2bipy)PtCl2 (I)b 2.4 0.1 0.002 5.9 2.023(3) 
2.027(3) 
2.8(6) 89.49(4) 
(5,5′-Me2bipy)PtCl2 (II)b 5.5 0.0 0.075 8.9 2.017(3) 5.56(6) 89.76(5) 
(6,6′-Me2bipy)PtCl2 (III)b 6.1 19.2 0.000 10.9 2.028(2) 
2.030(2) 
20.18(14) 86.25(2) 
(bipy)PtCl234 0.0 0.0 0.000 8.8 2.009(6) 0.0 89.1(1) 
(bipy)PdCl235 2.3 1.9 0.009 8.9 2.03(1) 3.0 89.9(1) 
(6,6′-Me2bipy)PdCl2c 1.2 15.7 0.039 10.0 2.059(1) 
2.043(1) 
15.7(2) 86.42(2) 
(6-Mebipy)PdCl2c 5.6 13.3 0.006 9.3 2.055(1) 
2.021(1) 
14.5(1) 88.74(1) 
(pyMe2t)PtCl26 2.4 1.9 0.003 8.9 2.020(3) 
2.001(3) 
2.9 89.13(3) 
(pyPht)PtCl26 2.1 9.3 0.008 8.1 2.011(11) 
1.996(11) 
9.4 90.12(13) 
(pyPh2t)PtCl26 6.2 2.2 0.032 8.4 2.027(3) 
1.996(3) 
6.6 89.16(3) 
[(4,4′-Me2bipy)2Pt](BF4)2 
(IV)b 
4.6 24.2 0.005 8.7 2.032(3) 24.8(2)  
[(pyPh2t)2Pt](BF4)26 4.1 0.2 0.031 8.5 2.050(3) 4.1  
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(table 5.2 continued)        
     2.019(3)   
[(bipy)2Pt](NO3)232 2.1 1.2 0.073 7.5 2.025(4) 2.3  
 10.4 0.4 0.006 7.4 2.028(5) 11.9  
[(bipy)2Pd](NO3)239 1.8 0.2 0.098 7.9 2.030(1) 
2.030(1) 
1.8  
 7.7 0.3 0.089 8.3 2.028(1) 
2.050(1) 
7.7  
[(bipy)2Pd](BF4)240 8.8 0.2 0.089 8.9 2.031(4) 
2.029(3) 
8.7  
 7.9 2.1 0.104 8.5 2.031(4) 
2.030(3) 
8.1  
[(bipy)2Pd](PF6)222 0.1 19.0 0.006 8.8 2.039(2) 
2.032(2) 
19.1  
a
 Angles are in degrees; ds and the M−N distances are in Å. θT, θB, θP, θdi and ds values were calculated by using a 
program in FORTRAN provided by Dr. Alan Hazell. θdi for structures reported in this work were calculated using 
SHELXL. b This work. c Newkome et al. (1982). Based on new refinements using 100 K data.27 
 
No substantial twisting or bowing distortions were observed for the unsubstituted bipy 
ligand in the (bipy)PtCl234 and (bipy)PdCl235 complexes (Table 5.2), although the small 
distortions that do occur may be the result of packing forces.36-38 These complexes do show 
typical θP (see below) values, but θdi values are small or zero (Table 5.2). 
 
 
Figure 5.5 Side (left) and front (right) view of (6,6′-Me2bipy)PtCl2 (III). 
 
Among the dichloro Pt complexes in Table 5.2, (6,6′-Me2bipy)PtCl2 (III) is the most 
distorted, with an exceptionally large bowing angle (θB = 19.2°) and a comparatively large twist 
angle (θT = 6.1°). These distortions can be attributed to steric repulsion resulting from the close 
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proximity of the 6,6′ methyl groups and the cis chlorides. The θS value shows that the aromatic 
portion of 6,6′-Me2bipy in III is out of the Pt coordination plane by 36.73(11)° (Figure 5.5). 
Similar out-of-plane distortions characterized by θS of 38.84(9)° for (6,6′-Me2bipy)PdCl2 and 
27.44(7)° for (6-Mebipy)PdCl2 (6-Mebipy = 6-methyl-2,2′-bipyridine) were observed. For all 
the other dichloro complexes in Table 5.2, the θS values are small, ranging from 0 to 8°. No S-
shaped distortion (Figure 5.2) is observed for III (Table 5.2). The S-shaped distortions 
characterized by the ds values and calculated for all the dichloro metal complexes listed in Table 
5.2, are within the 0-0.127 Å range reported by Hazell (2004). 
In contrast to the Pt/Pd dichloro complexes of 6,6′-Me2bipy and 6-Mebipy, for all the 
other Pt/Pd dichloro bipyridine complexes studied here and for those in Table 5.2, the distortion 
is characterized more by twisting than bowing (Table 5.2). The two pyridyl rings of the ligand in 
(4,4′-Me2bipy)PtCl2 (I) and (5,5′-Me2bipy)PtCl2 (II) were only slightly twisted with respect to 
each other. The θS values for I (3.9(5)°) and II (0.6(2)°) suggest that the aromatic portion of the 
ligands is only slightly out of the Pt coordination plane. The weakness of the interactions 
between the H6,6′ hydrogens and the cis chlorides may explain the relatively undistorted 
structures of I, II, (bipy)PtCl2 and (bipy)PdCl2. A comparison of these dichloro bipyridine 
complexes with (R1pyR2R3t)PtCl2 complexes is revealing. The twisting and bowing are smaller 
in (pyMe2t)PtCl2 (pyMe2t = 3-(pyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine) and generally similar 
for those in the dichloro bipyridine Pt/Pd complexes. In (pyPh2t)PtCl2 (pyPh2t = 3-(pyridin-2′-
yl)-5,6-diphenyl-1,2,4-triazine), the pyridyl and the triazine rings are more twisted (θT = 6.2°), 
whereas in (pyPht)PtCl2 (pyPht = 3-(pyridin-2′-yl)-5-phenyl-1,2,4-triazine), the pyridyl and the 
triazine rings are more bowed (θB = 9.3°). However, the interactions which can occur in the 
(R1pyR2R3t)PtCl2 complexes should be similar. Thus, the larger distortions in the complexes 
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with phenyl substituents are undoubtedly due to solid state effects. These effects are apparently 
less important for ligands with the smaller methyl substituents. 
 
 
Figure 5.6 (a) Canting, and (b) bow-incline deformations in [(bipy)2Pt]X2 complexes. 
 
5.3.1.2 Bis Chelate Pt/Pd Complexes. For bis bipyridine metal complexes, the hydrogen 
atoms on the 6,6′ carbons of opposite ligands are expected to have a non-bonded internuclear 
separation less than the sum of the van der Waals radii (2.4 Å).41 Consequently, to relieve this 
steric strain, the molecule undergoes either a tetrahedral deformation at the metal, resulting in 
canting of the ligands relative to each other, or bowing of the two pyridyl rings of the bipyridine 
ligand (Figure 5.6).6,42 The bis bipyridine Pt/Pd complexes are more distorted than the dichloro 
bipyridine complexes (Table 5.2). However, the ds values for the S-shaped distortion (Figure 5.2) 
calculated for all the bis chelate metal complexes in Table 5.2 were comparable to those for the 
dichloro metal complexes. The θT and θB values calculated for all the metal complexes in Table 
5.2, except θB in [(4,4′-Me2bipy)2Pt](BF4)2 (IV), lie within the range calculated by Hazell 
(2004). The strain induced by the close approach of the H6 hydrogens on the opposing ligands in 
IV is relieved partly by adopting an incline conformation and partly by bowing of the two 
pyridyl rings of the 4,4′-Me2bipy ligand. The incline conformation in bis chelate complexes is 
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characterized by the dihedral angle (θS), between the metal coordination plane and the NCC′N′ 
ligand plane (18.80(13)°). Figure 5.7 shows that the two pyridyl rings of 4,4′-Me2bipy ligands in 
IV are bowed (θB = 24.2°) away from each other. This type of bow-incline distortion has been 
described previously as a bow-step distortion.22 A slight twisting (θT = 4.6°) of the two pyridyl 
rings in 4,4′-Me2bipy in IV is also seen. 
 
 
Figure 5.7 Side (left) and front (right) view of [(4,4′-Me2bipy)2Pt](BF4)2 (IV). 
 
An alternative distortion to relieve steric stress is canting (Figure 5.6). The canting angle 
(θC) is defined by the dihedral angle between the best planes through the two bipyridine ligands. 
In contrast to the bow-incline distortion in IV, Pt and Pd complexes of the unsubstituted 
bipyridine distort more frequently by canting. In [(bipy)2Pt](NO3)2,32 the two bipy ligands are 
canted relative to one another (θC = 34.47°). In order to further relieve the repulsion due to the 
interligand 6,6′-hydrogens, each bipy ligand is also twisted, with one bipy twisted (θT = 10.4°) 
more than the other (θT = 2.1°). A very similar structure was reported for [(bipy)2Pd](NO3)239 
(Table 5.2). In [(bipy)2Pd](BF4)240 the two bipy ligands are canted (θC = 36.45°) and also twisted 
(θT = 8.8° and 7.9°). In contrast, a bow-incline distortion (θB = 19.0°, θS = 21.6°) similar to that 
in IV was found for the PF6 salt, [(bipy)2Pd](PF6)2.40 However, unlike IV, the bipy ligands in 
[(bipy)2Pd](PF6)2 are not twisted.  
In contrast to [(4,4′-Me2bipy)2Pt](BF4)2, the geometry of [trans-(pyPh2t)2Pt](BF4)2 is 
planar and symmetrical because of the trans relationship of the coordinated pyPh2t ligands.6 The 
complex, [trans-(pyPh2t)2Pt](BF4)2, has no apparent bowing or canting. The attractive 
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interaction between the lone pairs on the non-bonded triazine N of one ligand and the pyridyl 
H6′ of the opposing ligand is probably responsible for the planarity of [trans-(pyPh2t)2Pt](BF4)2. 
The interactions between the juxtaposed groups on the two rings ortho to the bridging carbons 
and on the periphery of the bidentate ligand are favorable for R1pyR2R3t ligands but unfavorable 
for 2,2′-bipyridine-type ligands. For all the bis bipyridine metal complexes discussed above, the 
interligand hydrogen-hydrogen separations are less than the sum of the van der Waals radii, 
indicating that unfavorable repulsions lead to the canting and bow-incline distortions. These 
distortions must be similar in energy with solid-state effects determining which distortion occurs 
for a particular cation/anion combination. 
5.3.2 In-Plane Bending and Coordination-Plane Distortion of Dichloro Pt(II)/Pd(II) 
Complexes 
 
5.3.2.1 In-Plane Bending. The in-plane bending for all the metal complexes studied here 
is well within the range (θP = 2.9-12.5°) reported by Hazell (2004). As mentioned, the repulsive 
interaction of the H3 to H3′ in the metal complexes bearing bipyridine ligands was postulated to 
cause an in-plane bending.32 However, for all the dichloro bipyridine Pt/Pd complexes and 
(R1pyR2R3t)PtCl2 complexes in Table 5.2, the M−N distances are comparable. It is noteworthy 
that in-plane bending in Pt complexes of R1pyR2R3t ligands, unlike bipyridines, cannot be 
increased by H3-H3′ repulsions because the pyridyl H3 is near the lone-pair-bearing triazine N; 
this juxtaposition should create a slight favorable attractive interaction. Therefore, any stress 
resulting from H3 to H3′ repulsion in bipyridine metal complexes does not produce any 
substantial effect on the in-plane bending. Rather, coordination of these bidentate ligands to the 
metal may require in-plane bending of the ligands in order to allow optimal overlap of the N and 
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metal orbitals. This interpretation is consistent with the report that the θP values decrease with 
increasing M−N distances.21 
The Cl–Pt–Cl bond angle is significantly smaller in III and (6,6′-Me2bipy)PdCl2 than in 
all other dichloro bipyridine metal complexes in Table 5.2. The Cl–M–Cl bond angle increases in 
the order: III ≈ (6,6′-Me2bipy)PdCl2 < (6-Mebipy)PdCl2 < (pyMe2t)PtCl2 ≈ (pyPh2t)PtCl2 < I ≈ 
II ≈ (bipy)PtCl2 ≈ (bipy)PdCl2 (Table 5.2). Complexes with larger θP values are observed to 
have generally smaller Cl−Pt−Cl bond angles (Table 5.2). 
For III and (6,6′-Me2bipy)PdCl2, the θP values are comparatively larger and the Cl–M–
Cl bond angles are smaller than those for all other dichloro metal complexes in Table 5.2. A 
large in-plane bending will cause the 6,6′ methyl groups to be closer to the Cl’s. The internuclear 
distances between the C’s of the methyl groups and the cis chlorides (CMe⋅⋅⋅Cl) are 3.138 and 
3.186 Å for III and 3.151 and 3.178 Å for (6,6′-Me2bipy)PdCl2. These values are even smaller 
than the sum of the minimum value calculated for the van der Waals radii of the methyl group43 
and the Cl atom (3.461 Å), as well as for the C and the Cl atoms (3.45 Å).41 Thus, the repulsions 
between the 6,6′ methyl groups and the cis chlorides push the Cl atoms toward one another, 
causing the Cl–Pt–Cl bond angle to be smaller than that for the other dichloro metal complexes 
in Table 5.2. The Cl to Cl internuclear distance (3.148 Å) in III and (6,6′-Me2bipy)PdCl2 is 
smaller than the sum of the van der Waals radii (3.5 Å), resulting in repulsive interactions.  
5.3.2.2 Coordination-Plane Distortion. Cl-to-Cl and Cl-to-methyl group repulsions can 
distort the coordination plane (Figure 5.8). This distortion is best analyzed using the dihedral 
angle (α) between the N,M,N′ plane and Cl,M,Cl plane. The α values for III and (6,6′-
Me2bipy)PdCl2 are 11.5(3)° and 14.3(1)°, whereas for the less distorted dichloro metal 
complexes listed in Table 5.1, the α values range from 0° to 4.3°. 
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Figure 5.8 Stick representation of (a) (6,6′-Me2bipy)PtCl2, (b) (6,6′-Me2bipy)PdCl2, (c) (6-
Mebipy)PdCl2, (d) ((−)-sparteine)PdCl2 and (e) ((−)-α-isosparteine)PdCl2.  
 
In order to understand better the steric effect of the group on the carbon adjacent to the 
coordinated N on the Cl−M−Cl grouping, we compared the complexes studied here with ((−)-α-
isosparteine)PdCl2 and ((−)-sparteine)PdCl2.44 For the symmetrical ((−)-α-isosparteine)PdCl2, 
the Cl–M–Cl angle (86.205(15)°) and the internuclear separations found between the C’s 
adjacent to the coordinated N’s and the cis Cl’s (3.130 and 3.168 Å) are comparable to those in 
III and in (6,6′-Me2bipy)PdCl2. Because of the bulk near the coordinated N’s of ((−)-α-
isosparteine)PdCl2, the Cl atoms are largely pushed out of the N,Pd,N′ plane (α = 22.1°) and are 
3.172 Å apart. Because of the less accommodating geometry of the (−)-sparteine than the (−)-α-
isosparteine or bipyridine-type ligands, ((−)-sparteine)PdCl2 has an even smaller Cl−Pd−Cl 
angle (83.09(3)°) and shorter C⋅⋅⋅Cl (3.034 and 3.072 Å) and Cl⋅⋅⋅Cl (3.071 Å) distances. One of 
the Cl atoms in the unsymmetrical ((−)-sparteine)PdCl2 complex is displaced from the N,Pd,N′ 
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plane, while the other Cl is located close to this plane (α = 9.9°) (Figure 5.8). For the 
unsymmetrical (6-Mebipy)PdCl2 complex, the Cl cis to the 6-methyl group is displaced from the 
N,Pd,N′ plane, but the Cl cis to the H6' is closer to the plane (Figure 5.8). Both the Cl–Pd–Cl 
angle and α (14.30(7)°) are larger than those for ((−)-sparteine)PdCl2. Thus, dichloro complexes 
with ligands accommodating distortions characterized by larger values of α tend to have a less 
distorted Cl−M−Cl grouping. 
5.4 Conclusions 
The platinum complexes characterized here have typical M−N distances of ~2.0 Å, and 
thus can be viewed as being representative of pseudo square-planar complexes of bipyridine-type 
ligands. When combined with literature data, the new results allow conclusions to be reached 
about the relative influence on structural distortions of intramolecular interactions vs. solid-state 
effects.  
The distortions in (6,6'-Me2bipy)PtCl2 (III) are best appreciated by comparison to its 
relatively undistorted isomers, I and II, which have 6,6′ hydrogens. The Cl−M−Cl grouping in 
the latter is normal, indicating good overlap of the metal and chloride bonding orbitals, a 
situation allowed by the weakness of the repulsive 6,6′-C to Cl interactions for the distances of 
~3.1 Å. Also, attractive interactions between the 6,6′ hydrogens and the cis chlorides may exist. 
However, the presence of 6,6′ methyl groups in the 6,6'-Me2bipy ligand of III and its Pd 
analogue gives rise to a highly distorted structure, characterized by large bowing and an incline 
of the aromatic ring relative to the coordination plane. This bow-incline distortion creates ~3.1 Å 
C to Cl distances and allows the chlorides to remain close to the coordination plane in these Pt 
and Pd complexes. When the bulky ligand is not aromatic, the complex must either distort the 
coordination plane (e.g. ((−)-α-isosparteine)PdCl2) or adopt an acute Cl-Pd-Cl angle (e.g. ((−)-
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sparteine)PdCl2) to maintain the ~3.1 Å C to Cl distances. The coordination plane of ((−)-
sparteine)PdCl2 is less distorted and has an α value similar to those in III and also in the 
structurally similar 2,9-Me2phen45 and Pd analogues of III. Thus, distortions found in dichloro 
complexes are quite diverse but are not dependent on whether the metal is Pt or Pd. In contrast, 
as discussed next, we can conclude that the highly distorted dichloro compounds have some 
features that can be related to those found for bis bipyridine-type complexes.  
In bis bipyridine complexes, the strain induced by the close proximity of the H’s on the 
C6 carbons of the opposing ligands is relieved either by a bow-incline distortion or by canting of 
the two bipyridine ligands. Of the five relevant structures in Table 5.2, three have canting and 
two have bow-incline distortion.  The structure of IV adds a new bipyridine ligand to the existing 
bis bipyridine structures and also demonstrates that the bow-incline distortion can occur in a Pt 
complex. Consequently, there are now examples of both types of distortions for both Pt and Pd. 
It is reasonable to conclude that these two types of distortions are similar in energy and that 
minor solid-state effects determine which distortion type is observed. In contrast to IV, [trans-
(pyPh2t)2Pt](BF4)2 has a relatively planar structure, which can be attributed to the favorable 
juxtaposition of the pyridyl H6′ proton and the triazine lone pair of electrons, adding support to 
the conclusion that the distortions in bis bipyridine complexes arise from interligand repulsions 
involving 6,6' hydrogens. 
Average values of θP for bipyridine complexes I to IV and for the four pyridyl triazine 
complexes in Table 5.2 are very similar. Thus, while the present study indicates that interligand 
repulsions involving H6 and H6' influence structure, sometimes dramatically, H3 to H3' 
intraligand repulsions have no evident effect on structure. 
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CHAPTER 6. SUMMARY AND CONCLUSIONS 
 
The platinum complexes of the type LPtCl2 and [L2Pt]2+ (L = bidentate sp2 N-
donor ligands) were successfully synthesized and crystallized. The platinum complexes 
characterized here have typical M−N distances of ~2.0 Å, and thus can be viewed as 
being representative of pseudo square-planar complexes of bipyridine-type ligands. The 
X-ray crystallographic data allowed conclusions to be reached about the relative 
influence of intramolecular interactions on the structural distortions.  
 The LPtCl2 complexes with L = dimethyl-2,2′-bipyridine (Me2bipy) have a more 
planar structure when compared to complexes having 3-(2′-pyridyl)-1,2,4-triazine (pyt) 
ligands. For the 4,4′- and the 5,5′- Me2bipy, the attractive interactions between the H6 
protons and the cis Cl results in a highly planar structure. However, presence of 6,6′ 
methyl groups in the 6,6'-Me2bipy ligand gives rise to a highly distorted structure, 
characterized by large bowing and an incline of the aromatic ring relative to the 
coordination plane. On the contrary the L2Pt2+ complexes with L = Me2bipy are more 
distorted than when L = pyt. The juxtaposition of the pyridyl H6 proton and the triazine 
lone pair of electrons in [L2Pt]X2 allows formation of a planar structure. Also, this 
juxtaposition favors the trans arrangement of the bidentate ligands in [(pyt)2Pt]X2.  For a 
given bidentate ligand, the interactions between the juxtaposed groups on the two rings 
ortho to the bridging carbons and on the periphery of the bidentate ligand are favorable 
for pyt ligands but unfavorable for Me2bipy. 
The reaction of LPtCl2 complexes (L = 5,5′-Me2bipy, MepyMe2t and bis-3,3′-
(5,6-disubstituted-1,2,4-triazine) (R4dt)) with guanine derivatives (G) were informative. 
The bulk of the bidentate sp2 N-donor ligands is sufficient to impede the rotation of the G 
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bases about the Pt–N7 bonds of the LPtG2 adducts; thus, H8 signals for conformers could 
be resolved and assigned. From NMR data (including EXSY results), for LPt(GMP)2, the 
qualitative rates of conformer interconversion follow the order, Me4dt > Et4dt > 
MepyMe2t > 5,5′-Me2bipy. Thus, we conclude that the pyridyl H6′ atom strongly 
impedes the rotation of the cis G base about the Pt–N7 bond by clashing with G O6, 
whereas the equivalently placed lone pair of the relevant non-bonded N of the triazine 
does not so strongly impede G rotation. Thus, the triazine ring has a lower overall steric 
effect than the pyridyl ring. Our conclusion that the lone pair on the non-bonded nitrogen, 
N1, of the triazine ring is not sterically demanding is also supported by results from the 
reaction of (MepyMe2t)PtCl2 with Guo to form a [(MepyMe2t)Pt(Guo)2]2+ adduct. The 
intermediate properties of MepyMe2t, with one triazine and one pyridyl ring led to 
EXSY data for the (MepyMe2t)Pt(5′-GMP)2 adduct that allowed us to unambiguously 
determine and assign the conformation of the two HH conformers, HHa and HHb.  
The nature of the carrier ligand in LPtG2 adducts influences the distribution of 
conformers and their characteristics. Typically, one HT conformer dominates over the 
other HT and the HH conformer at low pH (~4), especially at neutral pH. We have 
discovered that carrier ligands of the type, R4dt, lead to the HH having almost 
comparable abundance to the total of the two HT conformers for the (R4dt)Pt(5′-GMP)2 
adduct at equilibrium at pH 4. We conclude that the sterically less demanding nature of 
the R4dt ligand allows ample space for the HH conformer to exist with less significant 
clashes between the O6 atoms of the 5′-GMP’s. Normally, second-sphere communication 
raises the abundance of one HT conformer as the pH is raised to near neutrality. This 
trend was found for the (R4dt)Pt(5′-GMP)2 adducts. However, the abundance of the HH 
 146 
isomer remains high. Given the finding that carrier ligands favoring the HH conformer in 
the cross-link are associated with anticancer activity,1 Pt complexes of R4dt ligand 
should be tested for activity.  
The interesting results with (R4dt)Pt(GMP)2 adducts led us to expand our study to 
single-stranded (ss) DNA adducts. Studies with the (R4dt)Pt(d(G*pG*)) adduct provided 
the first evidence of formation of a substantial amount of a fourth form of an 
LPt(d(G*pG*)) adduct. HPLC data suggest that this is the elusive ΛHT conformer of the 
N7–Pt–N7 d(G*pG*) cross-link adduct. The putative ΛHT conformer of 
(R4dt)Pt(d(G*pG*)) is kinetically less favored when compared to the HH1, HH2 and 
∆HT conformers and becomes abundant slowly (~8 weeks) by conformer isomerization. 
It is possible that this ΛHT conformer was not detected in the previously reported less 
dynamic adducts, even after long time periods, because of its slow rate of formation. 
However, for the (R4dt)Pt(d(G*pG*)) adduct all four expected conformers could be 
identified and characterized by 1H NMR spectroscopy. Our results with (R4dt)Pt(5′-
GMP)2 revealed that the R4dt carrier ligand is sterically less demanding and allows a less 
restricted rotation of G about the Pt–N7 bond. The detection of all four conformers and 
absence of any EXSY cross-peaks for the (R4dt)Pt(d(G*pG*)) adduct provides the first 
clear evidence that the sugar-phosphodiester backbone between two adjacent G’s slows 
the exchange between the conformers. 
From the distribution of conformers for (R4dt)Pt(d(G*pG*)), (5,5′-
Me2bipy)Pt(d(G*pG*)),2 BipPt-(d(G*pG*))3,4 and Me2ppzPt(d(G*pG*))5 adducts, 
regardless of the carrier ligand the HH1 conformer is most abundant. However, the 
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thermodynamically favored putative ΛHT conformer for (Me4dt)Pt(d(G*pG*)) was 
almost as abundant as the HH1 conformer at equilibrium.  
NMR results in this study also show that the structure of the sugar-phosphodiester 
backbone differ from conformer to conformer, but the 31P NMR data for the 
(R4dt)Pt(d(TG*G*)) adduct, for the first time indicated that for a given conformer, the 
backbone structure may depend on the carrier ligand. The low steric effects of the N lone 
pairs of the R4dt ligand allow more space for the HH conformer to exist resulting in a 
less distorted backbone for the HH1 conformer.  
The effect of flanking residues in LPt(d(oligo)) adducts is presented here for the 
first time for L = planar sp2 N-donor ligand. Several important points have emerged from 
a comparison of the (R4dt)Pt(oligo) adducts with (R4dt)Pt(d(G*pG*)). For (R4dt)Pt 
adducts at equilibrium, d(G*pG*) and d(G*G*T) uniquely have all the four conformers 
(except for the (Et4dt)Pt(d(G*G*T)) ΛHT conformer which does not form). The ΛHT 
conformer becomes much less abundant in adducts with a 3′-residue. However, the 5′-
flanking T residue exclusively favors the HH1 L conformer. The highly L nature of the 
single-strand DNA adducts with a 5′-T residue is chiefly a consequence of the bulk of the 
5′ substituents; factors like H-bonding are inconsequential. Evidently, the 3′-flanking T 
residue has little or no effect, but the 5′-flanking T residue has a dramatic effect on the 
the d(G*pG*) cross-link structure, conformer distribution and canting.  
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APPENDIX A. SUPPLEMENTARY MATERIAL FOR CHAPTER 2 
A.1 1H NMR Spectra of [L2Pt]2+ Complexes. 
 
 
Figure A.1 1H NMR spectra of [(pyPht)2Pt]2+, [(pyPh2t)2Pt]2+, [(MepyMe2t)2Pt]2+, and 
[(MepyPh2t)2Pt]2+ in DMSO-d6 solution at 25 °C. The signals for the substituents on C5 and C6 
are assigned by type only, except for [(pyPht)2Pt]2+, which is completely assigned. 
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A.2 1H NMR Chemical Shifts for [L2Pt]2+ Complexes 
Table A.1 1H NMR Chemical Shifts (ppm) in DMSO-d6 for [L2Pt]X2 Complexes 
[L2Pt]2+ H6′ H5′ C4′ 
substituent 
H3′ C5, C6 substituentsa 
[(MepyMe2t)2Pt]2+ 9.99(d) 8.23(d) 2.74(s, CH3) 8.60(s) 2.91(s, CH3), 3.01(s, CH3) 
[(pyPht)2Pt]2+ 10.23(d) 8.80(t) 8.42(t, H) 9.15(d) 10.51(s, H), 8.78(d, o-PhH), 
7.96(t, p-PhH), 7.83(t, m-PhH) 
[(pyPh2t)2Pt]2+ 10.18(d) 8.81(t) 8.50(t, H) 9.06(d) 7.86(d, o-PhH), 7.95(d, o-PhH), 
7.71(t, m-PhH), 7.59(t, p-PhH) 
[(MepyPh2t)2Pt]2+ 9.99(d) 8.34(d) 2.58(s, CH3) 8.92(s) 7.83(d, o-PhH), 7.96(d, o-PhH), 
7.70(m-PhH), 7.58(t, p-PhH) 
aThe C5 and C6 substituents were not specifically assigned, except for [(pyPht)2Pt]2+. 
 
A.3 Reactions of pyMe2t and cis-Pt(Me2SO)2Cl2 Studied by 1H NMR Spectroscopy. 
A.3.1 Formation and Properties of (pyMe2t)PtCl2.  
Cis-Pt(Me2SO)2Cl2 (1.16 mg, 5 mM) was added to a DMSO-d6 solution (550 µL) of 
pyMe2t (0.51 mg, 5 mM) to obtain a 1:1 molar ratio of Pt:pyMe2t. Within 1 h of mixing, two 
new sets of bound pyMe2t signals in a ratio of ∼4:1 were observed (Figure A.2). The intensity of 
the new sets of signals increased with time. Two experiments were performed to assign the 
products and to determine if either product had the triazine ring bound to the Pt through N4 
instead of N2. 
Two separate solutions of (pyMe2t)PtCl2 (1.25 mg, 5 mM) in DMSO-d6 (550 µL) were 
prepared. Within 5 min of dissolving (pyMe2t)PtCl2 in DMSO-d6, two sets of signals were 
observed in a ratio of ∼4:1, which remained constant, even after three days. These were the same 
signals observed in the 1:1 reaction. To the first solution [NEt4]Cl (2 mM) was added; the H6′ 
signal corresponding to the minor complex (at 9.44 ppm) disappeared, while the intensity of the 
H6′ signal (at 9.61 ppm) of the major complex increased. We attribute this result to conversion 
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of a minor solvolysis product to the dichloro complex by the high concentration of chloride. 
Thus, the H6′ doublet at 9.61 ppm was assigned to (pyMe2t)PtCl2, and the doublet at ~9.44 ppm 
was assigned to [(pyMe2t)Pt(Me2SO-d6)Cl]+. To the second solution, 10% D2O was added, and 
within 30 min the intensity of the H6 signal at 9.44 ppm increased, while that of the signal at 
9.61 ppm decreased, confirming that the 9.44 and 9.61 signals are due to a solvolysis product and 
to the dichloro complex, respectively. No isomer of the pyridyl triazine with L bound via N4 was 
detected.  
A.3.2 Formation of [(pyMe2t)2Pt]2+.  
Cis-Pt(Me2SO)2Cl2 (1.16 mg, 5 mM) was added to a DMSO-d6 solution (550 µL) of 
pyMe2t (2.05 mg, 20 mM) to obtain a 1:4 molar ratio of Pt:pyMe2t. After 1 h of mixin, one set 
of new signals appeared in addition to the signals of the uncomplexed pyMe2t ligand (Figure 
A.2). In this 4:1 experiment, the same doublet found in the 1:1 experiment at 9.61 ppm was 
present as the most downfield of the four new signals and was assigned to (pyMe2t)PtCl2. Within 
~2 h, the neutral (pyMe2t)PtCl2 complex started precipitating. After ~1 day, four additional, but 
very weak signals for bound L were observed, the most downfield signal appearing at 10.2 ppm. 
This second reaction did not go to completion even in the presence of a threefold excess of 
pyMe2t ligand. However, on addition of 10% D2O to the sample, the signal at 10.2 ppm grew 
almost immediately. After ~1 h, signals assigned to (pyMe2t)PtCl2 disappeared, while the more 
downfield set of signals for bound L remained (Figure A.2). Again, no evidence for platinum 
binding at N4 of the triazine ring was observed in any spectra. The doublet at 10.2 ppm was thus 
assigned to the pyridyl H6′ of the [(pyMe2t)2Pt]2+ cation having a trans relationship of the bound 
pyMe2t ligands as found crystallographically for 8. These findings indicate that the bound 
dichloro complex is favored thermodynamically in DMSO-d6 and does not lose the chloro ligand 
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unless enough water is present to solvate the released chloride. Therefore, in studying the 
reaction of (pyMe2t)PtCl2 with Guo we used a D2O/DMSO-d6 solution as the solvent. 
 
 
Figure A.2 1H NMR spectra, using numbering system in Scheme 2.1, of DMSO-d6 solutions at 
25 °C: pyMe2t (bottom); 1:1 reaction mixture of pyMe2t and cis-Pt(Me2SO)2Cl2, 1 h after 
mixing (middle); and 4:1 reaction mixture of pyMe2t and cis-Pt(Me2SO)2Cl2, 1 h after addition 
of 10% D2O (top). 
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APPENDIX B. SUPPLEMENTARY MATERIAL FOR CHAPTER 3 
B.1 Conformer Assignment And Their Characteristics 
B.1.1 (Me4dt)Pt(5′-GMP)2.  
Within 24 h of mixing 1 equiv of (Me4dt)PtCl2 with 2 equiv of 5′-GMP at pH 4.0, six 
new broad and poorly resolved downfield H8 NMR signals (at ~25 °C) were observed, 
suggesting relatively fast 5′-GMP rotation. Most spectra were collected at 5 °C, where the 
reduced rate of G base rotation led to resolved sharp signals. Of the six new 5′-GMP H8 signals 
of (Me4dt)Pt(5′-GMP)2, the two comparably intense H8 signals at 8.87 and 8.82 ppm diminished 
with time, and after 4 days these were very small compared to the other four H8 signals (Figure 
B.1). These two H8 signals were the major signals when (Me4dt)PtCl2 and 5′-GMP were mixed 
in a 1:1 ratio and were absent when the two were mixed in a 1:3 ratio; thus, the two signals were 
assigned to the two rotamers of the mono 5′-GMP Pt adduct. The 5′-GMP in the mono 5′-GMP 
Pt adduct can have the H8 atom pointing either upward or downward out of the Pt coordination 
plane. 
 
 
Figure B.1 H8 region of 1H NMR spectra of (Me4dt)Pt(5′-GMP)2 at 5 °C. The H8 signals of the 
1:1 adduct are labeled with asterisks. 
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Figure B.2 ROESY spectrum of the (Me4dt)Pt(5′-GMP)2 adduct in the H8 region at pH 4.0 and 
5 °C. The cross-peak labeled as HH is an NOE between the H8 signals of the HH conformer. The 
other labeled cross-peaks are EXSY cross-peaks between the H8 signals of two different 
conformers.  
 
Solution studies of the (Me4dt)Pt(GMP)2 adducts were conducted in the pH range of ~4 
to ~7 because decomposition produced free GMP at high pH. For the (Me4dt)Pt(5′-GMP)2 
adduct, from pH 4.0-7.0 the two H8 signals at 9.10 and 8.66 ppm shifted downfield to 9.27 and 
8.74 ppm, respectively. These signals were assigned to the HH conformer because they remained 
nearly equal throughout the pH titration, and they were connected by an NOE cross-peak in a 
ROESY spectrum (Figure B.2). Upon aising the pH from 4.0 to 7.0, the H8 signals at 9.08 and 
8.96 ppm belonging to the HT rotamers shifted slightly upfield to 9.06 and 8.95 ppm, 
respectively (Table 3.1 and Figure B.1). At pH ~4, the HT H8 signals are nearly equal in 
intensity, the weak CD signal is consistent with nearly equal abundance of the ∆HT and ΛHT 
conformers. At pH 7.0 the H8 signal at 8.95 ppm became the dominant H8 signal. The CD signal 
shape at pH ~7 (Figure B.3) is characteristic of the ΛHT conformer1-5 favored by SSC on 
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phosphate deprotonation.5-8 Thus, the H8 signal at 8.95 ppm was assigned to the ΛHT 
conformer. The remaining H8 signal at 9.06 ppm (pH 7.0) was assigned to the ∆HT conformer.  
 
 
Figure B.3 CD spectra of (Me4dt)Pt(5′-GMP)2 and (Me4dt)Pt(3′-GMP)2 at 25 °C. 
 
For the (Me4dt)Pt(5′-GMP)2 adduct at pH 7.0, the H8 signal of the major ΛHT conformer 
is upfield to that of the minor ∆HT conformer, as also observed for the (Et4dt)Pt(5′-GMP)2 
adduct. In both cases, if the major ΛHT conformer is the ‘6-out’ form and the minor ∆HT 
conformer is the ‘6-in’ form, the canting is R-handed. 
A ROESY spectrum of (Me4dt)Pt(5′-GMP)2 at pH 4.0 shows four EXSY cross-peaks 
even at 5 °C (Figure B.2). Both the HHd signal (9.10 ppm) and the HHu signal (8.66 ppm) have 
an EXSY cross-peak with the H8 signal (8.96 ppm) of the ΛHT rotamer. A ∆HT H8 - HHu H8 
EXSY cross-peak is seen, but no ∆HT H8 - HHd H8 cross-peak could be detected because the 
two H8 signals have very similar shifts.  Also, the presence of a weak EXSY cross-peak between 
the H8 signals of the ∆HT and the ΛHT rotamers indicates that this interconversion is rapid, even 
though it proceeds via the intermediacy of the HH rotamer. Thus, relatively faster interchange 
occurs between the rotamers for the (Me4dt)Pt(5′-GMP)2 adduct than for adducts with ligands 
containing a pyridyl moiety. 
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Increasing the pH from 4.0 to 7.0 changed the abundance of the HH, ΛHT, and ∆HT 
atropisomers of (Me4dt)Pt(5′-GMP)2 adduct from 40%, 30%, and 30% to 35%, 46%, and 19%, 
respectively (Figure B.1). At pH 4.0, the two HT conformers are equally abundant, and the HH 
conformer has a relatively high abundance. With increasing pH, SSC effects favor the ΛHT 
conformer; however, the abundance of the HH conformer is still relatively high, as compared to 
previously studied LPt(5′-GMP)2 adducts. 
B.1.2 (Me4dt)Pt(3′-GMP)2.  
 
 
Figure B.4. H8 region of the 1H NMR spectrum of (Me4dt)Pt(3′-GMP)2 at pH 4.0 and 5 °C. The 
H8 signal of the 1:1 adduct is indicated by an asterisk. 
 
Three new H8 signals were observed downfield to the free 3′-GMP H8 signal at 5 °C and 
pH 4.0 (Figure B.4). The most upfield H8 signal (at 8.78 ppm, Figure B.4), which disappeared 
with time, was assigned to the two rapidly interconverting rotamers of the 1:1 3′-GMP adduct. 
After 2 days, only the two downfield H8 signals at 8.85 and 8.83 ppm were present in a 3:1 ratio. 
The CD signal shape observed at pH ~4 (Figure B.3) is characteristic of the ∆HT 
conformation,1,3,4,8  which is the usually favored conformer by SSC at pH ~7 and below.5-8  
Therefore, at pH 4.0, the dominant H8 signal at 8.85 ppm was assigned to the ∆HT conformer 
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(major) and that at 8.83 ppm was assigned to the ΛHT conformer (minor). The ‘6-in’ major form 
is the ∆HT R conformer and the ‘6-out’ minor form is the ΛHT R. No evidence for the HH 
rotamer of the (Me4dt)Pt(3′-GMP)2 adduct was detected, even at 5 °C. At pH 7.0 the H8 signals 
are highly overlapped, but we estimate that the percent abundance of the ∆HT H8 signal 
increases from 75% to over 80%. 
 
B.2 Chemical Shifts of the H1′ and H6/H6′ Signals of LPt(GMP)2 Adducts   
Table B.1 Chemical Shifts of the H1′ Signals of LPt(GMP)2 Adducts  (L = 5,5′-Me2bipy, Et4dt, 
Me4dt) and the H6/H6′ Signals of (5,5′-Me2bipy)Pt(GMP)2 Adducts at 5 °C a 
complex pH  ∆HT ΛHT HHd HHu 
(5,5′-Me2bipy)Pt(5′-GMP)2b 4.0 H1′ 6.03 6.00 6.10 6.08 
 4.0 H6/H6′ 7.78 7.90 7.72 7.82 
 7.5 H1′ 6.00 5.97 6.09 6.04 
 7.5 H6/H6′ 7.84 8.03 7.70 7.84 
(5,5′-Me2bipy)Pt(3′-GMP)2b 4.0 H1′ 6.12 6.03 c c 
 4.0 H6/H6′ 8.06 7.79 c c 
 7.5 H1′ 6.12 6.01 c c 
 7.5 H6/H6′ 8.24 7.82 c c 
(Et4dt)Pt(5′-GMP)2 4.0 H1′ 6.07 6.03 6.08 6.03 
(Et4dt)Pt(3′-GMP)2 4.0 H1′ 6.10 6.07 c c 
 7.5 H1′ 6.07 6.07 c c 
(Me4dt)Pt(5′-GMP)2 4.0 H1′ 6.11 6.06 6.11 6.02 
 7.0 H1′ 6.10 6.03 6.09 6.03 
(Me4dt)Pt(3′-GMP)2 4.0 H1′ 6.11 6.09 c c 
 7.0 H1′ 6.10 6.10 c c 
a
 Signal assignments are based on the 2D NMR studies. b NMR spectrum recorded at 25 °C. c 
Signal not detected. 
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Table B.2 Chemical Shifts of the H1′and the H6′ Signals of (MepyMe2t)Pt(GMP)2 Adducts at 
25 °C a  
complex pH  ∆HT ΛHT HHa HHb 
   ∆HTd 
(py) 
∆HTu 
 
(t) 
ΛHTd 
(py) 
ΛHTu 
(t) 
HHad 
(t) 
HHau 
(py) 
HHbd 
(t) 
HHbu 
(py) 
(MepyMe2t)Pt(5′-
GMP)2 
2.5 H1′ 6.05 6.09 6.05 6.05 6.05 6.05 6.07 6.07 
 2.5 H6′ 8.09  8.09   8.09  8.02 
 7.5 H6′ 8.10  8.25   8.10  7.99 
(MepyMe2t)Pt(3′-
GMP)2 
4.5 H1′ 6.12 6.09 6.07 6.06 b  b  
 4.5 H6′ 8.25  8.02      
 7.5 H1′ 6.29 6.29 6.25 6.25 b  b  
 7.5 H6′ 8.44  8.02      
a
 The py and t notations designate G's cis to the pyridyl and triazine rings, respectively. Signal 
assignments are based on the 2D NMR and pH titration studies. b Signal not detected. 
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APPENDIX C. SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
C.1 Conformational Features of (Et4dt)Pt(d(G*pG*)) Conformers.  
The H8 peaks of (Et4dt)Pt(d(G*pG*)) at 8.97 and 9.04 ppm are connected by H8-H8 
NOE cross-peaks. The H8-H2′ cross-peaks are stronger than the H8-H1′ cross-peaks (Figure 
C1), indicating a predominantly anti conformation for both 3′-G* and 5′-G* nucleotides. A 5′-G* 
H8-H3′ NOE cross-peak and a doublet for the H1′ signal (6.39 ppm) is characteristic of an N-
sugar of a 5′-G (Figure C1).1-6 The H8 signal at 8.97 ppm, which must be the 3′-G* H8 signal, 
has no H8-H3′ cross-peak, the H1′ signal at 6.43 ppm is doublet of a doublet, thus indicating an 
S-sugar pucker. Therefore, the dominant (Et4dt)Pt(d(G*pG*)) conformer is an anti,anti-HH1 
conformer, as observed for the (Me4dt)Pt(d(G*pG*)). 
 
 
Figure C1. 1H-1H ROESY spectrum (700 MHz, 600 ms mixing time) of a 1-week-old 
(Et4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks for 
the HH1, HH2, and ∆HT and ΛHT conformers. 
 
The two most downfield H8 signals at 9.23 and 9.10 ppm connected by an H8-H8 NOE 
cross-peak belong to the HH2 conformer (minor). The G* H8 signal at 9.10 ppm has a strong 
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H8-H3′ cross-peak, indicating an N-sugar pucker for the 5′-G* nucleotide (Figure C1). For the 
5′-G* residue, a strong H8-H2′ cross-peak and the absence of an H8-H1′ NOE cross-peak 
indicate an anti G* conformation (Figure C1). The 9.23 ppm H8 signal belongs to the 3′-G* 
because of the S-sugar pucker indicated by the absence of an H8-H3′ NOE cross-peak. This H8 
signal has a weak NOE cross-peak to the H1′ signal and a strong NOE to the H2′ signal. 
Therefore, this HH2 conformer has an anti,anti conformation.  
The upfield pair of H8 signals at 8.29 and 8.32 ppm for the (Et4dt)Pt(d(G*pG*)) adduct 
has no H8-H8 NOE cross-peak, indicating that the bases of this form adopt the HT 
arrangement.2,3,7 These upfield H8 signal positions are characteristic of the ∆HT conformer. The 
chemical shifts of these HT H8 signals were similar to those of the (Me4dt)Pt(d(G*pG*)) ∆HT 
conformer. The H8 peak at 8.32 ppm exhibits an intraresidue H8-H3′ NOE cross-peak (Figure 
C1) consistent with an N-sugar pucker. Because the H1′ signal of this conformer at 6.35 ppm 
overlaps with H1′ signals of the other (Et4dt)Pt(d(G*pG*)) conformers, the coupling pattern 
could not be determined. However, because all the d(G*pG*) adducts typically adopt a 5′-G* N-
sugar pucker, we can assign the downfield signal of this conformer to the 5′-G* sugar residue. 
The presence of a strong H8-H2′ cross-peak (Figure C2) and a weak H8-H1′ cross-peak indicates 
an anti 5′-G* conformation. The presence of an intraresidue H8-H1′ NOE cross-peak for the 
upfield ∆HT H8 signal at 8.29 ppm (which must be the 3′-G* H8) suggests that the conformation 
of 3′-G* is syn. Both the H8-H2′/H2′′ and the H8-H3′ cross-peaks were absent. The doublet of 
doublets coupling of the 3′-G* H1′ signal (6.19 ppm) is typical of an S-sugar. Thus, this 
(Et4dt)Pt(d(G*pG*)) conformer has an anti,syn-∆HT conformation. In contrast to the H8 shifts 
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of the (Me4dt)Pt(d(G*pG*)) ∆HT conformer, the 5′-G* H8 signal for the (Et4dt)Pt(d(G*pG*)) 
∆HT conformer is downfield to the 3′-G* H8 signal.  
For the (Et4dt)Pt(d(G*pG*)) adduct, no H8-H8 NOE cross-peak was observed for the 
fourth pair of G* H8 signals at 8.66 and 8.99 ppm, indicating that the bases adopt an HT 
arrangement that could possibly be the elusive ΛHT conformer. The G* H8 signals have strong 
H8-H2′ cross-peaks and weak H8-H1′ cross-peaks (Figure C1), indicating an anti conformation 
for both G* nucleotides. A strong H8-H3′ NOE cross-peak for the H8 signal at 8.99 ppm and a 
doublet for the H1′ signal indicate an N-sugar pucker. Thus, the 8.99 ppm H8 signal was 
assigned to the 5′-G* residue. For the H8 signal at 8.68 ppm, an H8-H3′ cross-peak was absent 
and the doublet of doublets coupling pattern indicated an S-sugar pucker. Thus, this upfield 
signal was assigned to the 3′-G*. This HT conformer has an anti,anti conformation. For the 
putative ΛHT conformer of the (Et4dt)Pt(d(G*pG*)) adduct, the 5-G* H8 signal is downfield of 
the 3-G* H8 signal, as observed for the putative ΛHT conformer of the (Me4dt)Pt(d(G*pG*)) 
adduct. 
C.2 (Me4dt)Pt(d(G*pG*)).  
Within ~30 min of mixing (Me4dt)PtCl2 and d(GpG) in a 1:1 molar ratio in 64:36 
D2O:DMSO-d6 solution at pH ∼4.0 at 5 °C, the (Me4dt)Pt(d(G*pG*)) adduct was fully formed. 
The eight H8 signals of the four conformers of the (Me4dt)Pt(d(G*pG*)) adduct are fully 
resolved (Figure C2). The intensity of the H8 signals for the putative ΛHT conformer at 9.04 and 
8.65 ppm slowly increased during a period ~3 months (Figure C2). A ROESY spectrum of this 
3-months-old sample (Figure C3) helped us to confirm the sugar signal assignment for the 
(Me4dt)Pt(d(G*pG*)) conformers. 
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Figure C2. 1H NMR spectra (400 MHz) in the H8 region for (Me4dt)Pt(d(G*pG*)) collected at 
25 °C after 1 week (bottom) and after 3 months (top) (pH 4.0, in D2O/DMSO-d6).  
 
 
 
Figure C3. 1H-1H ROESY spectrum (400 MHz, 500 ms mixing time) of a 3-months-old 
(Me4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks. 
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be “prior publication”, the paper will not be accepted for publication in that journal.  If you intend 
to submit your unpublished paper to ACS for publication, check with the appropriate editor prior to 
posting your manuscript electronically.  
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the first page of your article: “Reproduced (or 'Reproduced in part') with permission from [FULL 
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be disseminated electronically, until ACS has published your paper.  After publication of the paper by 
ACS, you may release the entire thesis (not the individual ACS article by itself) for electronic 
dissemination through the distributor; ACS’s copyright credit line should be printed on the first page of 
the ACS paper.   
  
Use on an Intranet:  The inclusion of your ACS unpublished or published manuscript is permitted in 
your thesis in print and microfilm formats.  If ACS has published your paper you may include the 
manuscript in your thesis on an intranet that is not publicly available.  Your ACS article cannot be posted 
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